<SEC-DOCUMENT>0001493152-23-003170.txt : 20230131
<SEC-HEADER>0001493152-23-003170.hdr.sgml : 20230131
<ACCEPTANCE-DATETIME>20230131170304
ACCESSION NUMBER:		0001493152-23-003170
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20230131
DATE AS OF CHANGE:		20230131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMPACT BIOMEDICAL INC.
		CENTRAL INDEX KEY:			0001834105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				853926944
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-253037
		FILM NUMBER:		23573288

	BUSINESS ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
		BUSINESS PHONE:		585 232 1500

	MAIL ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on January 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-253037</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Amendment
No. 8 to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>IMPACT
BIOMEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8731</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>85-3926944</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
    or other jurisdiction of</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation
    or organization)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
    Standard Industrial</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Classification
    Code Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
    Number)</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
Wiregrass Pkwy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>West
Henrietta, NY 14586</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+1-585-325-3610</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Heng
Fai Ambrose Chan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
Wiregrass Pkwy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>West
Henrietta, NY 14586</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+1-585-325-3610</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>With
a copy to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Darrin
M. Ocasio, Esq.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sichenzia
Ross Ference LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1185
Avenue of the Americas</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10036</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
+1-212-930-9700</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
soon as practicable after the effective date of this registration statement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Approximate
date of commencement of proposed sale to the public)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &thinsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&thinsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &thinsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this prospectus is not complete and may be changed. We may not issue these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not
soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT
TO COMPLETION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #FC0014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
PROSPECTUS DATED JANUARY [&nbsp;&nbsp;&nbsp;], 2023 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
BIOMEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>230,216,524
shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(par
value $0.001 per share)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is being furnished to you as a stockholder of DSS, in connection with the planned distribution to its stockholders of shares
of common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) of Impact BioMedical, Inc. (the &ldquo;<U>Company</U>,&rdquo;
&ldquo;<U>Impact</U>,&rdquo; &ldquo;<U>we</U>,&rdquo; &ldquo;<U>our</U>&rdquo; or &ldquo;<U>us</U>&rdquo; as applicable) beneficially
held by DSS, through its wholly-owned subsidiary, DSS BioHealth Security, Inc. (the &ldquo;<U>Distribution</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS&rsquo;s
long-term plans for the Company include taking the Company public through an initial public offering. In concert with this planned public
offering, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc. plans to distribute an aggregate of approximately _________
shares of our Common Stock (the &ldquo;<U>Impact Shares</U>&rdquo;) beneficially held by DSS BioHealth Security, Inc. in a distribution
to holders of DSS common stock, par value $0.02 per share (&ldquo;<U>DSS Common Stock</U>&rdquo;) as of ___________(the &ldquo;<U>Record
Date</U>&rdquo;), except DSS will not cause to be distributed by DSS BioHealth Security, Inc. any Impact Shares to the Chairman of the
Board of DSS, Mr. Chan Heng Fai Ambrose, or any of his affiliates that hold shares of DSS Common Stock. As of the Record Date, Mr. Chan,
individually and through affiliates, beneficially held ___________ shares of DSS Common Stock (the &ldquo;<U>Affiliate Shares</U>&rdquo;).
Except for the Affiliate Shares, each share of DSS Common Stock outstanding as of 5:00 p.m., New York City time, held on a Record Date,
will entitle the holder thereof to receive four (4) Impact Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the Distribution, DSS, through its wholly-owned subsidiary Impact BioMedical, Inc., will beneficially hold 100%, or 125,073,621
of the issued and outstanding shares of our Common Stock. The Distribution will be effective as of 5:00 p.m., New York City time, on
___________ (&ldquo;Distribution Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution will not occur until this Registration Statement becomes effective under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;). The Distribution will be made in book-entry form by a distribution agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of Common Stock are currently beneficially owned by DSS, through its wholly-owned subsidiary DSS BioHealth
Security, Inc. Accordingly, there currently is no public trading market for our Common Stock. Our Common Stock is currently not listed
for trading on any stock exchange or market. The Impact Shares may be illiquid as we cannot predict whether any trading market will develop.
We currently plan to apply for listing of our Common Stock on the over-the-counter board upon the effectiveness of the registration statement,
of which this prospectus forms a part. However, we can provide no assurance that our shares will be traded on the bulletin board or,
if traded, that a public market will materialize. If no market is ever developed for our shares, it will be difficult for shareholders
to sell their stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DSS
stockholders are not required to vote on or take any other action in connection with the Distribution. We are not asking you for a proxy,
and we request that you do not send us a proxy</B>. DSS stockholders will not be required to pay any consideration for the Impact Shares
that they receive in the Distribution, and they will not be required to surrender or exchange their shares of DSS Common Stock or take
any other action in connection with the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are an &ldquo;emerging growth company,&rdquo; as defined under the federal securities laws, and have elected to comply with certain reduced
public company reporting requirements for this prospectus and for future filings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involve a high degree of risk. Before buying any securities, you should carefully consider the matters described in
the section titled &ldquo;Risk Factors&rdquo; beginning on page 11  of this Prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus or any prospectus supplement or amendment hereto. We have not authorized
anyone to provide you with different information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined
if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
Prospectus is not an offer to sell, or a solicitation of an offer to buy, any securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this Prospectus is ________ ___, 2022.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="toc_011"></A>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_001">QUESTIONS AND ANSWERS ABOUT THE DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_002">SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_004">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_005">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE SPIN-OFF</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_006">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_007">DETERMINATION OF OFFERING PRICE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_008">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_009">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#gfd_010">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_001">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_002">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_003">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_004">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_005">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_006">DESCRIPTION OF OUR CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_007">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_008">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ax_009">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#zzz_001">INDEX TO FINANCIAL
    STATEMENTS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_011">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_001"></A>QUESTIONS
AND ANSWERS ABOUT THE DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following questions and answers briefly address some commonly asked questions about the Distribution. They may not include all the information
that is important to you. We encourage you to read carefully this entire Prospectus and the other documents to which we have referred
you. We have included references in certain parts of this section to direct you to a more detailed discussion of each topic presented
in this section.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    is the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is a method by which we will begin to separate from DSS. DSS currently beneficially owns through its wholly-owned subsidiary,
    DSS BioHealth Security, Inc., 125,073,621 shares of our Common Stock, representing 100% of our issued and outstanding capital
    stock. In connection with the Distribution, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc., will distribute
    to holders of DSS Common Stock an aggregate of ______ Impact Shares. Following the Distribution DSS, through its wholly-owned subsidiary
    DSS BioHealth Security, Inc., will retain approximately a ____ % ownership interest in the Company. or otherwise possess control
    over us. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Will
    the number of shares of DSS Common Stock I own change as a result of a Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No,
    the number of shares of DSS Common Stock you own will not change as a result of a Distribution. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    are the reasons for the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is a method by which DSS will begin to carry out the intention of management and the board of directors of DSS (&ldquo;DSS
    Board&rdquo;) to take the Company public and to reward DSS stockholders via the issuance of the Impact Shares. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    will I receive in a Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a holder of DSS Common Stock, you will receive a dividend of four Impact BioMedical Shares for every share of DSS Common Stock you
    hold on the Record Date. The distribution agent will distribute only whole Impact Shares in the Distribution. Your proportionate
    interest in DSS will not change as a result of the Distribution. For a more detailed description, see &ldquo;The Distribution.&rdquo;
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    is being distributed to holders of DSS Common Stock in the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    will cause its wholly-owned subsidiary DSS BioHealth Security, Inc. to distribute ________ Impact BioMedical Shares in the Distribution,
    which constitutes approximately __ % of our issued and outstanding shares of Common Stock. For more information on the shares being
    distributed in the Distribution, see &ldquo;Description of Our Capital Stock&mdash;Common Stock.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_011">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    is the record date for the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    DSS Board has designated 5:00 p.m., New York City time, on __________ as the record ownership date for the Distribution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>When
    will the Distribution to holders of DSS Common Stock occur?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution will be effective as of 5:00 p.m., New York City time on, 2022 (the &ldquo;Distribution Date&rdquo;). On or shortly
    after the Distribution Date, the Impact Shares will be credited in book-entry accounts for stockholders entitled to receive those
    shares in the Distribution. We expect that it may take the distribution agent up to two weeks after each Distribution Date to fully
    distribute the Impact Shares to DSS stockholders. See &ldquo;Questions and Answers About the Distribution&mdash;How will DSS distribute
    the Impact Shares?&rdquo; for more information on how to access your book-entry account or your bank, brokerage or other account
    holding Impact Shares that you will receive in the Distribution. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    do I have to do to participate in the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    are not required to take any action, but we urge you to read this Prospectus carefully. Holders of DSS Common Stock on the Record
    Date will not need to pay any cash or deliver any other consideration, including any shares of DSS Common Stock, in order to receive
    Impact Shares in the Distribution. No stockholder approval of the Distribution is required. We are not asking you for a vote, and
    we request that you do not send us a proxy card. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
    I sell my shares of DSS Common Stock on or before the Distribution Date, will I still be entitled to receive shares of Common Stock
    in the Distribution? </I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you hold shares of DSS Common Stock as of the Record Date and decide to sell them on or before the relevant Distribution Date, you
    will not be entitled to receive Impact Shares. You should discuss these alternatives with your bank, broker or other nominee. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
    will DSS distribute the Impact Shares?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registered
    stockholders</U>: If you are a registered stockholder (meaning you own your shares of DSS Common Stock directly through DSS&rsquo;s
    transfer agent, American Stock Transfer &amp; Trust Company, LLC), <FONT STYLE="background-color: white">V Stock Transfer LLC </FONT>our
    transfer agent, which is serving as the distribution agent in connection with the Distribution, will credit the Impact Shares you
    receive in the Distribution to a new book-entry account on or shortly after the Distribution Date. Our distribution agent will mail
    you a book-entry account statement that reflects the number of Impact Shares you own. You will be able to access information regarding
    your book-entry account holding the Impact Shares at <FONT STYLE="background-color: white">V Stock Transfer LLC</FONT>.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&ldquo;Street
    name&rdquo; or beneficial stockholders</U>: If you own your shares of DSS Common Stock beneficially through a bank, broker or other
    nominee, your bank, broker or other nominee will credit your account with the Impact Shares you receive in the Distribution on or
    shortly after the Distribution Date. Please contact your bank, broker or other nominee for further information about your account.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not issue any physical stock certificates to any stockholders, even if requested. See &ldquo;The Distribution&mdash;When and
    How You Will Receive Company Shares&rdquo; for a more detailed explanation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_011">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    is the U.S. federal income tax consequences to me of the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    shareholders will be subject to being taxed on the distribution of the Impact Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Material U.S. Federal Income Tax Consequences of the Distribution&rdquo; for more information regarding the potential tax
    consequences to you from the Distribution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    should consult your own tax advisors regarding the particular tax consequences of the Distribution to you, including the applicability
    and effect of any U.S. federal, state, local and non-U.S. tax laws.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Does
    the Company intend to pay cash dividends?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, we do not anticipate paying any dividends on Impact Shares in the foreseeable future. See &ldquo;Dividend Policy&rdquo;
    for more information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
    will our Common Stock trade?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    shares of Common Stock are not listed on any securities exchange and the Impact Shares may be illiquid as we cannot predict whether
    any trading market will develop.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Will
    my shares of DSS Common Stock continue to trade on the NYSE American LLC exchange (&ldquo;NYSE Amex&rdquo;) following the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Following the Distribution, DSS Common Stock will continue to trade on the NYSE Amex under the symbol &ldquo;DSS&rdquo; through and
    after the Distribution Date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Will
    the Distribution affect the trading price of my DSS Common Stock?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not expect the trading price of shares of DSS Common Stock immediately following the Distribution to be materially lower or higher
    than immediately prior to the Distribution. However, until the market has fully analyzed the value of DSS without its ownership of
    the Impact Shares, the trading price of shares of DSS Common Stock may fluctuate. We cannot assure you that, following the Distribution,
    the combined trading prices of the DSS Common Stock and Impact Shares will equal or exceed what the trading price of DSS Common Stock
    would have been in the absence of the Distribution. It is possible that after the Distribution, the combined equity value of DSS
    and the Impact Shares will be less than DSS&rsquo;s equity value before the Distribution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_011">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Do
    I have appraisal rights in connection with the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    Holders of DSS Common Stock are not entitled to appraisal rights in connection with the Distribution.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
    will the relationship be between DSS and the Company after the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc., will still have a continuing stock ownership
    interest in and is expected to possess control over the Company, until and if the proposed public offering of the Company is completed.
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Who
    is the transfer agent and registrar for our Common Stock? Who is the distribution agent in connection with the Distribution? </I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">V
    Stock Transfer LLC</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is the transfer agent and registrar
    for our Common Stock and is serving as the distribution agent in connection with the Distribution. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Are
    there risks associated with owning shares of our Common Stock?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Our business faces both general and specific risks and uncertainties. Our business also faces risks relating to the Distribution.
    Accordingly, you should read carefully the information set forth in the section titled &ldquo;Risk Factors&rdquo; in this Prospectus.
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Are
    there any conditions to completing the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    The Distribution is conditional upon a number of matters, including but not limited to the authorization and approval of the DSS
    Board (which has been obtained) and the declaration of effectiveness of our Registration Statement on Form S-1, of which this Prospectus
    is a part, by the Securities and Exchange Commission. See &ldquo;Summary&mdash;Summary of the Distribution&mdash; Conditions to the
    Distribution&rdquo; for a more detailed explanation of the conditions to completing the Distribution. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Can
    DSS decide to not proceed with the Distribution even if all the conditions to the Distribution have been met?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Until the Distribution has occurred, the DSS Board has the right to not proceed with the Distribution, even if all the conditions
    are satisfied. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Could
    there be any other classes of capital stock of the Company outstanding after the Distribution?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    After giving effect to the Distribution, the only class of our capital stock then outstanding is expected to be our Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
    </I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Where
    can I get more information?</I></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you have any questions relating to the mechanics of the Distribution, you should contact the distribution agent, <FONT STYLE="background-color: white">V
    Stock Transfer LLC</FONT>, at:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V
Stock Transfer LLC 18 Lafayette Place</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodmere,
NY 11598</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
212-828-8435</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@vstocktransfer.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.vstocktransfer.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_002"></A>SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information contained elsewhere in this Prospectus and may not contain all the information that is important
to you. To understand fully and for a more complete description of the terms and conditions of the Distribution, you should read this
Prospectus in its entirety, including the information presented under the section titled &ldquo;Risk Factors&rdquo; and the consolidated
financial statements and related notes, and the documents to which you are referred. See &ldquo;Where You Can Find More Information.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
where the context otherwise requires, or where otherwise indicated, references to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
or &ldquo;our&rdquo; are to are to Impact BioMedical, Inc. and its subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introduction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical is the developer of unique and differentiated technologies to address unmet healthcare and wellness needs. Our activities
range from the discovery of technologies and leveraging those technologies to create and commercialize product candidates. Currently,
our operations are conducted, and our assets are owned primarily through our principal subsidiaries: (i) Global BioLife, Inc.
(&ldquo;Global BioLife&rdquo;), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (&ldquo;Impact BioLife&rdquo;),
which was incorporated on August 28, 2020, Global BioMedical, Inc. (&ldquo;Global BioMedical&rdquo;), which was incorporated on April
18, 2017, and Sweet Sense, Inc. (&ldquo;Sweet Sense&rdquo;), which was incorporated on April 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Associated with Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.
You should carefully consider these risks. Some of these risks include, but are not limited to that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot guarantee that we will find third-parties or customers that are interested in purchasing, licensing, or co-developing our
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if we are able to establish licensing arrangements, we cannot guarantee that licensors will be successful in their development efforts
    of products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot guarantee that our products will ever be approved for clinical testing or commercialization by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have not yet generated any revenue from our operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have a history of net losses, negative cash flows, and accumulated deficits over the last two years; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    occurrence of an uncontrolled event such as the Covid-19 pandemic, is likely to negatively affect our operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company and a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, (the &ldquo;JOBS
Act&rdquo;). As such, we may take advantage of reduced disclosure and other requirements otherwise generally applicable to public companies,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">presentation
    of only two years of audited financial statements and related financial disclosure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the requirement to have our registered independent public accounting firm attest to management&rsquo;s assessment of our internal
    control over financial reporting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from compliance with the requirement of the Public Company Accounting Oversight Board, or PCAOB, regarding the communication of critical
    audit matters in the auditor&rsquo;s report on the financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure about our executive compensation arrangements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the requirement to hold non-binding advisory votes on executive compensation or golden parachute arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least
$1.07 billion in annual revenue; (2) the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700.0 million of
equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities
during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of the IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of this status, we have taken advantage of reduced reporting requirements in this prospectus and may elect to take advantage
of other reduced reporting requirements in our future filings with the SEC. In particular, in this prospectus, we have provided only
two years of audited financial statements and only two years of related management&rsquo;s discussion and analysis of financial condition
and results of operations, and we have not included all of the executive compensation-related information that would be required if we
were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company may take advantage of an extended
transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they
would apply to private companies unless it otherwise irrevocably elects not to avail itself of this exemption. We have elected to use
this extended transition period for complying with new or revised accounting standards until we are no longer an emerging growth company
or until we affirmatively and irrevocably opt out of the extended transition period. As a result, our consolidated financial statements
may not be comparable to the financial statements of companies that comply with new or revised accounting pronouncements as of public
company effective dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (&ldquo;Impact&rdquo;) targets urgent medical needs and expands the borders of medical and pharmaceutical science.
Impact drives mission-oriented research and development, and commercialization of solutions for medical advances in human wellness
and healthcare. By leveraging technology and new science with strategic partnerships, Impact BioMedical provides advances in drug
discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other exciting
technologies include a breakthrough alternative sugar aimed to combat diabetes and functional fragrance formulations aimed at the
industrial and medical industry. The research and development efforts have been primarily conducted in collaboration with
GRDG Sciences, LLC (&ldquo;GRDG&rdquo;) and with the expertise of Mr. Daryl Thompson as its Director of Scientific
Initiatives. We have initiated research regarding universal therapeutics as part of an attempt to help address some of the
world&rsquo;s deadliest diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business model of Impact BioMedical revolves around two methodologies &ndash; Licensing and Sales Distribution. Impact BioMedical
develops valuable and unique patented technologies which will be licensed to pharmaceutical, large consumer package goods companies
and venture capitalists in exchange for usage licensing and royalties. Impact also utilizes the DSS ecosystem to leverage distribution
networks on a global scale. Impact will engage in branded and private labelling of certain products for sales generation through these
channels. This global distribution model will give direct access to end users of Impact&rsquo;s nutraceutical and health related products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioLife Science, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioMedical, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioLife, Inc.; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
    Sense, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Impact
BioLife Science, Inc</U>.</I> We are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Global
Biomedical, Inc.</U></I> We own 90.91% of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy
Tang.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Global
BioLife, Inc</U></I>. Through our majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global
BioLife, Inc. The other equity owner is Holista CollTech Limited (&ldquo;Holista&rdquo;) (10%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Sweet
Sense, Inc</U></I><U>.</U> We are the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar,
Inc. (&ldquo;BioLife Sugar&rdquo;).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_001.jpg" ALT="" STYLE="height: 647px; width: 500px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical and our majority-owned subsidiaries own or have rights to a portfolio of biomedical intellectual property and leverages its
scientific know-how and intellectual property rights to develop various emerging technologies, including biopharmaceuticals, antivirals,
antimicrobials, sugar alternatives, insect repellents, fragrances, bioplastics and natural preservatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical has had several important and valuable products, technology, or compounds that are in continuing development and/or licensing
stages. The Company has not conducted and has no current plans to conduct any preclinical testing for these products, technology,
or compounds:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LineBacker:
    Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer, and infectious diseases.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir:
    A compound intended for antiviral infection treatments. Equivir/Nemovir is a novel blend of FDA Generally Recognized as Safe
    (&ldquo;GRAS&rdquo;) eligible natural compounds. These compounds are generally sourced from fruits, vegetables, and other
    natural substances. Please note, the FDA has not approved this product, GRAS designation means that the FDA does not question the
    basis for a notifier&rsquo;s GRAS determination, and GRAS determination does not increase the likelihood that product candidates
    will receive marketing approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laetose:
    Laetose technology is derived from a unique combination of sugar and other naturally occurring compounds which demonstrate
    the ability to inhibit the inflammatory and metabolic response of sugar alone. This compound is a sugar alternative aimed to combat diabetes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F:
    A botanical compound intended to serve as an insect repellent and anti-microbial agent. 3F is a unique formulation of specialized
    ingredients from naturally occurring botanical sources.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F Mosquito Repellent:
    3F repellent contains botanical ingredients that mosquitos avoid. These ingredients affect the mosquito&rsquo;s
    receptors, essentially making the insect blind to a human&rsquo;s presence. This can be utilized as a stand-alone repellent or as
    an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F
    Antimicrobial: 3F antimicrobial contains botanical ingredients known to kill viruses. These ingredients are intended to inhibit
    viral replication. This can be utilized as a stand-alone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics,
    and other substances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercialization
Business Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model revolves mainly around two approaches &ndash; Licensing and Sales Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>1.
Licensing</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing strategy includes developing unique patented technologies which would then be licensed to external partners for developing,
registration, and commercialization as appropriate. We believe that interest in licensing certain projects may rise over time as validating
data becomes available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June of 2022, Impact BioMedical signed a License Agreement with ProPhase Labs to produce and distribute compound Equivir, which
has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July of 2022, Global BioLife, Inc., a subsidiary
of Impact, executed a license agreement with ProPhase BioPharma, Inc. (&ldquo;PBIO&rdquo;), a subsidiary of ProPhase Labs, Inc., a rapidly
growing and diversified diagnostics, genomics and biotech company, for Global BioLife&rsquo;s Linebacker portfolio (LB-1 and LB-2), two
patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.
Sales Distribution</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are intending to pursue 3<SUP>rd</SUP> party partnerships specifically with large manufactures in the pharmaceutical, food, health and
beauty, and nutraceutical industries to commercialize our products, ideas and intellectual property. We will leverage their product development,
commercialization and distribution capabilities to take products to market through a licensing and/or private label sales model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Research and Development</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured arrangements with certain affiliates to undertake activities to improve existing product candidates and develop new ones.
We believe the timely development of new, and the enhancement of our existing products, is essential to our success. Although we intend
to invest a substantial amount of our resources in research and development, there is no guarantee that our investment will translate
into improvements of existing products or the development of new products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&rsquo; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &ldquo;Global BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Global BioLife Stockholder&rsquo;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &ldquo;Linebacker Patents&rdquo; as defined
in the Global BioLife Stockholders&rsquo; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&rsquo; budget</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&rsquo; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&rsquo;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. Current monthly payments approximate to $43,000.
For the year ended December 31, 2021, the Company incurred expenses of $509,176. The Company incurred expenses of $329,409 (predecessor
&ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash; August 22, 2020 to December 31, 2020). On December
31, 2021, and December 31, 2020, the Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and
$35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Global BioLife Stockholders&rsquo; Agreement,
Holista has agreed to (i) assist in the global commercialization of Global BioLife&rsquo;s intellectual property, (ii) assist in the
initiation and development of joint venture opportunities for Global BioLife, and (iii) provide the expertise of Dr. Rajen M. Dato to
Global BioLife as strategic director.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&rsquo; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&rsquo; Agreement entered into Amendment No. 1 to the agreement (&ldquo;Amendment
No. 1 to the Global BioLife Stockholders Agreement&rdquo;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&ldquo;Amendment No. 2 to the Global BioLife Stockholders Agreement&rdquo;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&rsquo; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Licensing
Proceeds Distribution Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, Impact entered into a new licensing proceeds distribution agreement whereas GRDG will continue to invent and develop
Improvements and Discoveries for and on behalf Impact and agree to assign any such Discoveries/Improvements/advances to Impact generated
by its efforts and through the resources funded by Impact, directly or indirectly. Any such Discoveries assigned to Impact would be considered
Intellectual Property under this Agreement such that GRDG would receive 20% of the gross licensing or sale proceeds received by Impact
from the licensing of such discoveries. Under the same agreement, GRDG transferred all of its right, title, and interest that GRDG has,
if any, in Global as set forth in the Global Agreement back to Global, and all right, title and interest that GRDG has, if any, in Impact
back to Impact, and hereinafter having no further ownership, control, or interest in either Global or Impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholder&rsquo;s agreement with its stockholders Impact BioMedical and GRDG (the &ldquo;Impact
BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Impact BioLife Stockholders&rsquo; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&rsquo; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&rsquo; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&rsquo; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time and efforts
to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&rsquo;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&rsquo;s business plan
and budget (the &ldquo;Impact BioLife Budget&rdquo;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. For the year ended December 31, 2021, the Company incurred expenses of $509,176.
The Company incurred expenses of $329,409 (predecessor &ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash;
August 22, 2020 to December 31, 2020). On December 31, 2021, and December 31, 2020, the Company owed this related party $0 and
had prepaid monthly fees approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&rsquo; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain
a stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of the Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&rsquo; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&rsquo;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&rsquo; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&rsquo; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&rsquo;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&rsquo; written notice by either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Licensing Proceeds Distribution Agreement
between GRDG Sciences, LLC, Global BioLife, Inc., and Impact BioLife Sciences, Inc., to include Impact Biomedical Inc.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2022, the Company and Impact BioLife Sciences, Inc. (together, &ldquo;Impact&rdquo;), entered into a Licensing Proceeds Distribution Agreement (the &ldquo;LPDA&rdquo;)
with the Company&rsquo;s subsidiary, Global BioLife, Inc. (&ldquo;Global,&rdquo; and together with Impact BioLife Sciences, Inc. and
the Company, the &ldquo;Impact Parties&rdquo;), and GRDG Sciences, LLC (&ldquo;GRDG&rdquo;), pursuant to which the parties clarified
the consideration due to GRDG under pre-existing agreements by and between GRDG and the Impact Parties. Pursuant to the LPDA, GRDG will
receive 20% of the gross licensing or sale proceeds from any of its developed improvements for and on behalf of Global and the Impact
Parties. Further, Impact agreed to provide periodic payments to GRDG for the purpose of paying or reimbursing certain salaries, overhead,
office rent reimbursements, and other operating costs. As compensation, GRDG will receive 20% of the gross licensing or sale proceeds
received by the Impact Parties for any intellectual property generated. Pursuant to the GRDG, Impact retroactively acknowledged that
GDRG (1) is not a shareholder in any company or subsidiary of the Impact Parties, and (2) that GDRG&rsquo;s full consideration for the
improvement developments which it has or will develop is/was (a) monthly operating cash flow payments, and (2) 20% of the gross proceeds
from any licensing or sale of such improvements and discoveries. In addition, GRDG agreed to transfer all of its right, title and interest
in Global to Global, and all right, title and interest in Impact to Impact. Global has agreed to provide GRDG a financial interest in
revenue received directed to the licensing of the Global intellectual property, and Impact has agreed to provide GRDG an interest in
revenue received directed to the licensing of the impact intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
Exchange Transaction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, we closed on a Share Exchange Agreement by and among DSS, DSS BioHealth Security, Inc., Alset International Ltd. (formerly
Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&ldquo;GBM&rdquo;), pursuant to which we became a wholly-owned subsidiary
of DSS BioHealth Security, Inc. Shortly after closing, Frank D. Heuszel, Jason Grady, and John Thatch were appointed directors,
and Mr. Heng Fai Ambrose Chan remained on the Board of Directors and appointed Chief Executive Officer, Mr. Heuszel was appointed President,
Mr. Grady was appointed Chief Operating Officer and Todd Macko was appointed Secretary and Treasurer, replacing the officers and directors
who resigned in connection with the share exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chan is the Chief Executive Officer and largest shareholder of Alset International Ltd., as well as the Chairman of the Board and largest
shareholder of the DSS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 275
Wiregrass Parkway, West Henrietta, NY 14586. Our telephone number is +1-585-325-3610. Our website address is https://www.impbio.com.
Our website and the information contained thereon, or connected thereto, does not and will not constitute part of this Prospectus or
the Registration Statement on Form S-1 of which this Prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributing
    Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS,
    Inc., a New York corporation, which beneficially owns through its wholly-owned subsidiary DSS BioHealth Security, Inc. _________
    shares of our Common Stock, representing 100% of our outstanding shares of our Common Stock prior to the Distribution. After the
    Distribution, DSS will own approximately __% of our Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributed
    Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioMedical, Inc., a Nevada corporation and a subsidiary of DSS. At the time of the Distribution, we operate primarily through our
    principal subsidiaries, Impact BioLife, Global Biomedical, Global BioLife and Sweet Sense. Through our principal subsidiaries, we
    are committed to both funding research, developing and commercializing new offerings in pharmaceuticals, consumer and wellness products,
    including, but not limited to, a focus on: (i) the development of a universal therapeutic drug platform; (ii) a new sugar substitute;
    and (iii) a multi-use fragrance developed for industrial and medical applications, including an insect repellant, and (iv) an
    OTC medication with broad antiviral activity. Impact. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributed
    Securities in the Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________shares
    of our Common Stock indirectly owned by DSS, which represent approximately ___% of our Common Stock issued and outstanding immediately
    prior to the Distribution. Based on _________ shares of DSS Common Stock outstanding as of the close of business on the Record Date,
    not including the Affiliate Shares, this reflects a distribution ratio of four (4) Impact Shares for every one (1) share of DSS Common
    Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Record Date is 5:00 p.m., New York City time, on _____________. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distribution
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution Date is _______, 2022, and we expect that the Distribution will be effective as of 5:00 p.m., New York City time.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distribution
Ratio</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    holder of DSS Common Stock will receive four (4) shares of our Common Stock for every one (1) share of DSS Common Stock it holds
    on the Record Date. The distribution agent will distribute only whole shares of our Common Stock in the Distribution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    note that if you sell your shares of DSS Common Stock on or before the Distribution Date, the buyer of those shares will in most
    circumstances be entitled to receive the shares of our Common Stock to be distributed in respect of the DSS shares that you sold.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the Distribution Date, DSS will release the shares of our Common Stock to the distribution agent to distribute to DSS stockholders.
    DSS will distribute our shares in book-entry form, and thus we will not issue any physical stock certificates. We expect that it
    will take the distribution agent up to two weeks to electronically issue shares of our Common Stock to you or your bank or brokerage
    firm on your behalf by way of direct registration in book-entry form. If you own your shares of DSS Common Stock through a bank,
    broker or other nominee, your bank, broker or other nominee will credit your account with the whole shares of our Common Stock that
    you receive in the Distribution on or shortly after the Distribution Date. You will not be required to make any payment, surrender
    or exchange your shares of DSS Common Stock or take any other action to receive your shares of our Common Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditions
to the Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is subject to the satisfaction, or the DSS Board&rsquo;s waiver, of the following conditions:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    DSS Board shall have authorized and approved the Distribution by its wholly-owned subsidiary DSS BioHealth Security, Inc. and not
    withdrawn such authorization and approval, and shall have declared the dividend of our Common Stock to DSS stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    SEC shall have declared effective our Registration Statement on Form S-1, of which this Prospectus is a part, under the Securities
    Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and no stop order suspending the effectiveness of our Registration Statement
    shall be in effect and no proceedings for that purpose shall be pending before or threatened by the SEC;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal restraint or prohibition
    preventing consummation of the Distribution shall be in effect, and no other event outside the control of DSS shall have occurred
    or failed to occur that prevents the consummation of the Distribution; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    other events or developments shall have occurred prior to the Distribution Date that, in the sole judgment of the DSS Board, would
    result in the Distribution having a material adverse effect on DSS or its stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 253pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fulfillment of the foregoing conditions will not create any obligation on the part of DSS to effect the Distribution. We are not
    aware of any material federal, foreign or state regulatory requirements with which we must comply, other than SEC rules and regulations,
    or any material approvals that we must obtain, other than the SEC&rsquo;s declaration of the effectiveness of the Registration Statement,
    in connection with the Distribution. DSS has the right not to complete the Distribution if, at any time, the DSS Board determines,
    in its sole and absolute discretion, that the Distribution is not in the best interests of DSS or its stockholders or is otherwise
    not advisable. For a more detailed description, see &ldquo;The Distribution&mdash;Conditions to the Distribution.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Market</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our outstanding shares of Common Stock are currently beneficially owned by DSS through its wholly-owned subsidiary DSS BioHealth
    Security, Inc. Accordingly, there currently is no public trading market for the Common Stock. The Common Stock is currently not listed
    for trading on any stock exchange or market. The Common Stock may be illiquid as we cannot predict whether any trading market will
    develop.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
    Consequences to DS Stockholders</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    shareholders will be subject to a taxable event on the distribution of the Impact Shares. See &ldquo;Material U.S. Federal Income
    Tax Consequences of the Distribution&rdquo; for more information regarding the potential tax consequences to you of the Distribution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    should consult your own tax advisors regarding the particular tax consequences of the Distribution to you, including the applicability
    and effect of any U.S. federal, state, local and non-U.S. tax laws.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
    Policy</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. See &ldquo;Dividend
    Policy&rdquo; for more information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
    Agent and Distribution Agent</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V
    Stock Transfer LLC, the transfer agent and registrar for our Common Stock, will serve as distribution agent in connection with the
    Distribution.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business faces both general and specific risks and uncertainties. Our business also faces risks relating to the Distribution. Accordingly,
    you should read carefully the information set forth under the section titled &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="gfd_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should carefully consider all the information in this Prospectus and each of the risks described below, which we believe are the principal
risks that we face. Some of the risks relate to our business, others to the </I>Distribution<I>. Some risks relate principally to the
securities markets and ownership of our Common Stock. The risks and uncertainties described below are not the only ones faced by us.
Additional risks and uncertainties not presently known or that are currently deemed immaterial also may impair our business operations.
If any of the following risks occur, our business, financial condition, operating results and cash flows and the trading price of our
Common Stock could be materially adversely affected.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Distribution may not be completed on the terms or timeline currently contemplated, if at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are actively engaged in planning for the Distribution, unanticipated developments could delay or negatively affect the Distribution,
including, but not limited to, those related to the filing and effectiveness of appropriate filings with the SEC and receiving any required
regulatory approvals. In addition, until a Distribution has occurred, the DSS Board, in its sole discretion, has the right to not proceed
with the Distribution, even if all the conditions are satisfied. Therefore, the Distribution may not be completed on the terms or timeline
currently contemplated, if at all<B><I>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>DSS
expects the Distribution to be treated as a taxable non-liquidating distribution to its stockholders. As a result, a U.S. stockholder
of DSS may have a U.S. Federal income tax liability in respect of the Distribution without the receipt of cash from DSS or Impact.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
expects the Distribution to be treated as a taxable, non-liquidating distribution to its stockholders. As such, for U.S. federal income
tax purposes, each U.S. stockholder of DSS receiving shares of Impact Common Stock in the Distribution would be treated as if such stockholder
had received a distribution in an amount equal to the fair market value of Impact Common Stock received, which would result in (1) a
taxable dividend to the extent of such stockholder&rsquo;s pro rata share of DSS&rsquo;s current and accumulated earnings and profits,
(2) a reduction in such stockholder&rsquo;s basis (but not below zero) in DSS common stock to the extent the amount received exceeds
such stockholder&rsquo;s share of earnings and profits and (3) a taxable gain to the extent the amount received exceeds the sum of the
amount treated as a dividend and the stockholder&rsquo;s basis in the DSS Common Stock. Accordingly, such stockholder may have a U.S.
federal income tax liability in respect of the Distribution without the receipt of cash from DSS or Impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more detailed discussion, see the section entitled &ldquo;The Distribution &ndash; U.S. Federal Income Tax Consequences of the Distribution&rdquo;
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a limited operating history, and our historical financial information may not be a reliable indicator of our future results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no historical financial information about us upon which to base an evaluation of our performance. As of the date of this report, we
have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is
subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays our
research, testing and marketing efforts or wider economic downturns. For additional information about our past financial performance
and the basis of presentation of our financial statements, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; and our historical financial statements and the notes thereto included elsewhere in this Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not adequately protect our intellectual property rights, our operations may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on and expect to continue to rely on agreements with parties with whom we have relationships, as well as patent, trademark and trade
secret protection laws, to protect our intellectual property and proprietary rights. We cannot assure you that we can adequately protect
our intellectual property or successfully prosecute potential infringement of its intellectual property rights. Also, we cannot assure
you that others will not assert rights in, or ownership of, trademarks and other proprietary rights of ours or that we will be able to
successfully resolve these types of conflicts to our satisfaction. Our failure to protect our intellectual property rights may result
in a loss in potential revenue and could materially harm our operations and financial condition</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>New
legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs
and decrease any potential revenue we might otherwise make.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
spend a significant amount of resources on its patent assets. If new legislation, regulations or rules are implemented either by Congress,
the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;) or the courts that impact the patent application process, the patent enforcement
process or the rights of patent holders, these changes could negatively affect its expenses, potential revenue and could negatively impact
the value of its assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Safety
and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational
damage.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific
evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the FDA (or its
counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage.
These circumstances can also result in damage to brand image, brand equity and consumer trust in products. Product recalls could in the
future prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related
sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
challenges or delays in our innovation and development of new products, technologies and indications could have an adverse impact on
our long-term success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
continued growth and success depend on our ability to innovate and develop new and differentiated products and services that address
the evolving health care needs of patients, providers and consumers. Development of successful products and technologies may also be
necessary to offset revenue losses should our products lose market share due to various factors such as competition and loss of patent
exclusivity. We cannot be certain when or whether we will be able to develop, license or otherwise acquire companies, products and technologies,
whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially
successful. We pursue product development through internal research and development as well as through collaborations, acquisitions,
joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly
biotechnology products, requires a significant commitment of resources over many years. Only a very few biopharmaceutical research and
development programs result in commercially viable products. The process depends on many factors, including the ability to discern patients&rsquo;
and healthcare providers&rsquo; future needs; develop new compounds, strategies and technologies; achieve successful clinical trial results;
secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market,
successfully differentiate its products from competing products and approaches to treatment. New products or enhancements to existing
products may not be accepted quickly or significantly in the marketplace for healthcare providers, and there may be uncertainty over
third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and
efficacy findings in larger patient populations, as well as market entry of competitive products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to risks related to corporate social responsibility and reputational matters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reputation and the reputation of our brands, including the perception held by our customers, end-users, business partners, investors,
other key stakeholders and the communities in which we do business are influenced by various factors. There is an increased focus from
our stakeholders on ESG practices and disclosure - and if we fail, or are perceived to have failed, in any number of ESG matters, such
as environmental stewardship, inclusion and diversity, workplace conduct and support for local communities, or to effectively respond
to changes in, or new, legal or regulatory requirements concerning climate change or other sustainability concerns, our reputation or
the reputation of our brands may suffer. Such damage to our reputation and the reputation of our brands may negatively impact our business,
financial condition and results of operations. In addition, negative or inaccurate postings or comments on social media or networking
websites about the Company or our brands could generate adverse publicity that could damage our reputation or the reputation of our brands.
If we are unable to effectively manage real or perceived issues, including concerns about product quality, safety, corporate social responsibility
or other matters, sentiments toward the Company or our products could be negatively impacted, and our financial results could suffer.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B><I>We may not have adequate funds to implement
our business plan</I></B>.</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="background-color: white">Although
we have received capital from our parent companies to meet our working capital and financing needs in the past, additional financing
may be required in order to meet our current and projected cash requirements for operations.&nbsp;</FONT>We cannot assure that we will
secure all or any of the funding we anticipate. If our entire original capital is fully expended and additional costs cannot be funded
from borrowings or capital from other sources, then our financial condition, results of operations and business performance would be
materially adversely affected. We cannot assure that we will have adequate capital or financing to conduct our business or to grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Currently,
there is no public market for our securities, and there can be no assurances that any public market will ever develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our Common Stock is not listed or quoted on any public market, exchange, or quotation system. Although we plan to take steps to have
our Common Stock publicly traded, a market for our Common Stock may never develop. Even if we are successful in developing a public market,
there may not be enough liquidity in such market to enable stockholders to sell their stock. If a public market for our Common Stock
does not develop, DSS stockholders may not be able to re-sell the shares of our Common Stock that they have received, rendering their
shares effectively worthless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of our Common Stock in the public market could lower our stock price, and any additional capital raised by us through the sale
of equity or convertible securities may dilute our stockholders&rsquo; ownership in us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell additional shares of our Common Stock in public or private offerings. We also may issue convertible debt or equity securities.
No prediction can be made as to the effect, if any, that future sales or distributions of our Common Stock will have on the market price
of our Common Stock from time to time. Sales or distributions of substantial amounts of our Common Stock, or the perception that such
sales or distributions are likely to occur, could adversely affect the prevailing fair market price for our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our Common Stock must
come from increases in the fair market value of our Common Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to pay cash dividends on our Common Stock in the foreseeable future. We expect to retain future earnings, if any, for reinvestment
in our business. Also, any credit agreements, which we may enter into, may restrict our ability to pay dividends. Whether we pay cash
dividends in the future will be at the discretion of our Board and will be dependent upon our financial condition, results of operations,
cash requirements, future prospects and any other factors our Board deems relevant. Therefore, any return on your investment in our Common
Stock must come from increases in the fair market value of our Common Stock. For more information, see &ldquo;Dividend Policy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Your
percentage ownership in the Company may be diluted in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
percentage ownership in the Company may be diluted in the future because of equity awards that we may grant to our directors, officers
and other employees. In addition, we may issue equity as all or part of the consideration paid for acquisitions and strategic investments
that we may make in the future or as necessary to finance our ongoing operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_004"></A>CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Prospectus contains &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws. Forward-looking statements
give our current expectations or forecasts of future events. You can identify these statements because they do not relate strictly to
historical or current facts. In some cases, these forward-looking statements can be identified by words or phrases such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;aim,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;is/are likely to&rdquo; or other similar
expressions. They also appear in any discussion of future operating or financial performance. In particular, these include statements
relating to future actions, future performance of our products, level of expenses and anticipated expense reductions, the outcome of
any legal proceedings, and financial results. Although we believe that we are basing our expectations and beliefs on reasonable assumptions
within the bounds of what we currently know about our business and operations, there can be no assurance that our actual results will
not differ materially from what we expect or believe. The following factors could cause our actual results to differ from our expectations
or beliefs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential adverse impact on our business resulting from the Distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adverse effect from a decline in the securities markets or from catastrophic, unpredictable events like a global health pandemic;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the performance of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    general downturn in the economy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in government policy or regulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our ability to attract or retain key employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and other effects related to legal proceedings or investigations of governmental and self-regulatory organizations; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors (including the risks contained in the section titled &ldquo;Risk Factors&rdquo;) relating to our industry, our operations
    and results of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements are not
historical facts, and are based on current expectations, estimates and projections about our industry, management&rsquo;s beliefs and
certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly,
you are cautioned that any forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties
and assumptions that are difficult to predict. Although we believe that the expectations reflected in our forward-looking statements
are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law, we also disclaim any obligation to update our view of any such risks
or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
currently beneficially owns through its wholly owned subsidiary, DSS BioHealth Security, Inc., 125,073,621 shares of our Common Stock,
which represents 100% of the shares outstanding. These shares were acquired on August 21, 2020, upon closing of the Share Exchange Agreement.
DSS is deemed to be a beneficial owner of the shares of our Common Stock covered by this Prospectus because it has voting and dispositive
power over such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
_________, the DSS Board approved the Distribution. DSS will distribute part of its equity interest that it holds in us, consisting of
___ shares of our Common Stock, to DSS stockholders, except for the holders of the Affiliate Shares. Following the Distribution, DSS
will own an equity interest in us of approximately __%, giving DSS effective control over us. No approval of DSS Common Stockholders
is required in connection with the Distribution, and DSS stockholders will not have any appraisal rights in connection with the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution is subject to the satisfaction, or the DSS Board&rsquo;s waiver, of a number of conditions. In addition, DSS has the right
not to complete the Distribution if, at any time, the DSS Board determines, in its sole and absolute discretion, that the Distribution
is not in the best interests of DSS or its stockholders or is otherwise not advisable. For a more detailed description, see &ldquo;The
Distribution&mdash;Conditions to the Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasons
for the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution is the method by which DSS will begin to carry out the intention of management of DSS and the DSS Board to take the Company
public and to reward DSS stockholders via the issuance of our shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When
and How You Will Receive Company Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
will distribute to its stockholders, as a dividend, ___________ shares of our Common Stock for every share of DSS Common Stock outstanding,
except for the Affiliate Shares, as of 5:00 p.m., New York City time, ____________, the Record Date of the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Distribution, DSS will deliver the Common Stock to the distribution agent. V Stock Transfer LLC, the transfer agent and registrar
for our Common Stock, will serve as distribution agent in connection with the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you own DSS common stock on the Record Date, the shares of our Common Stock that you are entitled to receive in the Distribution will
be issued to your account as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Registered
    stockholders</I>. If you own your shares of DSS Common Stock directly through DSS&rsquo;s transfer agent, American Stock Transfer
    &amp; Trust Company, you are a registered stockholder. In this case, our transfer agent, V Stock Transfer LLC, which is serving as
    the distribution agent in connection with the Distribution, will credit the whole shares of our Common Stock you receive in the Distribution
    to a new book-entry account established on or shortly after the Distribution Date. Registration in book-entry form refers to a method
    of recording share ownership where no physical stock certificates are issued to stockholders, as is the case in the Distribution.
    You will be able to access information regarding your book-entry account holding our shares of Common Stock at V Stock Transfer LLC.
    Commencing on or shortly after the Distribution Date, the distribution agent will mail to you an account statement that indicates
    the number of whole shares of our Common Stock that have been registered in book-entry form in your name. We expect it will take
    the distribution agent up to two weeks after the Distribution Date to complete the distribution of the shares of our Common Stock
    and mail statements of holding to all registered stockholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<I>Street
    name</I>&rdquo; <I>or beneficial stockholders</I>. If you own your shares of DSS Common Stock beneficially through a bank, broker
    or other nominee, the bank, broker or other nominee holds the shares in &ldquo;street name&rdquo; and records your ownership on its
    books. If you own your shares of DSS Common Stock through a bank, broker or other nominee, your bank, broker or other nominee will
    credit your account with the whole Impact Shares that you receive in the Distribution on or shortly after the Distribution Date.
    We encourage you to contact your bank, broker or other nominee if you have any questions concerning the mechanics of having shares
    held in &ldquo;street name.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not issue any physical stock certificates to any stockholders, even if requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you sell any of your shares of DSS Common Stock on or before a Distribution Date, the buyer of those shares will in most circumstances
be entitled to receive the Impact Shares to be distributed in respect of the shares of DSS Common Stock you sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not asking DSS stockholders to take any action in connection with the Distribution. No approval of the holders of DSS Common Stock
is required for the Distribution. We are not asking you for a proxy and request that you not send us a proxy. We are also not asking
you to make any payment or surrender or exchange any of your shares of DSS Common Stock for Impact Shares. The number of outstanding
shares of DSS Common Stock will not change as a result of the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
of Shares You Will Receive</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Distribution Date, you will receive four Impact Shares for every share of DSS Common Stock you held on the Record Date, unless you
sell any of your shares of DSS Common Stock on or before a Distribution Date, in which case the buyer of those shares may be entitled
to receive the Impact Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the Distribution, we expect to have approximately [&bull;] holders of shares of our Common Stock, based on the number of DSS stockholders
and shares of DSS Common Stock outstanding. The actual number of holders of shares of our Common Stock will depend on the actual number
of holders of shares of DSS Common Stock outstanding on the Record Date. The Distribution will not affect the number of outstanding shares
of DSS Common Stock or any rights of DSS stockholders, although it is possible that the trading price of shares of DSS Common Stock immediately
following the Distribution may be lower than immediately prior to the Distribution because the trading price of DSS Common Stock will
no longer reflect the value of DSS ownership stake immediately before the Distribution. Nevertheless, we do not expect the trading price
of shares of DSS Common Stock immediately following the Distribution to be materially lower. However, until the market has fully analyzed
the value of DSS without the value represented by the Impact Shares distributed to DSS stockholders, the trading price of shares of DSS
Common Stock may fluctuate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
and Trading of our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of Common Stock are currently beneficially owned by DSS. Accordingly, there currently is no public trading
market for the Impact Shares. Our Common Stock is currently not listed for trading on any stock exchange or market. The Impact Shares
may be illiquid as we cannot predict whether any trading market will develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conditions
to the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that each Distribution will be effective on the Distribution Date, provided that the following conditions shall have been satisfied
or waived by DSS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    DSS Board shall have authorized and approved the Distribution and not withdrawn such authorization and approval, and shall have declared
    the dividend of our Common Stock to DSS stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    SEC shall have declared effective our Registration Statement on Form S-1, of which this Prospectus is a part, under the Securities
    Act, and no stop order suspending the effectiveness of our Registration Statement shall be in effect and no proceedings for that
    purpose shall be pending before or threatened by the SEC;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal restraint or prohibition
    preventing consummation of the Distribution shall be in effect, and no other event outside the control of DSS shall have occurred
    or failed to occur that prevents the consummation of the Distribution; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    other events or developments shall have occurred prior to the Distribution Date that, in the judgment of the DSS Board, would result
    in the Distribution having a material adverse effect on DSS or its stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
shall, in its sole and absolute discretion, determine the Record Date, the Distribution Date and all terms of the Distribution, including
the form, structure and terms of any transactions and/or offerings to effect the Distribution and the timing of and conditions to the
consummation thereof. In addition and notwithstanding anything to the contrary set forth in this Prospectus, DSS may at any time and
from time to time until the Distribution decide to abandon the Distribution including by accelerating or delaying the timing of the consummation
of all or part of the Distribution or modifying or changing the terms of the Distribution if, at any time, the DSS Board determines,
in its sole and absolute discretion, that the Distribution is not in the best interests of DSS or its stockholders or is otherwise not
advisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasons
for Furnishing this Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this Prospectus solely to provide information to DSS&rsquo;s stockholders who will receive Impact Shares in the Distribution.
You should not construe this Prospectus as an inducement or encouragement to buy, hold or sell any of our securities or any securities
of DSS. We believe that the information contained in this Prospectus is accurate as of the date set forth on the cover. Changes to the
information contained in this Prospectus may occur after that date, and neither we nor DSS undertakes any obligation to update the information
except in the normal course of our and DSS&rsquo;s public disclosure obligations and practices and except as required by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_005"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
to U.S. Holders of DSS Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax consequences to holders of DSS Common Stock in connection with the Distribution.
This summary is based on the Code, the Treasury Regulations promulgated under the Code and judicial and administrative interpretations
of those laws, in each case as in effect and available as of the date of this Prospectus and all of which are subject to change at any
time, possibly with retroactive effect. Any such change could affect the tax consequences described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is limited to holders of DSS Common Stock that are U.S. Holders, as defined immediately below, that hold their DSS Common Stock
as a capital asset. A &ldquo;U.S. Holder&rdquo; is a beneficial owner of DSS Common Stock that is, for U.S. federal income tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual who is a citizen or a resident of the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of
    the United States or any state thereof or the District of Columbia;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate the income of which is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust if a court within the United States is able to exercise primary jurisdiction over its administration and one or more U.S. persons
    have the authority to control all of its substantial decisions or, in the case of a trust that was treated as a domestic trust under
    law in effect before 1997, a valid election is in place under applicable Treasury Regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not discuss all tax considerations that may be relevant to stockholders in light of their particular circumstances, nor
does it address the consequences to stockholders subject to special treatment under the U.S. federal income tax laws, such as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers
    or traders in securities or currencies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    entities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    financial institutions or insurance companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real
    estate investment trusts, regulated investment companies or grantor trusts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who acquired DSS Common Stock pursuant to the exercise of employee stock options or otherwise as compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    who own, or are deemed to own, 10% or more, by voting power or value, of DSS equity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    owning DSS Common Stock as part of a position in a straddle or as part of a hedging, conversion or other risk reduction transaction
    for U.S. federal income tax purposes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    former citizens or long-term residents of the United States or green card holders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    who are subject to the alternative minimum tax; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who own DSS Common Stock through partnerships, certain trusts or other pass-through entities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not address any U.S. state, local or non-U.S. tax consequences or any estate, gift or other non-income tax consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership, or any other entity treated as a partnership for U.S. federal income tax purposes, holds DSS Common Stock, the tax treatment
of a partner in that partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner
or partnership should consult its own tax advisor as to its tax consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>YOU
SHOULD CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF THE DISTRIBUTION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution will be treated as a taxable non-liquidating distribution to DSS stockholders, As such, each U.S. stockholder receiving
Impact Shares in the Distribution will be treated as if such stockholder had received a distribution in an amount equal to the fair market
value of our Common Stock received, which would result in (1) a taxable dividend to the extent of such stockholder&rsquo;s pro rata share
of Impact&rsquo;s current and accumulated earnings and profits, (2) a reduction in such stockholder&rsquo;s basis (but not below zero)
in DSS Common Stock to the extent the amount received exceeds such stockholder&rsquo;s share of earnings and profits and (3) a taxable
gain to the extent the amount received exceeds the sum of the amount treated as a dividend and the stockholder&rsquo;s basis in the DSS
Common Stock. Any such gain would generally be a capital gain if the DSS Common Stock is held by such stockholder as a capital asset
on the Distribution Date and subject to long-term capital gain treatment if the DSS Common Stock has been held by such stockholder for
more than one year on the Distribution Date. Distributions treated as dividends will be subject to tax at favorable long-term capital
gains rates provided that the stockholder has held his DSS stock for the period required for preferential dividend tax treatment generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. stockholder also may be subject to information reporting with respect to the Distribution. In addition, such stockholder may be
subject to &ldquo;backup withholding&rdquo; on the Distribution, unless such stockholder provides proof of any applicable exemption or
a correct taxpayer identification number, and otherwise complies with the requirements of the backup withholding rules. Backup withholding
is not an additional tax, and it may be refunded or credited against a U.S. stockholder&rsquo;s U.S. federal income tax liability if
the required information is timely supplied to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="gfd_007"></A><B>DETERMINATION
OF OFFERING PRICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
consideration will be paid for the Impact Shares in the Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="gfd_008"></A><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend, following the Distribution, to pay cash dividends on our Common Stock in the foreseeable future. We expect to retain future
earnings, if any, for reinvestment in our business. Any credit agreements which we may enter into may restrict our ability to pay dividends.
The payment of dividends in the future will be subject to the discretion of our Board and will depend, among other things, on our financial
condition, results of operations, cash requirements, future prospects and any other factors our Board deems relevant. There can be no
assurance that a payment of a dividend will occur in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="gfd_009"></A><B>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of September 30, 2022. The following table should be read in conjunction
with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our historical consolidated
financial statements and the notes thereto included elsewhere in this Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
                                            of</B></FONT></P>
                    <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
                    30, 2022</B></FONT></P></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual</FONT></TD><TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash
    equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo; equity:</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $.001
    par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on December 31, 2021) &nbsp;</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</FONT></TD><TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital &nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit &nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,092,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; equity of the company &nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,091,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
    interest in subsidiary &nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,115,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholder&rsquo;s
    equity &nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,206,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total capitalization</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,206,000</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="gfd_010"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited
and unaudited financial statements and related notes, respectively, beginning on page F-1 below of this Prospectus. Some of the information
contained in this discussion and analysis constitutes forward-looking statements that involve risks and uncertainties. Actual results
could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences
include, but are not limited to, those discussed below and elsewhere in this Prospectus, particularly under the section titled &ldquo;Cautionary
Statement Concerning Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Impact BioMedical, Inc. targets urgent medical
needs and expands the borders of medical and pharmaceutical science. Impact drives mission-oriented research and development, and
commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new science with
strategic partnerships, Impact Bio provides advances in drug discovery for the prevention, inhibition, and treatment of
neurological, oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to
combat diabetes and functional fragrance formulations aimed at the industrial and medical industry. The research and development
efforts are primarily conducted in collaboration with GRDG Sciences, LLC (&ldquo;GRDG&rdquo;) and with the expertise of Mr.
Daryl Thompson as its Director of Scientific Initiatives. We have initiated research regarding universal therapeutics as part of an
attempt to help address some of the world&rsquo;s deadliest diseases.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business model of Impact BioMedical revolves around a Licensing methodology for commercialization, sales and distribution. Impact
develops valuable and unique patented technologies which will be licensed to pharmaceutical, food, large consumer package goods
companies and venture capitalists in exchange for usage licensing and royalties. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioLife Science, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    Biomedical, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioLife, Inc.; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
    Sense, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Impact BioLife Science, Inc</U>.</I> We
are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Global Biomedical, Inc.</U></I> We own 90.91%
of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy Tang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Global BioLife, Inc</U></I>. Through our
majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global BioLife, Inc. The other equity owner
is Holista CollTech Limited (&ldquo;Holista&rdquo;) (10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Sweet Sense, Inc</U></I><U>.</U> We are
the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar, Inc. (&ldquo;BioLife Sugar&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_002.jpg" ALT="" STYLE="height: 647px; width: 500px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our majority-owned subsidiary Global BioLife, we own or have rights to a portfolio of biomedical intellectual property, including intellectual
property assigned to Global BioLife by GRDG. Global BioLife leverages its scientific know-how and intellectual property rights to develop
various emerging technologies, including biopharmaceuticals, antivirals, antimicrobials, sugar alternatives, insect repellents, fragrances,
bioplastics and natural preservatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotech
and Impact BioMedical have several important and valuable products, technology or compounds that are in continuing development and/or
licensing stages:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Linebacker</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Linebacker is a multi-faceted therapeutic platform
intended for metabolic, neurologic, cancer, and infectious diseases. Our process features a molecular tuning technique that is
believed to modify a natural compound to induce potency, efficacy, bioavailability, and trans-membrane permeability while maintaining
safety, toxicity, and tolerability. Natural compounds used in the Linebacker platform may have potential in treating and
preventing a range of diseases by inhibiting TNF-alpha and indication specific causes (e.g. neurology, anti-inflammatory diseases, oncology).
Linebacker&rsquo;s intended use is subject to FDA regulation, and the FDA must approve any drug or biologic product before it can be
marketed in the United States. In addition, prior to being sold outside the United States, our Linebacker technology must be approved
by the regulatory agencies of foreign governments. Prior to filing a new drug application or biologics license application with the FDA,
we would have to perform extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical
testing which could take several years and may require substantial expenditures. To date, we have not conducted no preclinical testing
or clinical trials (human or otherwise) on Linebacker, nor have we received any FDA approval to conduct such any such preclinical testing
or clinical trials. Further, because we have not conducted any testing or studies on Linebacker, we are not able to substantiate or demonstrate
that Linebacker will function as planned, nor can we seek FDA approval to market and sell Linebacker. To date, we have not performed
the extensive preclinical testing necessary to begin any clinical trials for Linebacker; and until we have conducted the necessary clinical
trials, we will not be able to seek FDA approval for Linebacker. Currently, we have no plans to conduct preclinical testing or clinical
trials (human or otherwise) involving Linebacker.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage our
Linebacker technology. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any
such agreements or that such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Laetose</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laetose
technology is derived from a unique combination of sugar and other compounds, which is intended to inhibit the inflammatory response
of sugar alone. Based on our intended use for Laetose, Laetose is intended to be an high-intensity sweetener, yet to
be determined by the FDA. High-intensity sweeteners are commonly used as sugar substitutes or sugar alternatives because they are
many times sweeter than sugar but contribute only a few to no calories when added to foods. High-intensity sweeteners, like all other
ingredients added to food in the United States, must be safe for consumption. Further, a high intensity sweetener is regulated as a food
additive, unless its use as a sweetener is generally recognized as safe (GRAS). The use of a food additive must undergo premarket review
and approval by FDA before it can be used in food. In contrast, use of a GRAS substance does not require premarket approval. Rather,
the basis for a GRAS determination based on scientific procedures is that experts qualified by scientific training and experience to
evaluate its safety conclude, based on publicly available information, that the substance is safe under the conditions of its intended
use. A company can make an independent GRAS determination for a substance with or without notifying FDA. Regardless of whether a substance
is approved for use as a food additive or its use is determined to be GRAS, scientists must determine that it meets the safety standard
of reasonable certainty of no harm under the intended conditions of its use. This standard of safety is defined in FDA&rsquo;s regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of this date, we have not performed any scientific testing to determine the safety of Laetose for human consumption, and no qualified
experts have evaluated the safety of Laetose. Therefore, we have not been able to make any determination that Laetose is safe for human
consumption. Currently, we have no plans to conduct any scientific testing relating to the safety of Laetose, and any there can be no
guarantee that any such testing will conclude that Laetose is safe for human consumption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Laetose.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently seeking to license Laetose by way of a business development agreement between Sweet Sense, Inc., a joint venture
established by Global BioLife and Quality Ingredients, LLC (&ldquo;Sweet Sense&rdquo;), and BFS. Sweet Sense was established for the
development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet
Sense Inc. from Quality Ingredients, LLC for $91,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Functional
Fragrance Formulation (&ldquo;3F&rdquo;)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3F is a unique formulation of specialized ingredients
from naturally occurring botanical sources with intended application as an insect repellent and an antimicrobial. Currently,
approximately 20 combination insect repellent-sunscreen drug products are available for consumers. These products consist of one of three
insect repellents (N,N-diethyl-meta-toluamide (DEET), oil of citronella, or IR3535) and a sunscreen component (one or more sunscreen
ingredients). Internal repellent tests results demonstrated the prevention and limitation of insect bites up to eight (8) hours. To date,
we have not conducted studies to establish marketing claims.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage 3F.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equivir</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equivir/Nemoviris a novel blend of naturally occurring
compounds that are sourced from fruits, vegetables, and other natural substances. Equivir is designed to work by impeding virulence while
also blocking multiple methods used by viruses to infect and replicate in host cells, following deployment in a manner similar to a vitamin,
and this intended use is subject to FDA regulation. The FDA must approve any drug or biologic product before it can be marketed in
the United States. In addition, prior to being sold outside the United States, our Equivir technology must be approved by the regulatory
agencies of foreign governments. Prior to filing a new drug application or biologics license application with the FDA, we would have
to perform extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical testing
which could take several years and may require substantial expenditures. To date, we have conducted no preclinical testing or clinical
trials (human or otherwise) on Equivir. Further, because we have not conducted any testing or studies on Equivir, we are not able to
substantiate or demonstrate its benefits as a health supplement or seek FDA approval at this time. Currently, we have no plans to conduct
any preclinical testing or clinical trials (human or otherwise) involving Equivir.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Equivir.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other Equivir analogues are under development and provisional patents have been filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018, and established a fiscal year end
of December 31st. The Company issued 9,000 shares to Global BioMedical Pte. Ltd., which was wholly&ndash;owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&ldquo;SGXST&rdquo;). On March 31, 2020, the Company issued 125,064,621 shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&rsquo;s common
stock issued and outstanding was split into nine shares of the Company&rsquo;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 12, 2020 Alset International Limited (&ldquo;Alset&rdquo;),
a related party, Global BioMedical Pte Ltd., a related party, DSS, Inc (&ldquo;DSS&rdquo;), a related party, and DSS BioHealth Security
Inc. (&ldquo;DSS BioHealth&rdquo;), a related party, signed Term Sheets and subsequently on April 21, 2020, these four companies entered
into Share Exchange Agreement (&ldquo;Share Exchange&rdquo;), based on which Global BioMedical Pte Ltd., agreed to sell all of
the issued and outstanding shares of the Company to DSS BioHealth in exchange for the combination of common and preferred shares of DSS.
Under the terms of the Share Exchange, DSS issued 483,334 shares of the DSS Common Stock nominally valued at $6.48 per share, and 46,868
newly issued shares of the DSS Series A Convertible Preferred Stock (&ldquo;<U>Series A Preferred Stock</U>&rdquo;), with a stated value
of $46,868,000, or $1,000 per share, for a total consideration valued at $50 million. Due to several factors, including a discount for
illiquidity, the value of the Series A Preferred Stock was discounted from $46,868,000 to $35,187,000, thus reducing the final consideration
given to approximately $38,319,000. The Company&rsquo;s Chairman, Heng Fai Ambrose Chan, a related party, who is also the largest shareholder
of Alset, at the time of the signing of the Share Exchange Agreement was the beneficial owner of approximately 18.3% of the outstanding
shares of DSS and is the Chairman of the Board of Directors of DSS. On August 21, 2020, the transaction was concluded, and the Company
became a direct wholly owned subsidiary of DSS BioHealth. In connection with the acquisition, and the related accounting determination,
DSS BioHealth has elected to apply push-down accounting and reflect in its financial statements of Impact BioMedical, the fair value
of its assets and liabilities. The Company&rsquo;s Consolidated Financial Statements for periods following the close of the acquisition
are labeled &ldquo;Successor&rdquo; and reflect DSS BioHealth&rsquo; s basis in the fair values of the assets and liabilities of Impact
BioMedical. All periods prior to the closing of the acquisition reflect the historical accounting basis in the Company&rsquo;s assets
and liabilities and are labeled &ldquo;Predecessor&rdquo;. The fair value of the consideration transferred was approximately $38,319,000.
Utilizing an income approach, the Company has completed its valuations of certain developed technology and pending patents assets acquired
in the transaction as well the fair value of the non-controlling interests. More specifically, a Multi-Period Excess Earnings Method
(&ldquo;MPEEM&rdquo;) estimates the value of an intangible asset by quantifying the amount of residual (or excess) estimated cash flows
generated by the asset and discounting those cash flows to the present. These have been valued at approximately $22,260,000 and $3,910,000,
respectively, and are included on the Consolidated Balance Sheet on December 31, 2020. Estimated useful life of these assets is
twenty years, based on the remaining terms of the related patents, with annual amortization approximating $1,112,000. The Company has
also completed its valuation of goodwill and deferred tax liabilities of Impact BioMedical, and has recorded goodwill of approximately
$25,093,000, driven by other intangible assets that do not qualify for separate recognition, and a deferred tax liability of approximately
$5,234,000. The goodwill is not deductible for tax purposes and has been allocated to Impact BioMedical in totality as a single reporting
unit. The Company is committed to both funding research and developing intellectual property portfolio.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated any revenues from operations. We cannot guarantee we will be successful in our business
operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible delays our
research, testing and marketing efforts or wider economic downturns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Months Ended September 30, 2022, compared
to Nine Months Ended September 30, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of operations for the nine months ended September 30, 2022, as compared to nine months ended September 30,
2021.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost
and expenses:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,
    2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,
    2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Sales, general and administrative compensation</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">286,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">282,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">704,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">645,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-style: italic; text-align: left">Total costs and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,414,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,111,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Selling,
general and administrative compensation</U> costs increased 1% for the nine months ended September 30, 2022, as compared to the nine
months ended September, 2021 due to increases in employee related cost to the Company. Also, the Company is allocated certain administrative
labor cost from DSS as shared resources which approximates $17,000 per month during the nine months ended September 30, 2022, as compared
to $9,300 per month during the nine months ended September 30, 2021.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Depreciation
and Amortization expense</U> of $835,000 for the nine months ended September 30, 2022, and 2021 represents the amortization of the associated
with the developed technology and patents acquired as part of the acquisition of Impact BioMedical by DSS. Amortization of these assets
began on January 1, 2021, and will have a 20-year term.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Professional
fees</U> increased 71% for the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021 mostly
due to increases in consulting and legal services associated with developing and implementing Impact BioMedical&rsquo;s business plan.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Research
and development</U> costs represent costs consisted primarily of independent, third-party testing of the various properties of each
technology the Company owns possesses as well as research on new technologies. Research and development increased 9% for the nine months
ended September 30, 2022, as compared to the nine months ended September 30, 2021 primarily due to exploration and development of new
technologies during 2022.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
general expenses </U>consist primarily of office supplies, IT support, travel and insurance costs. These costs remained flat for the
nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
income (expense):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,
    2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Interest Income</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">21,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">83,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-75</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest Expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(133,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(178,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-25</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other Income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-12</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-style: italic; text-align: left">Total other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(46,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(20,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other income and expense as of September 30, 2022, represents interest income and origination fee income associated with the Company&rsquo;s
notes receivable offset by interest expense on its note payable to DSS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,
    2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,718,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,903,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in net loss of 95% for the nine months ended September 30, 2022, as compared to the nine months
ended September 30, 2021 is driven by the increase in professional fees, research and development costs, and selling, general
and administrative compensation costs as the Company continues to develop and implement its business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
Year Ended December 31, 2021, compared to Year Ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of operations for the year ended December 31, 2021, as compared to year ended December 31, 2020, illustrating the results of operations
prior to and subsequent to the acquisition of Impact BioMedical, Inc., by DSS BioHealth Security, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost
and expenses:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor
    Period <BR> from August 22, 2020, to December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Predecessor
    Period <BR> from January 1, 2020, to August 21,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">%
    Change (1)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Costs
    and expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Selling,
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">general and administrative compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">398,000</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81,701</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">387</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Amortization</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,112,941</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional
    fees</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">551,796</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">132,220</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">151,838</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">317</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,080,051</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">184,284</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">329,409</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">486</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    general expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,553</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,825</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,449</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">631</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    costs and expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,185,341</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">404,030</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">492,696</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">688</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Reflects the change in percentage from the
successor period.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Selling,
general and administrative compensation</U> costs, were $ 397,999 for the year ended December 31, 2021, as compared to the $81,701
during the Successor period of August 22, 2020 through December 31, 2020 and $0 for the Predecessor period of January 1, 2020 through
August 21, 2020, due to the addition of two employees to the Company. Also, the Company is allocated certain administrative labor cost
from DSS as shared resources which approximates $17,000 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Research
and development</U> costs of $1,080,051 for the year ended December 31, 2021, as compared to the $184,284 during the Successor
period of August 22, 2020 through December 31, 2020 and $329,409 for the Predecessor period of January 1, 2020 through August 21, 2020
represents costs consisted primarily of independent, third-party testing of the various properties each technology possesses. During
the twelve months ended December 31, 2021, the Company spent approximately spent approximately $45,000, $102,000, and $293,000 on its
3F, Linebacker, and Laetose technologies. The remaining $640,000 was spent on various other technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Professional
fees</U> of $551,796 for the year ended December 31, 2021, as compared to the $132,220 during the Successor period of August 22,
2020 through December 31, 2020 and $151,838 for the Predecessor period of January 1, 2020 through August 21, 2020 increased 317% mostly
due to increases in consulting and legal services associated with developing and implementing Impact BioMedical&rsquo;s business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amortization
expense</U> was $1,112,941 and $0 during the years ended December 31, 2021, and 2020, respectively, and represents the amortization
of the associated with the developed technology and patents acquired as part of the acquisition of Impact BioMedical by DSS. Amortization
of these assets began on January 1, 2021, and will have a 20-year term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
general expenses </U>of $42,553 for the year ended December 31, 2021, as compared to the $5,825 during the Successor period of
August 22, 2020 through December 31, 2020 and $11,449 for the Predecessor period of January 1, 2020 through August 21, 2020 consist primarily
of office supplies, IT support, travel and insurance costs. These costs increased 631% year over year as the Company significantly increased
operations in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
expense:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor
                                            Period <BR> from August 22, 2020, to</FONT></P>
                                                                  <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
                                            31,</FONT></P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Predecessor
    Period <BR> from January 1, 2020, to August 21,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-left: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">%
    Change (1)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    Income (Expense)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    Income</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">164,794</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    Expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(300,010</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    Income </FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">77,350</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 20pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    other income</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(57,866</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Reflects the change in percentage from the
successor period.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other income and expense as of December 31, 2021, is driven by interest income and origination fee income associated with the
Company&rsquo;s Promissory Note 2 offset by interest expense on its note payable to DSS. Also, the Company, through its distribution
agreement, as an agent with BioMed Technologies Asia Pacific Holdings Limited, sold $82,664 of product during the year ended December
31, 2021. This was offset by costs of approximately $78,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
tax benefit:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Successor</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Successor Period <BR> from August 22, 2020, to December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Predecessor Period <BR> from January 1, 2020, to August 21,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,395,146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">82,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Reflects the change in percentage from the successor period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in income tax benefit during year ended December 31, 2021, as compared to the year ended December 31, 2020, is a direct result
in the increase in loss from operations year over year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor
    Period <BR> from August 22, 2020, to December 31,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Predecessor
    Period <BR> from January 1, 2020, to August 21,</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">%
    Change (1)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,848,061</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(322,030</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-left: Black 1.5pt solid; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(492,697</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">127</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Reflects the change in percentage from the
successor period.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in net loss of 127% during year ended December 31, 2021, as compared to the year ended December 31, 2020, is driven by
increased head count at the Company, costs for continued research and development of the acquired product formulations, the amortization
of the acquired technology assets, and the utilization of consultants and legal services associated with developing and implementing
Impact BioMedical&rsquo;s business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
expense:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIQUIDITY
AND CAPITAL RESOURCES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has historically met its liquidity and
capital requirements primarily through the sale of its equity securities and debt financings. As of September 30, 2022, the Company
had cash of approximately $101,000. As of September 30, 2022, the Company believes that it has sufficient availability
to cash via its revolving promissory note with DSS to meet its cash requirements for at least the next 12 months from the filing date
of this Prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
Accounting Policies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements and related disclosures in conformity with generally accepted accounting principles in the U.S. (&ldquo;U.S.
GAAP&rdquo;) requires management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial
statements and accompanying notes. The Company&rsquo;s consolidated financial statements for the year ended December 31, 2021,
describe the significant accounting policies and methods used in the preparation of the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&rsquo;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Investments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in equity securities with a readily
determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included
in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment,
plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included
in earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For equity method investments, the Company regularly
reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary,
the investment is written down to fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Goodwill
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests if an
event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with
the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination
that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative
factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors
affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that
it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to
a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely
than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes multiple valuation
methodologies, including a market approach (market price multiples of comparable companies) and an income approach (discounted cash flow
analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection
of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital,
and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable
and based on available market information, but variations in any of the assumptions could result in materially different calculations
of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to
make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections
are derived from one-year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management.
Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely
to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and
unrecognized assets and liabilities of the reporting unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 15, 2020, a third party engaged by the Company had completed a valuation of the acquisition price of ImpactBio by DSS BioHealth
Security, Inc. It was determined that DSS BioHealth Security, Inc.&rsquo;s parent company, DSS (NYSE: DSS) publicly traded stock price
on the valuation date of August 21, 2020, reflected all relevant data regarding the transaction and was applied to both the common A
shares and preferred A shares given as consideration for the acquisition of ImpactBio. The preferred A shares contained certain sell
restrictions and a liquidity discount was applied. Further, a valuation of the assets acquired was also completed as of the valuation
date on March 25, 2021. As no factors changed between, the completion of the valuation of the consideration given and the completion
valuation of the assets received no impairment was recorded during the fiscal year end December 31, 2021. Subsequently, as no events
or circumstances occurred as of September 30, 2022, no impairment of goodwill was recorded for the nine months ended September
30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair values of acquired intangibles
are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets
are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are
not amortized but are reviewed for impairment at least annually as of December 31<SUP>st</SUP>, or more frequently whenever events or
changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment is tested
under ASC 350. No impairment was recognized during the years ended December 31, 2021, or 2020. Subsequently, as no events or circumstances
occurred as of September 30, 2022, no impairment of goodwill was recorded for the nine months ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continuing
Operations and Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&rsquo;s management intends to take actions necessary to continue as a going concern. Management&rsquo;s
plans concerning these matters includes, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Related
Party Transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&rsquo;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of December 31, 2021, this funding approximates $43,000 per month, and incurred $509,176 in expenses. For the year
ended December 31, 2021, the Company incurred expenses of $509,176. The Company incurred expenses of $329,409 (predecessor &ndash; January
1, 2020, to August 21, 2020) and $184,284 (successor &ndash; August 22, 2020 to December 31, 2020). On December 31, 2021,
and December 31, 2020, the Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, Inc. (&ldquo;DSS&rdquo;) on behalf of the Company which are passed through
to the Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on
estimated time spent on behalf of the Company. These costs approximate $17,000 per month. As of December 31, 2021, the Company incurred
$155,361 in related expenses. The Company incurred expenses of $0 (predecessor &ndash; January 1, 2020, to August 21, 2020) and
$26,359 (successor &ndash; August 22, 2020 to December 31, 2020).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Off-Balance
Sheet Arrangements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any material off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition,
financial statements, revenues or expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_001"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introduction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we are a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April
14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research
in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Impact BioMedical, Inc. targets urgent medical
needs and expands the borders of medical and pharmaceutical science. Impact drives mission-oriented research and development, and
commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new science with
strategic partnerships, Impact Bio provides advances in drug discovery for the prevention, inhibition, and treatment of
neurological, oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to
combat diabetes and functional fragrance formulations aimed at the industrial and medical industry. The research and development
efforts are primarily conducted in collaboration with GRDG Sciences, LLC (&ldquo;GRDG&rdquo;) and with the expertise of Mr.
Daryl Thompson as its Director of Scientific Initiatives. We have initiated research regarding universal therapeutics as part of an
attempt to help address some of the world&rsquo;s deadliest diseases.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
                                            BioLife Science, Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
                                            Biomedical, Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
                                            BioLife, Inc.; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
                                            Sense, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Impact BioLife Science, Inc</U>.</I> We
are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Global Biomedical, Inc.</U></I> We own 90.91%
of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy Tang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Global BioLife, Inc</U></I>. Through our
majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global BioLife, Inc. The other equity owner
is Holista CollTech Limited (&ldquo;Holista&rdquo;) (10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Sweet Sense, Inc</U></I><U>.</U> We are
the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar, Inc. (&ldquo;BioLife Sugar&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_003.jpg" ALT="" STYLE="height: 647px; width: 500px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our majority-owned subsidiaries, Global BioLife and Impact BioLife, we own or have rights to a portfolio of biomedical intellectual property,
including intellectual property assigned to Global BioLife by GRDG. Global BioLife leverages its scientific know-how and intellectual
property rights to develop various emerging technologies, including biopharmaceuticals, antivirals, antimicrobials, sugar alternatives,
insect repellents, fragrances, bioplastics and natural preservatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Linebacker</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Linebacker is a multi-faceted therapeutic platform
intended for metabolic, neurologic, cancer, and infectious diseases. Our process features a molecular tuning technique that is intended
to modify a natural compound to induce potency, efficacy, bioavailability, and trans-membrane permeability while maintaining safety,
toxicity, and tolerability. Natural compounds used in the Linebacker platform is designed to treat and prevent a range
of diseases by inhibiting TNF-alpha and indication specific causes (e.g., neurology, anti-inflammatory diseases, oncology). Linebacker&rsquo;s
intended use is subject to FDA regulation, and the FDA must approve any drug or biologic product before it can be marketed in the United
States. In addition, prior to being sold outside the United States, our Linebacker technology must be approved by the regulatory agencies
of foreign governments. Prior to filing a new drug application or biologics license application with the FDA, we would have to perform
extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical testing which could
take several years and may require substantial expenditures. To date, we have not conducted preclinical testing or clinical trials (human
or otherwise) on Linebacker nor have we received any FDA approval to conduct such any such preclinical testing or clinical trials. Further,
because we have not conducted any testing or studies on Linebacker, we are not able to substantiate or demonstrate that Linebacker will
function as planned, nor can we seek FDA approval to market and sell Linebacker. To date, we have not performed the extensive preclinical
testing necessary to begin any clinical trials for Linebacker; and until we have conducted the necessary clinical trials, we will not
be able to seek FDA approval for Linebacker. Currently, we have no plans to conduct preclinical testing or clinical trials (human or
otherwise) involving Linebacker.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage our
Linebacker technology. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any
such agreements or that such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Laetose</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laetose technology is derived from a unique combination
of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory response of sugar alone. Based on our
intended use for Laetose, Laetose may be classified as a high-intensity sweetener by the FDA. High-intensity sweeteners are commonly
used as sugar substitutes or sugar alternatives because they are many times sweeter than sugar but contribute only a few to no calories
when added to foods. High-intensity sweeteners, like all other ingredients added to food in the United States, must be safe for consumption.
Further, a high intensity sweetener is regulated as a food additive, unless its use as a sweetener is generally recognized as safe (GRAS).
The use of a food additive must undergo premarket review and approval by FDA before it can be used in food. In contrast, use of a GRAS
substance does not require premarket approval. Rather, the basis for a GRAS determination based on scientific procedures is that experts
qualified by scientific training and experience to evaluate its safety conclude, based on publicly available information, that the substance
is safe under the conditions of its intended use. A company can make an independent GRAS determination for a substance with or without
notifying FDA. Regardless of whether a substance is approved for use as a food additive or its use is determined to be GRAS, scientists
must determine that it meets the safety standard of reasonable certainty of no harm under the intended conditions of its use. This standard
of safety is defined in FDA&rsquo;s regulations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of this date, we have not performed any scientific testing to determine the safety of Laetose for human consumption, and no qualified
experts have evaluated the safety of Laetose. Therefore, we have not been able to make any determination that Laetose is safe for human
consumption. Currently, we have no plans to conduct any scientific testing relating to the safety of Laetose, and any there can be no
guarantee that any such testing will conclude that Laetose is safe for human consumption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Laetose.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently seeking to license Laetose by way of a business development agreement between Sweet Sense, Inc., a joint venture
established by Global BioLife and Quality Ingredients, LLC (&ldquo;Sweet Sense&rdquo;), and BFS. Sweet Sense was established for the
development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet
Sense Inc. from Quality Ingredients, LLC for $91,000. Sweet Sense is now an 81.8% owned subsidiary of the Impact BioMedical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Functional
Fragrance Formulation (&ldquo;3F&rdquo;)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F
is a unique formulation of specialized ingredients (e.g., terpenes) from botanical sources with potential application as an insect
repellent and an antimicrobial. Currently, approximately 20 combination insect repellent-sunscreen drug products are available for consumers.
These products consist of one of three insect repellents (N,N-diethyl-meta-toluamide (DEET), oil of citronella, or IR3535) and a sunscreen
component (one or more sunscreen ingredients). Internal repellent test results demonstrated the prevention and limitation of insect bites
up to eight (8) hours. To date, we have not conducted studies to establish marketing claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage
3F. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or
that such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equivir</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir/Nemovir
is a novel blend of naturally occurring compounds that are sourced from fruits, vegetables, and other natural substances. Equivir is
designed to work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells,
following deployment in a manner similar to a vitamin, and this intended use is
subject to FDA regulation. The FDA must approve any drug or biologic product before it can be marketed in the United States. In addition,
prior to being sold outside the United States, our Equivir technology must be approved by the regulatory agencies of foreign governments.
Prior to filing a new drug application or biologics license application with the FDA, we would have to perform extensive clinical trials,
and prior to beginning any clinical trial, we would need to perform extensive preclinical testing which could take several years and
may require substantial expenditures. To date, we have conducted no preclinical testing or clinical trials (human or otherwise) on Equivir.
Further, because we have not conducted any testing or studies on Equivir, we are not able to substantiate or demonstrate its benefits
as a health supplement or seek FDA approval at this time. Currently, we have no plans to conduct any preclinical testing or clinical
trials (human or otherwise) involving Equivir.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Equivir.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other Equivir analogues are under development and provisional patents have been filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
Products</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Though
not of substantive material impact to our business currently, we have three additional products; VanXin, Quantum, and CRST1, which we
believe to have high potentiality of viability and commercialization. VanXin is a natural food preservative booster made up of natural
occurring compounds, that can extend the shelf life of various products. Quantum, our Patent Cliff solution, uses advanced methods to
modify natural compounds and existing drugs, while maintaining the safety attributes of the original molecules. CRST 1 is our advanced
adjuvant for next generation vaccine applications. We intend to commercialize these future portfolio products through partnerships with
large manufactures in the pharmaceutical, food, health and beauty, and nutraceutical industries. We will leverage their product development,
commercialization, and distribution capabilities to take products to market through a licensing and/or private label sales model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>BioMed
Technologies Asia Pacific Holdings Limited Investment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, the Company, entered into a subscription agreement (the &ldquo;Subscription Agreement&rdquo;) with BioMed Technologies
Asia Pacific Holdings Limited (&ldquo;BioMed&rdquo;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase 525 ordinary shares or 4.99% of BioMed at a purchase price of approximately $630,000. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Subscription Agreement, on December 9, 2020, the Company entered into an exclusive distribution agreement (the
&ldquo;Distribution Agreement&rdquo;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed
products, which focus on manufacturing natural probiotics, to resellers. The Distribution Agreement is for an initial term of ten
years, and upon expiration, renews for additional successive one-year terms unless either party elects not to renew. The
Distribution Agreement may be terminated by either party for cause as specified therein. Pursuant to the Distribution Agreement,
BioMed provides its products to the Company at the prices set forth in the Distribution Agreement, such prices being firm and not
subject to increase except for as provided in the Distribution Agreement. Further, pursuant to the Distribution Agreement, BioMed is
solely responsible for all costs and expenses relating to the Company&rsquo;s distribution of BioMed&rsquo;s products. This
investment is valued at cost as it does not have a readily determined fair value. As of December 31, 2021, the Company has generated
approximately $83,000 through the sale of BioMed&rsquo;s products under the Distribution Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&rsquo;s PGut Premium Probiotics&reg;,
PGut Allergy Probiotics&reg;, PGut SupremeSlim Probiotics&reg;, PGut Kids Probiotics&reg;, and PGut Baby Probiotics&reg;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vivacitas
Investment </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &ldquo;Vivacitas Agreement #1&rdquo;) with Vivacitas Oncology
Inc. (&ldquo;Vivacitas&rdquo;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&rsquo;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&rsquo;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&ldquo;Seller&rdquo;) to purchase from
the Seller&rsquo;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&ldquo;IOPL&rdquo;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&rsquo;s board of directors and its largest shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&ldquo;Vivacitas Agreement #2&rdquo;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&rsquo;s equity position in Vivacitas to approximately 120,000
shares or 16% as of September 30, 2022. As of September 30, 2022, and December 31, 2021, the fair value of the Company&rsquo;s investment
in Vivacitas is not readily available, and therefore is recorded at cost in the amount of $4,100,000 and $4,035,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivacitas
is a clinical stage biotech company pursuing development of next generation camptothecin technology to treat solid tumors in oncology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Promissory
Note 1</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&ldquo;Promissory Note 1&rdquo;) with an individual. The Company
loaned the principal sum of $206,000, with interest at a rate of 6.5%, and maturity date of August 19, 2022. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. This note is secured by certain real property situated in Collier
County, Florida. The outstanding principal and interest as of December 31, 2021, approximated $197,000 and is classified in current notes
receivable on the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Promissory
Note 2</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&ldquo;DSS PureAir&rdquo;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&ldquo;Promissory Note 2&rdquo;) with a limited liability company registered in the state of Texas (&ldquo;Borrower&rdquo;). The
Promissory Note 2 has an aggregate principal balance up to $5,000,000, to be funded at request of the borrower. The Promissory Note 2,
which incurs interest at a rate of 6.5% due quarterly, has a maturity date of May 14, 2023. The Promissory Note 2 contains an options
conversion clause that allows the Company to convert all, or a portion of all, into new issued member units of the borrower with the
maximum principal amount equal to 18% of the total equity position at conversion. The outstanding principal and interest as of March
31, 2022, approximated $5,164,000, which is classified as Notes receivable on the consolidated balance sheet. Subsequent to the execution
of the Promissory Note 2, DSS PureAir entered into distribution agreement with Borrower, who is in the business of manufacturing and
supplying proactive air and surface purification systems, to sell its products within specified territories. In June of 2022, the Company
transferred its 100% of its interest in DSS Pure Air, Inc. to DSS Biohealth Holdings, Inc., a related party and wholly owned subsidiary
of DSS BioHealth Security, Inc. Associated with this transfer is Promissory Note 2 and the related Note payable, related party.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>DSS
Note </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on September 30, 2022, the Company executed a Revolving Promissory Note (&ldquo;Note&rdquo;) with
DSS, a related party which accrues interest at a rate of 4.25% and is due in full at the maturity date of September 30, 2023. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. As of September 30, 2022 and December 31, 2021,
this Note had an outstanding balance of $9,280,000 and $12,523,615, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although there is no formal written agreement
to fund the Company, DSS may continue to fund the operations of the Company on an as needed basis to be decided by its board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>GRDG
Licensing Proceeds Distribution Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company entered into a Licensing Proceeds Distribution Agreement (the &ldquo;Licensing Agreement&rdquo;) with
GRDG Sciences, LLC (&ldquo;GRDG&rdquo;), Global BioLife, Inc., and Impact BioLife Sciences, Inc., pursuant to which GRDG will receive
20% of the gross licensing or sale proceeds received by the Company from the licensing of improvements with patent and patent applications
(the &ldquo;Improvements&rdquo;), and all research and technology, developed, made, owned, conceived, by GRDG in exchange for funding
from the Company for research and technology development activities. Pursuant to the Licensing Agreement, Impact continues to receive
consulting payments (the &ldquo;Consulting Payments&rdquo;) approximating $43,000 per month for the purpose of paying or reimbursing
certain salaries, overhead, office rent reimbursement, and other operating costs. As of December 1, 2022, the Company not made
any payments under the Licensing Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the Licensing Agreement is from February 15, 2022, through the later of (1) the date of the last to expire of a valid patent
of intellectual property, or (2) the date of the last license or fee income generated from the Improvements. The Licensing Agreement
provides for termination for cause, which includes failure to make payment when due, unauthorized disclosure of confidential information,
and unauthorized assignment of the agreement. The parties may terminate the Licensing Agreement with or without cause by providing the
other party with at least two months advance written of a notice of intention of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ProPhase
License Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2022, the Company entered into a License Agreement (the &ldquo;License Agreement&rdquo;) with ProPhase Labs, Inc. (&ldquo;ProPhase&rdquo;)
and Global BioLife, Inc., pursuant to which ProPhase obtained a license to intellectual property rights of Global BioLife, Inc. in exchange
for a royalty fee of five- and one-half percent (5.5%) of net sales. Pursuant to the License Agreement, Global BioLife, Inc. shall reimburse
ProPhase for fifty percent (50%) of the development costs up to one million two hundred fifty dollars ($1,250,000). The term (the &ldquo;Term&rdquo;)
of the License Agreement is the later of (a) the expiration date of the last to expire a valid claim comprising the licensed patents,
or (b) twelve (12) years from the date of first commercial sale. ProPhase may terminate this Agreement for any or no reason upon thirty
(30) days prior written notice to Global BioLife, Inc. In addition, At any time prior to expiration of the Term, either party may terminate
the License Agreement for cause by providing written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2022, the Company entered into a License Agreement (&ldquo;July License Agreement&rdquo;) by and between ProPhase, and Global
BioLife, Inc., pursuant to which Global BioLife, Inc. licensed compounds to ProPhase for research purposes for a one-time upfront license
fee of fifty thousand dollars ($50,000). The July License Agreement contains milestones that may result in payment to Global BioLife,
Inc. of (a) nine hundred thousand dollars ($900,000) upon successful completion of a first Phase 3 study, which may be required by the
FDA, and (b) one million dollars ($1,000,000) for regulatory approval of an NDA for the first licensed product. In addition, ProPhase
will pay to Global BioLife, Inc. 3% royalties on net revenue of each licensed product from the date of first commercial sale and for
the term of the agreement. The term of the July License Agreement is automatically upon the last to occur of the expiration of the last-to-expire
licensed patent. ProPhase has the right to terminate the July License Agreement for any reason or for convenience in its sole discretion.
Global BioLife, Inc. has the right to terminate the July License Agreement only for uncured material breaches by ProPhase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
space is provided to by DSS at no cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercialization
Business Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model revolves mainly around two approaches &ndash; Licensing and Sales Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>1.
Licensing</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing strategy includes developing unique patented technologies which would then be licensed to external partners for developing,
registration, and commercialization as appropriate. We believe that interest in licensing certain projects may rise over time as validating
data becomes available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.
Sales Distribution</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
affiliates of ours have relationships with developing global distribution networks. We currently intend to pursue private labelling opportunities
in these and other networks. In addition, we intend to utilize our affiliates newly launched retail e-commerce site to allow us to take
orders and deliver products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Distribution
Agreement by and between BioMed Technologies Asia Pacific Holdings Limited and the Company</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2020, the Company entered into a distribution agreement (the &ldquo;BioMed Distribution Agreement&rdquo;) with BioMed Technologies
Asia Pacific Holdings Limited (&ldquo;BioMed Technologies&rdquo;), whereby BioMed Technologies agreed to sell to the Company, and the
Company agreed to purchase and resell BioMed Technologies&rsquo; BioMed Gut Health Products (the &ldquo;BioMed Products&rdquo;) as identified
in the BioMed Distribution Agreement. Pursuant to the BioMed Distribution Agreement, the Company will act as the exclusive distributor
of the BioMed Products in the U.S., Canada, Singapore, Malaysia, and South Korea. The BioMed Distribution Agreement does not preclude
the Company from selling competing products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the BioMed Distribution Agreement is ten (10) years from the December 9, 2020, effective date, unless earlier
terminated. Upon its expiration, the BioMed Distribution Agreement shall automatically renew for additional successive one (1) year term
unless and until either party provides notice of nonrenewal at least sixty (60) days before the end of the then-current term. The Company
may terminate the BioMed Distribution Agreement if BioMed Technologies: (a) repudiates any of its obligations under the BioMed
Distribution Agreement; (b) materially breaches any its representations, warranties or covenants; (c) fails to or threatens to fail to,
timely deliver the BioMed Products; (d) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due
and payable, (ii) files or has filed against it, a petition for voluntary or involuntary bankruptcy, (iii) seeks reorganization, arrangement,
adjustment, winding-up, liquidation or dissolution or other relief from its debts, (iv) makes or seeks to make a general assignment for
the benefit of its creditors, (v) or applies for or has a receiver, trustee, custodian, or similar agent appointed by order of any court
of competent jurisdiction or (e) is unable to perform its obligations for more than thirty (30) consecutive business days due to a force
majeure event. In addition, the Company may terminate the BioMed Distribution Agreement at its option, at any time, and for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>3.
Research and Development</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&rsquo; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &ldquo;Global BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Global BioLife Stockholder&rsquo;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &ldquo;Linebacker Patents&rdquo; as defined
in the Global BioLife Stockholders&rsquo; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife has agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&rsquo; budget</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&rsquo; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&rsquo;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. Current monthly payments approximate to $43,000.
For the year ended December 31, 2021, the Company incurred expenses of $509,176. The Company incurred expenses of $329,409 (predecessor
&ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash; August 22, 2020 to December 31, 2020). On December
31, 2021, and December 31, 2020, the Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and
$35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Global BioLife Stockholders&rsquo; Agreement, Holista has agreed to (i) assist in the global commercialization of Global BioLife&rsquo;s
intellectual property, (ii) assist in the initiation and development of joint venture opportunities for Global BioLife, and (iii) provide
the expertise of Dr. Rajen M. Dato to Global BioLife, who shall be available to provide management service and assist in the strategic
director of Global BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&rsquo; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&rsquo; Agreement entered into Amendment No. 1 to the agreement (&ldquo;Amendment
No. 1 to the Global BioLife Stockholders Agreement&rdquo;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&ldquo;Amendment No. 2 to the Global BioLife Stockholders Agreement&rdquo;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&rsquo; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholders agreement with its stockholders Impact BioMedical and GRDG (the &ldquo;Impact
BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Impact BioLife Stockholders&rsquo; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&rsquo; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&rsquo; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&rsquo; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time per week
to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&rsquo;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&rsquo;s business plan
and budget (the &ldquo;Impact BioLife Budget&rdquo;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. For the year ended December 31, 2021, the Company incurred expenses of $509,176.
The Company incurred expenses of $329,409 (predecessor &ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash;
August 22, 2020 to December 31, 2020). On December 31, 2021, and December 31, 2020, the Company owed this related party $0 and
had prepaid monthly fees approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&rsquo; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain
a stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of the Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&rsquo; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&rsquo;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&rsquo; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&rsquo; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&rsquo;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&rsquo; written notice by either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have two employees focused primarily on the development and marketing of existing technologies as well as identifying new opportunities.
Certain services are provided to us and our subsidiaries by DSS as well as by GRDG, a related party, pursuant to the Global BioLife Stockholders&rsquo;
Agreement and the Impact BioLife Stockholders&rsquo; Agreement. At the present time, Global BioLife pays GRDG approximately $43,000
per month for services provided by GRDG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are
not currently a party to any material legal proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biohealth business is highly competitive. Existing and future competitors may introduce products and services in the same markets we
serve, and competing products or services may have better performance, lower prices, better functionality and broader acceptance than
our products. This competition could result in increased sales and marketing expenses, thereby materially reducing our operating margins,
and could harm our ability to increase, or cause us to lose, market share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most,
if not all, of our current and potential competitors may have significantly greater resources or better competitive positions in certain
product segments, geographic regions or user demographics than we do. These factors may allow our competitors to respond more effectively
than us to new or emerging technologies and changes in market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may develop products, features or services that are similar to its own or that achieve greater acceptance, may undertake
more far-reaching and successful product development efforts or marketing campaigns, or may adopt more aggressive pricing policies. Certain
competitors could use strong or dominant positions in one or more markets to gain competitive advantage us in its target market or markets.
As a result, our competitors may acquire and engage customers or generate revenue at the expense of our own efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future
Research/Emerging Technologies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our current technologies, we continue our exploration and discovery efforts. Current areas of interest include natural entities
for drug development/treatment, food preservatives, and other categories. These efforts may result in new intellectual property, drug
treatments, and consumer and wellness offerings subject to study/data results. They may also never reach development milestones, prove
effective, or result in material value to the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect the intellectual property that we believe is important to our business, including seeking and maintaining patent protection
intended to cover the composition of matter of our product candidates, their methods of use, their methods of production, related technologies
and other inventions. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not
amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of technical know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important
technologies, inventions and know-how related to our business, defend and enforce our intellectual property rights, particularly our
patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property
rights of others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions for companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition,
the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted
and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain
protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in
any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors.
Any patents that we hold may be challenged, circumvented or invalidated by third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our material patents and the expiration date of each patent as of March 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 6%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product</I></B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent No.</I></B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Status</I></B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expiration Date</I></B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 25%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ex US Status</I></B></FONT></TD></TR>
  <TR>
    <TD ROWSPAN="4">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LineBacker</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 8,034,838</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method/Composition for Treatment of Neurological Disorders
    with Modified Flavonoid Compound</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,123,991</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of Electrophilically Enhanced Phenolic
    Compounds (any chlorinated myricetin) for Treating Inflammatory Diseases and Disorders</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US17/32897 (Foreign Filed in AU, BR, CA, CN, EP, HK, IN, JP, KR, RU)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,966,954</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of Electrophilically Enhanced Phenolic
    Compounds (specific mono and di-chlorinated myricetin) for Treating Inflammatory Diseases and Disorders</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/032897 (Foreign
    AU, BR, CN, EP, JP, KR, RU) (30-month date: Nov. 16, 2018)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US21/22538</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method and Compositions for Treating, Preventing or
    Limiting the Occurrence of Viral Infection</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US21/22538 (30-month
    date: Sept. 16, 2022)</FONT></TD></TR>
  <TR>
    <TD ROWSPAN="4">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equivir Nemovir</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equivir G</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,383,842; US 15/043,472</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method/Composition for
    Preventing and Treating Viral Infections (Influenza)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US2017/032897* (Foreign AU, BR, CN, EP, JP,
    KR, RU) (30-month date: Nov. 16, 2018) (* disclosure of both Linebacker and Equivir)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 11,033,528</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method/Composition for
    Preventing and Treating Viral Infections (Ebola, Rhinovirus)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US17/048892** (Foreign AU, CA, CN, JP, KR,
    EPO, RU) (** Equivir w/gallic acid) (30-month date: Feb. 28, 2020)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 17/346,569</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method/Composition for Preventing and Treating Viral
    Infections (potentially Covid, others).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD></TR>
  <TR>
    <TD></TD>
    <TD STYLE="text-align: justify"></TD>
    <TD></TD>
    <TD STYLE="text-align: justify"></TD>
    <TD></TD>
    <TD STYLE="text-align: justify"></TD>
    <TD></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD>
    <TD></TD>
    <TD STYLE="text-align: justify"></TD></TR>
  <TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laetose</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/698,159</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (4)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A composition including a select sugar source and
    myo-inositol that impacts the signaling of TNF-a and pro-inflammatory cytokines when metabolized, with ability to control blood glucose
    levels, treat diabetes and inflammatory diseases.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US18/49965</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign Filed in AU, BR, CA, CN, EP, HK, IN,
    JP, KR and RU (30-month date: Mar. 7, 2020)</P></TD></TR>
  <TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3F (Anti-Viral)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/212,966</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (5)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of natural elements for use as an antibacterial
    and antiviral agent</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US19/64254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign Filed in AU, BR, CA, CN, EP, IN, JP,
    KR and RU (30- month Jun. 7, 2021</P></TD></TR>
  <TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3F (DB Repellent)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">U.S. 16/593,693; U.S. 10,966,424</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US520/54042</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2039</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique weight-based
    composition/method of natural elements with DEET for use as insect repellent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT Filed October 2, 2020,
    PCT/US20/54042) &ndash; 30 Month Date April 4, 2022 (currently no foreign national stage countries pending </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3F (Anti-Insect)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/270,857</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (6)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique weight-based composition/method of natural elements without DEET for use as insect repellent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US20/17183 (Foreign Filed in CA, JP, CN, KR, EPO, RU) (30 month: Jun. 7, 2021)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1. The expiration date of pending patents are currently unknown
but typically approximately 20 years from filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Patent application filed on September 23, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Patent application filed on June 14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Patent application filed on September 7, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Patent application filed December 7, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Patent application filed February 8, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
of the Biohealth Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies,
primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The U.S. Food and Drug Administration,
or FDA, has broad regulatory powers. Extensive testing and documentation is required for FDA approval of new drugs and devices, increasing
the expense of product introduction. Significant expenses are also evident in major markets outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and
legislative bodies around the world. In the United States, attention has been focused on drug prices and profits and programs that encourage
doctors to write prescriptions for particular drugs, or to recommend, use or purchase particular medical devices. The regulatory agencies
under whose purview Impact BioMedical may operate in the future have administrative powers that may subject partners to whom Impact BioMedical
licenses products to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, business practices in the health care industry have come under increased scrutiny, particularly in the United States, by government
agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal
penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partners
to whom we license products in the future may need to rely on global supply chains, and production and distribution processes, that are
complex, subject to increasing regulatory requirements, and may be faced with unexpected changes that may affect sourcing, supply and
pricing of materials used in products which we have or will develop. These processes also are subject to lengthy regulatory approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
Exchange Transaction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, we closed on a Share Exchange Agreement by and among DSS, DSS BioHealth Security, Inc., Alset International Ltd. (formerly
Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&ldquo;GBM&rdquo;), pursuant to which we became a wholly-owned subsidiary
of DSS BioHealth Security, Inc. Shortly after closing, Frank D. Heuszel, Jason Grady and John Thatch were appointed directors, and Mr.
Heng Fai Ambrose Chan remained on the Board of Directors and appointed Chief Executive Officer, Mr. Heuszel was appointed President,
Mr. Grady was appointed Chief Operating Officer and Todd Macko was appointed Secretary and Treasurer, replacing the officers and directors
who resigned in connection with the share exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chan is the Chief Executive Officer and largest beneficial owner of outstanding shares of common stock of Alset International Ltd., as
well as the Chairman of the Board and largest beneficial owner of outstanding shares of common stock of DSS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limited
Operating History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no historical financial information about us upon which to base an evaluation of our performance. As of the date of this report, we
have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is
subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays our
research, testing and marketing efforts or wider economic downturns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 6 Framark
Drive, Victor, New York 14564. Our telephone number is +1-585-325-3610. Our website address is https://www.impbio.com. Our website and
the information contained thereon, or connected thereto, does not and will not constitute part of this Prospectus or the Registration
Statement on Form S-1 of which this Prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_002"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Officers
and Board of Directors Following the Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nevada law, the business and affairs of the Company is managed under the direction of our Board. Our Amended and Restated Articles of
Incorporation provide that the number of directors may be fixed by our Board from time to time. Members of the Board are elected and
serve for one-year terms or until their successors are elected qualify. The following sets forth information regarding individuals who
are currently officers and directors in office and are expected to continue to serve in their positions after the Distribution (ages
as of June 24, 2022):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position
    </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Director </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary
    and Treasurer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    &ldquo;JT&rdquo; Thatch</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Daryl Thompson*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">52</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Director of Scientific Initiatives</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Mr. Thompson provides his services to the
Company in his capacity as Director of Scientific Initiatives through GRDG pursuant to the Global BioLife Stockholders Agreement and
the Impact BioLife Stockholders Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biographical
and certain other information concerning the Company&rsquo;s officers and directors is set forth below. There are no familial relationships
among any of our directors. Except as indicated below, none of our directors is a director in any other reporting companies. None of
our directors has been affiliated with any company that has filed for bankruptcy within the last ten years. We are not aware of any proceedings
to which any of our directors, or any associate of any such director is a party adverse to us or any of our subsidiaries or has a material
interest adverse to us or any of our subsidiaries. Each executive officer serves at the pleasure of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director/Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Since</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Occupation or Directorships</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Chan Heng Fai has served as an Executive director of DSS, Inc. (NYSE: DSS) (formerly known as Document Security Systems, Inc.) since
    January 2017 and as Executive Chairman of the Board since March 2019. Mr. Chan founded Alset EHome International, Inc. and has served
    as Chairman of the Board and Chief Executive Officer since inception in March 2018. Mr. Chan is an expert in banking and finance,
    with 45 years of experience in these industries. He has restructured numerous companies in various industries and countries during
    the past 40 years. Mr. Chan has served as the Chief Executive Officer of Alset EHome International Inc.&rsquo;s subsidiary Alset
    International Limited (&ldquo;Alset&rdquo;) (SGX: 40V) since April 2014. Mr. Chan joined the Board of Directors of Alset in May 2013.
    Mr. Chan has served as a Director of Sharing Services Global Corporation since April 2020. Mr. Chan has served as a director of Alset&rsquo;s
    99.69%-owned subsidiary GigWorld Inc. since October 2014. He also served as a director of Alset&rsquo;s indirect subsidiary LiquidValue
    Development Inc. since January 2017. Mr. Chan has also appointed as Chairman and Chief Executive Officer of Alset Capital Acquisition
    Corp, a New York Stock Exchange Listed company, since October 2021. In addition, Mr. Chan appointed as a board member of Value Exchange
    International, Inc. since December 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Heuszel has served as a director and President of the Company since August 2020. Since April 11, 2019, he has served as the Chief
    Executive Officer of DSS since April 11, 2019, DSS&rsquo;s Interim Chief Financial Officer from April 2019 to October 2020, and a
    director of DSS since July 30, 2018. Mr. Heuszel has extensive expertise in a wide array of strategic, business, turnaround, and
    regulatory matters across several industries as a result of his executive management, educational, and operational experience. Prior
    to joining DSS, Mr. Heuszel had a very successful career in commercial banking. For over 35 years, Mr. Heuszel served in many senior
    executive roles with major US and international banking organizations. As a banker Mr. Heuszel has served as General Counsel, Director
    of Special Assets, Credit Officer, Chief Financial Officer and Auditor. Mr. Heuszel also operated a successful law practice focused
    on the litigation, corporate restructures, and merger and acquisitions, and collections. In addition to being an attorney and executive
    manager, Mr. Heuszel is also a Certified Public Accountant (retired), and a Certified Internal Auditor. Mr. Heuszel graduated from
    The University of Texas at Austin and from The South Texas College of Law, Houston.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko has been Secretary and Treasurer of the Company since January 2021. Mr. Macko was promoted to Interim Chief Financial Officer
    of DSS effective October 28, 2020, and was appointed Chief Financial Officer on August 16, 2021. Mr. Macko previously served
    as the Vice President of Finance of DSS. As the Vice President of Finance, Mr. Macko&rsquo;s responsibilities included assisting
    DSS&rsquo;s Interim Chief Financial Officer in all aspects of financial and regulatory reporting. In addition, his responsibilities
    included the day-to-day management of the Company&rsquo;s Accounting and Finance team and the financial leadership in the directing
    and improving of the accounting, reporting, audit, and tax activities. Prior to his role as Vice President of Finance for the Company,
    Mr. Macko joined the wholly owned subsidiary of DSS, Premier Packaging Corporation in January 2019, as its Vice President of Finance.
    Mr. Macko is a Certified Public Accountant with over 25 years of public and corporate financial management, business leadership and
    corporate strategy. Mr. Macko brings a wealth of experience with strengths in financial planning and analysis, business process re-engineering,
    budgeting, merger and acquisitions, financial reporting systems, project evaluation and treasury and capital management. Prior to
    joining the Company, Mr. Macko served as the Corporate Controller for Baldwin Richardson Foods, a leading custom ingredients manufacturer
    for the food and beverage industry from November 2015 until January 2019. Prior to that, Mr. Macko served as the Controller for The
    Outdoor Group, LLC., Genesis Vision, Inc., Complemar Partners, Inc., and Level 3 Communications, Inc. Mr. Macko obtained is Bachelor
    of Science in Accounting from Rochester Institute of Technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Thatch</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Thatch has served as a director of the Company since August 2020. Since May 9, 2019, he has been director of DSS and as Lead
    Independent Director of DSS since December 9, 2019. Mr. Thatch is an accomplished professional and entrepreneur who has started,
    owned and operated several businesses in various industries and in both the public and private arena. The industries in which his
    companies have operated include the service, retail, wholesale, education, finance, real estate management and technology industries.
    Since March 2018, Mr. Thatch has served as the Chief Executive Officer and a director of Sharing Services Global Corporation, a publicly
    traded holding company focused on the direct selling and marketing industry. He is also a principal owner of Superior Wine
    &amp; Spirits, a Florida-based company that imports, wholesales and distributes wine and liquor throughout the State of Florida.
    He has been involved in this business venture since February of 2016. Mr. Thatch served as Chief Executive Officer of Universal Education
    Strategies, Inc. from January 2009 - January 2016, an organization consisting of six companies that specialized in the development
    and sales of educational products and services. From 2000 - 2005, he was the Chief Executive Officer of Onscreen Technologies, Inc.,
    currently listed on NASDAQ as CUI Global, Inc., a global leader in the development of cutting-edge thermal management technologies
    for integrated LED technologies, circuits and superconductors. Mr. Thatch was responsible for all aspects of the company including
    board and shareholder communications, public reporting and compliance with Sarbanes-Oxley, structuring and managing the firm&rsquo;s
    financial operations, and expansion initiatives for all corporate products and services. Mr. Thatch&rsquo;s public company financial
    and management experience in the strategic growth and development of various companies qualify him to Board serve on the Company&rsquo;s
    Board of Directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell has served as a director of the Company since January 2021. Dr. Brownell has more than 20 years of biotechnology and
    pharmaceutical project management experience with a proven track record of advancing programs through clinical development. She serves
    as a Life Sciences entrepreneurial advisor for ASTIA, the nation&rsquo;s premier entrepreneurial organization focused on women-led
    businesses. Dr. Brownell is also a member of the Editorial Advisory Board for Contract Pharma Magazine, and previous Chair of the
    Leaders Network program of Women in Consulting. She is the co-founder of ZephyrBiotech, LLC, a project management firm dedicated
    to advancing therapeutic candidates through development to key inflection points for clients. Earlier, Dr. Brownell was a founding
    member, head of project management and senior director of Aerovance, Inc., a venture-backed biotechnology company spun out from Bayer
    Healthcare, where she created and managed effective team processes to bring product candidates into full scale clinical Phase 1 and
    2 developments. Prior to Aerovance, Dr. Brownell acted as head of project management for Bayer&rsquo;s Biotechnology Unit,
    where she integrated project strategies to meet therapeutic and market needs. Other roles included building and negotiating partnerships
    with third parties to support development programs, leading research teams through early bench-to-clinic development phases, as well
    as entrepreneurial investment experience with Angel&rsquo;s Forum. Dr. Brownell received her M.S., M.Phil. and Ph.D. in biology from
    Yale University and her B.S. in biology from Allegheny College.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Daryl Thompson</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">52</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2015</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since 2015, Daryl Thompson has served as the Director
    of Science Initiatives at GRDG Sciences, LLC. From 2006 to 2014, Mr. Thompson served as the President and Director of Research at
    ATM Metabolics LLC, providing oversight of research and identification of capital, business opportunities, and research partnerships for an entrepreneurial start-up company specializing in the development of food supplements and pharmaceuticals naturally
    derived from phyto-chemical platforms aimed at preventing and reversing metabolic diseases. Mr. Thompson obtain a degree in chemistry
    and biology at Florida Southern College.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of the Company plans to adopt corporate governance guidelines that serve as a flexible framework within which our
Board of Directors and its committees operate. These guidelines will cover a number of areas including the size and composition of the
board, board membership criteria and director qualifications, director responsibilities, board agenda, roles of the chairman of the board
and Chief Executive Officer, meetings of independent directors, committee responsibilities and assignments, board member access to management
and independent advisors, director communications with third parties, director compensation, director orientation and continuing education,
evaluation of senior management and management succession planning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presently do not have any committee of our Board. Currently, our full Board serves as the audit committee and approves, when applicable,
the appointment of auditors and the inclusion of financial statements in our periodic reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure and Role in Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is primarily responsible for overseeing our risk management processes on behalf of our Company. The Board of Directors
receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company&rsquo;s
assessment of risks. The Board of Directors focuses on the most significant risks facing our company and our company&rsquo;s general
risk management strategy, and also ensures that risks undertaken by our Company are consistent with the board&rsquo;s appetite for risk.
While the board oversees our company&rsquo;s risk management, management is responsible for day-to-day risk management processes. We
believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board
leadership structure supports this approach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of directors and executive officers has been involved in legal proceedings that would be material to an evaluation of our management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any compensation to any directors since inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Ownership of Directors and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;Security Ownership of Certain Beneficial Owners and Management.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_003"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any compensation to any name executive officers or directors since inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_004"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
currently beneficially owns 100% of all of our Common Stock. After the Distribution, DSS will own approximately __% of the outstanding
shares of our Common Stock. The following table provides information with respect to the expected beneficial ownership of our Common
Stock after giving effect to the Distribution by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person or entity that we believe, based on the assumptions described below, will be a beneficial owner of more than 5% of our outstanding
    Common Stock following the Distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person who we expect will serve as a director following the Distribution and each named executive officer; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    our expected directors and executive officers following the Distribution as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise noted in the footnotes below, we based the share amounts on each person&rsquo;s or entity&rsquo;s existing beneficial ownership
of our Common Stock and the number to be distributed to holders of DSS Common Stock at the distribution ratio of 4-1 shares of our Common
Stock for each share of DSS Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent our directors and officers own DSS Common Stock at the time of the Distribution, they will participate in the Distribution
on the same terms as other holders of DSS Common Stock, except for holders of any Affiliate Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise noted in the footnotes below, each person or entity identified below has sole voting and investment power with respect to
such securities. The address of all of the officers and directors listed in the table below are in the care of Impact BioMedical, Inc.,
275 Wiregrass Parkway, West Henrietta, NY 14586, unless otherwise indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, there were 125,073,621 shares of our Common Stock issued and outstanding. The actual number of shares of
our Common Stock outstanding following the Distribution will depend on several factors including then number of issued and outstanding
shares of DSS at the record date and the number of shares eliminated as a result of the cash out of fractional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares <BR> Beneficially Owned<BR> Before Distribution</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    of Shares <BR> Beneficially Owned<BR> Before Distribution</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares<BR> Beneficially Owned<BR> After Distribution</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    of Shares<BR> Beneficially Owned<BR> After Distribution</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 40%; font-weight: bold; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">5%
    or More Stockholders</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">DSS,
    Inc.</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors
    and Executive Officers</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Heng
    Fai Ambrose Chan</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">John
    Thatch</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Frank
    D. Heuszel</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Elise Brownell</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Todd D. Macko</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">-</P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">-</P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Daryl Thompson</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">-</P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">-</P></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    officers and directors as a group (6  persons)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    indirectly owns the shares through DSS BioHealth Security, Inc., its wholly-owned subsidiary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_005"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, DSS completed its acquisition of the Company, pursuant to a Share Exchange Agreement by and among DSS, DSS BioHealth
Security, Inc., Alset International Ltd. (formerly Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&ldquo;GBM&rdquo;) (the
&ldquo;<U>Share Exchange</U>&rdquo;). Under the terms of the Share Exchange, DSS issued 483,334 shares of the DSS Common Stock nominally
valued at $6.48 per share, and 46,868 newly issued shares of the DSS Series A Convertible Preferred Stock (&ldquo;<U>Series A Preferred
Stock</U>&rdquo;), with a stated value of $46,868,000, or $1,000 per share, for a total consideration valued at $50 million. Due to several
factors, including a discount for illiquidity, the value of the Series A Preferred Stock was discounted from $46,868,000 to $35,187,000,
thus reducing the final consideration given to approximately $38,319,000. As a result of the Share Exchange, Impact BioMedical became
a wholly-owned subsidiary of DSS BioHealth Security, Inc., DSS&rsquo;s wholly-owned subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Fai Ambrose Chan, the Chief Executive Officer
and Chairman of the Board of the Company, is the Chief Executive Officer and largest shareholder of Alset International Ltd., as well
as the Chairman of the Board and largest shareholder of DSS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the execution of the Share Exchange Agreement, our ownership of a suite of antiviral and medical technologies was valued at $382 million. Because the valuation was higher than the previously agreed value, the purchase price was capped
at a value of $50 million, pursuant to the terms of the Share Exchange Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">research and development efforts are currently
headed by Mr. Daryl Thompson, Founder and Owner of GRDG. Pursuant to a stockholders&rsquo; agreement between Impact
BioLife, a majority-owned subsidiary of the Company, and its stockholders (including GRDG) and a stockholders agreement between Global
BioLife, a majority-owned subsidiary of the Company, and its stockholder (including GRDG), Mr. Thompson has agreed, through GRDG, to
conduct the development and research work on the biomedical products for Impact BioLife and Global BioLife, respectively. Mr. Thompson
also serves as the Director of Scientific Initiatives at Impact BioLife. The above-referenced stockholders&rsquo; agreements are described
more fully below. For services provided by GRDG, Global BioLife pays GRDG approximately $43,000 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, entered into a Stock Purchase Agreement (the &ldquo;Agreement&rdquo;) with Vivacitas Oncology Inc. (&ldquo;Vivacitas&rdquo;),
to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase 1,500,000 additional shares
at the per share price of $1.00. This option will terminate upon one of the following events: (i) The Seller&rsquo;s board of directors
cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii) the date on which the
Seller receives more than $1.00 per share of the Company&rsquo;s common stock in a private placement with gross proceeds of $500,000.
Under the terms of the Agreement, the Company will be allocated two seats on the board of Vivacitas. On July 22, 2021, the Company exercised
its right to purchase 1,000,000 additional shares of Vivacitas at the per share price of $1.00. On March 18, 2021, the Company entered
into an agreement with Alset EHome International, Inc. (&ldquo;Seller&rdquo;) to purchase from the Seller&rsquo;s its wholly owned subsidiary
Impact Oncology PTE Ltd. (&ldquo;IOPL&rdquo;) for a purchase price $2,480,000. The acquisition of IOPL has been treated as an asset acquisition
as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns 2,480,000 shares of common stock of Vivacitas along
with the option to purchase an additional 250,000 shares of common stock. As a result of these two transactions, the Company will have
an approximate 15.7% (subsequent transactions increase the Company ownership to approximately 19%) equity position in Vivacitas.
As of September 30, 2022, and December 31, 2021, the fair value of the Company&rsquo;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $4,100,000 and $4,035,000, respectively. The Sellers largest shareholder is Mr.
Heng Fai Ambrose Chan, the Chief Executive Officer and Chairman of DSS&rsquo;s board of directors and the largest shareholder
of DSS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&rsquo; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &ldquo;Global BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Global BioLife Stockholder&rsquo;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &ldquo;Linebacker Patents&rdquo; as defined
in the Global BioLife Stockholders&rsquo; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife has agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&rsquo; budget</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&rsquo; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&rsquo;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. The current agreement provides for monthly
payments of approximately $43,000. For the year ended December 31, 2021, the Company incurred expenses of $509,176. The Company
incurred expenses of $329,409 (predecessor &ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash; August 22, 2020
to December 31, 2020). On December 31, 2021, and December 31, 2020, the Company owed this related party $0 and had prepaid monthly fees
approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Global BioLife Stockholders&rsquo; Agreement, Holista has agreed to (i) assist in the global commercialization of Global BioLife&rsquo;s
intellectual property, (ii) assist in the initiation and development of joint venture opportunities for Global BioLife, and (iii) provide
the expertise of Dr. Rajen M. Dato to Global BioLife, who shall be available to provide management service and assist in the strategic
director of Global BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&rsquo; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&rsquo; Agreement entered into Amendment No. 1 to the agreement (&ldquo;Amendment
No. 1 to the Global BioLife Stockholders Agreement&rdquo;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&ldquo;Amendment No. 2 to the Global BioLife Stockholders Agreement&rdquo;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&rsquo; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholders agreement with its stockholders Impact BioMedical and GRDG (the &ldquo;Impact
BioLife Stockholders&rsquo; Agreement&rdquo;). Pursuant to the Impact BioLife Stockholders&rsquo; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&rsquo; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&rsquo; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&rsquo; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time and efforts
each week to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&rsquo;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&rsquo;s business plan
and budget (the &ldquo;Impact BioLife Budget&rdquo;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. For the year ended December 31, 2021, the Company incurred expenses of $509,176.
The Company incurred expenses of $329,409 (predecessor &ndash; January 1, 2020, to August 21, 2020) and $184,284 (successor &ndash;
August 22, 2020 to December 31, 2020). On December 31, 2021, and December 31, 2020, the Company owed this related party $0 and
had prepaid monthly fees approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&rsquo; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain a
stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&rsquo; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&rsquo;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&rsquo; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&rsquo; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&rsquo;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&rsquo; written notice by either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &ldquo;Vivacitas Agreement #1&rdquo;) with Vivacitas Oncology
Inc. (&ldquo;Vivacitas&rdquo;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&rsquo;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&rsquo;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&ldquo;Seller&rdquo;) to purchase from
the Seller&rsquo;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&ldquo;IOPL&rdquo;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&rsquo;s board of directors and its largest shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&ldquo;Vivacitas Agreement #2&rdquo;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 22, 2021, the Company exercised 1,000,000
of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along with the shares received as part Vivacitas Agreement
#2 increased the Company&rsquo;s equity position in Vivacitas to approximately 4,070,000 shares or 19% as of December 31, 2021. As of
December 31, 2021, the fair value of the Company&rsquo;s investment in Vivacitas is not readily available, and therefore is recorded
at cost in the amount of $4,035,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on December 31, 2021, March 31, 2022, and September 30, 2022, the Company executed a Revolving
Promissory Note (&ldquo;Note&rdquo;) with DSS which accrues interest at a rate of 4.25% and is due in full at the maturity date of September
30, 2023. The revolving nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. DSS has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through
a year from the date these financial statements were available to be issued. As of December 31, 2021, and 2020, this Note had an outstanding
balance of $12,523,615 and $1,059,229, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>GRDG Licensing Proceeds Distribution Agreement</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2022, the Company entered into
a Licensing Proceeds Distribution Agreement (the &ldquo;Licensing Agreement&rdquo;) with GRDG Sciences, LLC (&ldquo;GRDG&rdquo;), Global
BioLife, Inc., and Impact BioLife Sciences, Inc., pursuant to which GRDG will receive 20% of the gross licensing or sale proceeds received
by the Company from the licensing of improvements with patent and patent applications (the &ldquo;Improvements&rdquo;), and all research
and technology, developed, made, owned, conceived, by GRDG in exchange for funding from the Company for research and technology development
activities. The term of the Licensing Agreement is from February 15, 2022, through the later of (1) the date of the last to expire of
a valid patent of intellectual property, or (2) the date of the last license or fee income generated from the Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>ProPhase License Agreement</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2022, the Company entered into a
License Agreement (the &ldquo;License Agreement&rdquo;) with ProPhase Labs, Inc. (&ldquo;ProPhase&rdquo;) and Global BioLife, Inc., pursuant
to which ProPhase obtained a license to intellectual property rights of Global BioLife, Inc. in exchange for a royalty fee of five- and one-half percent (5.5%) of net sales. Pursuant to the License Agreement, Global BioLife, Inc. shall reimburse ProPhase for fifty percent
(50%) of the development costs up to one million two hundred fifty dollars ($1,250,000). The term (the &ldquo;Term&rdquo;) of the License
Agreement is the later of (a) the expiration date of the last to expire a valid claim comprising the licensed patents, or (b) twelve
(12) years from the date of first commercial sale. ProPhase may terminate this Agreement for any or no reason upon thirty (30) days prior
written notice to Global BioLife, Inc. In addition, at any time prior to expiration of the Term, either party may terminate the License
Agreement for cause by providing written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2022, the Company entered into a License
Agreement (&ldquo;July License Agreement&rdquo;) by and between ProPhase, and Global BioLife, Inc., pursuant to which Global BioLife,
Inc. licensed compounds to ProPhase for research purposes for a one-time upfront license fee of fifty thousand dollars ($50,000). The
July License Agreement contains milestones that may result in payment to Global BioLife, Inc. of (a) nine hundred thousand dollars ($900,000)
upon successful completion of a first Phase 3 study, which may be required by the FDA, and (b) one million dollars ($1,000,000) for regulatory
approval of an NDA for the first licensed product. In addition, ProPhase will pay to Global BioLife, Inc. 3% royalties on net revenue
of each licensed product from the date of first commercial sale and for the term of the agreement. The term of the July License Agreement
is automatically upon the last to occur of the expiration of the last-to-expire licensed patent. ProPhase has the right to terminate
the July License Agreement for any reason or for convenience in its sole discretion. Global BioLife, Inc. has the right to terminate
the July License Agreement only for uncured material breaches by ProPhase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>DSS PureAir, Inc. Assignment Agreement </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">On June 1, 2022, Impact Biolife Science, Inc. assigned and transferred
its entire interest of 100 shares of common stock of DSS PureAir, Inc.&nbsp;to DSS BioHealth Holdings, Inc. for consideration of $100.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ax_006"></A>DESCRIPTION
OF OUR CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation authorizes us to issue up to 3,000,000,000 shares of Common Stock, $0.001 par value per
share, and 100,000,000 shares of preferred stock, par value $0.001 per share. As of September 30, 2022, there were 125,073,621
shares of our Common Stock and no shares of preferred stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the rights of holders of any then-outstanding preferred stock, each holder of our Common Stock is entitled to one vote for each share
on all matters submitted to a vote of the stockholders, including the election of directors. Under our Amended and Restated Articles
of Incorporation, our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of
Common Stock entitled to vote in any election of directors can elect all of the directors standing for election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the rights of holders of any then-outstanding preferred stock, the holders of our Common Stock are entitled to receive ratably those
dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. We do not anticipate
paying any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of
any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preemptive
or Similar Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Common Stock have no preemptive, conversion or subscription rights and there is no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
shares of preferred stock are currently outstanding. We have no present plans to issue any shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
of Liability and Indemnification Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation contains provisions that limit the liability of our current and former directors for monetary
damages to the fullest extent permitted by Nevada law. Nevada law provides that directors of a corporation will not be personally liable
for monetary damages for any breach of fiduciary duties as directors, except liability for intentional misconduct, fraud or a knowing
violation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our Common Stock is V Stock Transfer, LLC. The transfer agent&rsquo;s address is 6201 15th Avenue, Brooklyn,
New York 11219 and the telephone number is (800) 937-5449.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is not listed on any securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ax_007"></A><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of our Common Stock to be distributed in the Distribution will be passed upon for the Company by Sichenzia Ross Ference LLP,
New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ax_008"></A><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of Impact BioMedical
Inc. and subsidiaries as of and for the year ended December 31, 2021, included in this prospectus and elsewhere in the registration
statement have been so included in reliance upon the report of <I>Turner, Stone &amp; Company. LLP.,</I> independent registered public
accountants upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Impact BioMedical Inc. and subsidiaries as of and for the year ended December 31, 2020, have
been included in reliance on the report of by <I>Freed Maxick CPAs, P.C</I>, an independent registered public accounting firm, as stated
in its report incorporated by reference herein, and have been so incorporated in reliance upon such report and upon the authority of
such firm as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ax_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act to register the shares of our Common Stock to be
distributed in the Distribution. The term registration statement means the original registration statement and any and all amendments
thereto, including the exhibits and schedules to the original registration statement and any amendments. This Prospectus, which constitutes
a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits
and schedules filed therewith. For further information with respect to us, reference is made to the registration statement and the exhibits
and schedules filed therewith. Statements contained in this Prospectus regarding the contents of any contract or any other document that
is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects
by reference to the full text of such contract or other document filed as an exhibit to the registration statement. A copy of the registration
statement, along with the exhibits and schedules filed therewith, may be inspected without charge at the SEC&rsquo;s Internet website.
The SEC maintains an Internet website at <I>www.sec.gov</I> that contains reports, proxy and information statements and other information
regarding registrants that file electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information contained on or accessible through our website or the SEC&rsquo;s website shall not be deemed to be a part of this Prospectus
or the Registration Statement on Form S-1, of which this Prospectus is a part.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to give any information or make any representation about the Distribution or of the Company that is different
from, or in addition to, that contained in this Prospectus. Therefore, if anyone does give you information of this sort, you should not
rely on it. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this
Prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities,
then the offer presented in this Prospectus does not extend to you. The information contained in this Prospectus speaks only as of the
date of this Prospectus unless the information specifically indicates that another date applies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="zzz_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_011" STYLE="font-style: italic">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="toc_001"></A>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAGE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="#f_0001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reports of Independent Registered Public Accounting Firm</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
    Financial Statements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fs_002">Consolidated Balance Sheets</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fs_003">Consolidated Statements of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fs_004">Consolidated Statements of Stockholder&rsquo;s Equity</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fs_005">Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fs_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="f_0001"></A>Report
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and the Board of Directors of Impact BioMedical Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated financial statements of Impact BioMedical Inc. and its subsidiaries, which comprise the consolidated
balance sheet as of December 31, 2020 (Successor), the related consolidated statements of operations, changes in stockholders&rsquo;
equity (deficit), and cash flows for the period from August 22, 2020 through December 31, 2020 (Successor) and the period from January
1, 2020 through August 21, 2020 (Predecessor), and the related notes to the consolidated financial statements (collectively, the financial
statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2020 (Successor), and the results of its operations and its cash flows for the period from August 22, 2020,
through December 31, 2020 (Successor) and the period from January 1, 2020 through August 21, 2020 (Predecessor), in conformity with accounting
principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the <FONT>Public Company
Accounting Oversight Board (United States) (</FONT>PCAOB<FONT STYLE="color: black">)</FONT> and are required to be independent with respect
to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain
an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of
the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Freed Maxick CPAs, P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We served as the Company&rsquo;s auditor for 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rochester,
New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Impact BioMedical, Inc. and subsidiaries (collectively, the &ldquo;Company&rdquo;)
as of December 31, 2021, and the related consolidated statements of operations, stockholders&rsquo; equity and cash flows for
the period ended December 31, 2021, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our
opinion, the financial statements present fairly, in all material respects, the financial position for the Company as of December 31,
2021, and the results of its operations and its cash flows for the period ended December 31, 2021, in conformity with accounting principles
generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatements, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain
an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of
the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Turner, Stone &amp; Company, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
24, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fs_002"></A>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
of December 31,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,980</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of notes receivable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">197,268</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,604</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">286,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    investments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,816,660</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">632,100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    receivable, net of current portion</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,080,911</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    intangible assets, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,147,060</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,260,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,424,483</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,092,447</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND STOCKHOLDER&rsquo;S EQUITY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,046</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,267</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">269</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable, related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,523,615</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,059,229</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,644,008</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,068,765</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax liability, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,856,444</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,251,590</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,500,452</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,320,355</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (Note 11)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder&rsquo;s
    equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on December
    31, 2020)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,207</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,207</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,574,342</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271,224</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholder&rsquo;s equity of the company</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,608,939</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,912,057</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
    interest in subsidiary</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,315,092</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,860,035</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholder&rsquo;s equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,924,031</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,772,092</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholder&rsquo;s equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,424,483</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,092,447</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fs_003"></A>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor
    Period from <BR> August 22, 2020<BR> to December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Predecessor
    Period from <BR> January 1, 2020, <BR> to August 21,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
    and expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">398,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,701</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    &amp; Development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,080,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,284</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">329,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    Services</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">551,796</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132,220</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">151,838</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,112,941</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    General Expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,553</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,825</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,450</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    costs and expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,185,341</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">404,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,185,341</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(404,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (expense):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,794</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,350</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(300,010</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations before income taxes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,243,207</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(404,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax benefit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,395,146</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,848,061</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(322,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from continuing operations attributed to noncontrolling interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">544,943</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,806</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,579</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to common stockholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,303,118</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271,224</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(326,118</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    per common share:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    used in computing loss per common share:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,437,380</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,437,380</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fs_004"></A>Consolidated
Statements of Stockholder&rsquo;s Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid-in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-
    controlling Interest in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,207</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271,224</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,860,035</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,772,092</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,303,118</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(544,943</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,848,061</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,207</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,574,342</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,315,092</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,924,031</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,732,582</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,646,208</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,027</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132,410</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,064,621</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,065</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(125,065</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from shareholder</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325,910</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,090</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(326,118</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(166,579</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    August 21, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,426</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,972,326</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,462</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,712</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Close
    out of predecessor equity</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,983,788</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,972,326</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,462</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,362</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,712</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    August 22, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,362</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,712</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Push
    down adjustments of acquisition of Impact Biomedical, Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,108,569</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,910,841</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,019,410</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271,224</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,806</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(322,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,073,621</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,074</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,207</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271,224</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,860,035</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,772,092</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fs_005"></A>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successor</B></FONT></P>
                                                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Period
                                                                                         from<BR> August 22, 2020<BR> to December 31, </B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predecessor</B></FONT></P>
                                                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Period
                                                                                         from<BR> January 1, 2020<BR> to August 21, </B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,848,061</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(322,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(492,697</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used by operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,112,941</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax benefit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,395,146</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(82,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    (increase) in assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,603</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,300</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    (decrease) in liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,779</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,395</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,643</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,077</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">266</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used by operating activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,028,013</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(427,159</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(471,354</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from investing activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of investment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,184,560</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(632,100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    receivable investment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,278,180</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used by investing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,462,740</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(632,100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from financing activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
    from note payable, related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,464,386</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,059,229</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,464,386</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,059,229</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    decrease in cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,367</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36,354</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents at beginning of year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,377</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,731</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents at end of year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,980</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,347</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,377</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fs_006"></A>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Nature of Operations and Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nature
of Operations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &ldquo;Company&rdquo;, &ldquo;Impact BioMedical&rdquo;, &ldquo;We&rdquo;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&ldquo;Global BioLife&rdquo;), one of the Company&rsquo;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &ldquo;Linebacker&rdquo; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &ldquo;Laetose,&rdquo;; (iii) a multi-use fragrance called &ldquo;3F&rdquo; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Linebacker</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Laetose</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &ldquo;Laetose,&rdquo;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&ldquo;Sweet Sense&rdquo;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet Sense Inc.
from Quality Ingredients, LLC for $91,000. Sweet Sense is now an 81.8% owned subsidiary of the Impact BioMedical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Functional
Fragrance Formulation (&ldquo;3F&rdquo;)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&ldquo;Chemia&rdquo;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equivir</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equivir, is a compound in antiviral infection treatments
Equivir is a patented compound, that potentially could have broad antiviral effects against multiple types of infectious disease.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018, and established a fiscal year end
of December 31st. The Company issued 9,000 shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly&ndash;owned by
Alset International Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange
Securities Trading Limited (&ldquo;SGXST&rdquo;). On March 31, 2020, the Company issued 125,064,621 shares of common stock to
its sole shareholder Global BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of
the Company&rsquo;s common stock issued and outstanding was split into nine shares of the Company&rsquo;s common stock. The numbers of
authorized common stock and issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock
split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays our research, testing and marketing efforts or wider economic downturns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 12, 2020 Alset International Limited (&ldquo;Alset&rdquo;), a related party, Global BioMedical Pte Ltd., a related party, DSS,
Inc (&ldquo;DSS&rdquo;), a related party, and DSS BioHealth Security Inc. (&ldquo;DSS BioHealth&rdquo;), a related party, signed Term
Sheets and subsequently on April 21, 2020, these four companies entered into Share Exchange Agreement (&ldquo;Share Exchange&rdquo;),
based on which Global BioMedical Pte Ltd. agreed to sell all of the issued and outstanding shares of the Company to DSS BioHealth in
exchange for the combination of common and preferred shares of DSS. Under the terms of the Share Exchange, DSS issued 483,334 shares
of the DSS Common Stock nominally valued at $6.48 per share, and 46,868 newly issued shares of the DSS Series A Convertible Preferred
Stock (&ldquo;<U>Series A Preferred Stock</U>&rdquo;), with a stated value of $46,868,000, or $1,000 per share, for a total consideration
valued at $50 million. Due to several factors, including a discount for illiquidity, the value of the Series A Preferred Stock was discounted
from $46,868,000 to $35,187,000, thus reducing the final consideration given to approximately $38,319,000. The Company&rsquo;s Chairman,
Heng Fai Ambrose Chan, a related party, who is also the largest shareholder of Alset, at the time of the signing of the Share Exchange
Agreement was the beneficial owner of approximately 18.3% of the outstanding shares of DSS and is the Chairman of the Board of Directors
of DSS. On August 21, 2020, the transaction was concluded, and the Company became a direct wholly owned subsidiary of DSS BioHealth.
In connection with the acquisition, and the related accounting determination, DSS BioHealth has elected to apply push-down accounting
and reflect in its financial statements of Impact BioMedical, the fair value of its assets and liabilities. The Company&rsquo;s Consolidated
Financial Statements for periods following the close of the acquisition are labeled &ldquo;Successor&rdquo; and reflect DSS BioHealth&rsquo;
s basis in the fair values of the assets and liabilities of Impact BioMedical. All periods prior to the closing of the acquisition reflect
the historical accounting basis in the Company&rsquo;s assets and liabilities and are labeled &ldquo;Predecessor&rdquo;. The fair value
of the consideration transferred was approximately $38,319,000. Utilizing an income approach, the Company has completed its valuations
of certain developed technology and pending patents assets acquired in the transaction as well the fair value of the non-controlling
interests. More specifically, a Multi-Period Excess Earnings Method (&ldquo;MPEEM&rdquo;) estimates the value of an intangible asset
by quantifying the amount of residual (or excess) estimated cash flows generated by the asset and discounting those cash flows to the
present. These have been valued at approximately $22,260,000 and $3,910,000, respectively, and are included on the Consolidated Balance
Sheet on December 31, 2020. Estimated useful life of these assets is twenty years, based on the remaining terms of the related
patents, with annual amortization approximating $1,112,000. The Company has also completed its valuation of goodwill and deferred tax
liabilities of Impact BioMedical, and has recorded goodwill of approximately $25,093,000, driven by other intangible assets that do not
qualify for separate recognition, and a deferred tax liability of approximately $5,234,000. The goodwill is not deductible for tax purposes
and has been allocated to Impact BioMedical in totality as a single reporting unit. The Company is committed to both funding research
and developing intellectual property portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basis
of Presentation and Principles of Consolidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&ldquo;U.S. GAAP&rdquo;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&ndash;controlling
interest represents the minority equity investment in the Company&rsquo;s subsidiaries, plus the minority investors&rsquo; share of the
net operating results and other components of equity relating to the non&ndash;controlling interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of consolidated subsidiary</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    or other jurisdiction of incorporation or organization</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of incorporation or formation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attributable
    interest as of <BR> December 31, <BR> 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attributable
    <BR> interest as of <BR> December 31, <BR> 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioMedical, Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    18, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioLife, Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    14, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLife
    Sugar, Inc</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    23, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Happy
    Sugar Inc</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    17, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
    Sense Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SeD
    BioLife International, Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SeD
    BioMedical International Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    Sugar Solutions Inc.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    7, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the aggregate noncontrolling interest was equity of $3,315,092 and $3,860,035, respectively, which
are separately disclosed on the Consolidated Balance Sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Summary of Significant Accounting and Reporting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Use
of estimates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Earnings
(Loss) per Share</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed similar to basic income
(loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2021, or 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&rsquo;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
and cash equivalents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were no cash equivalents as of December 31, 2021, and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 5 for further
discussion on investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Goodwill</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one-year budgeted amounts plus an estimate of later period cash
flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates
that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No impairment was recognized during
the years ended December 31, 2021, or 2020 (see Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intangible
Assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired
intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31<SUP>st</SUP>,
or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated
fair values. Impairment is tested under ASC 350. No impairment was recognized during the years ended December 31, 2021, or 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $1,080,051 for the year ended December 31,
2021, and $329,409 for the predecessor period January 1, 2020, to August 21, 2020 and $184,284 for the successor period from August
22, 2020 to December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Standards</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2021, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continuing
Operations and Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&rsquo;s management intends to take actions necessary to continue as a going concern. Management&rsquo;s
plans concerning these matters includes, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. Prepaid Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses for the years ended December 31, 2021, and 2020 include mostly research and development fees paid to GRDG Sciences, LLC. (&ldquo;GRDG&rdquo;),
a related party, approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. Notes Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&ldquo;Promissory Note 1&rdquo;) with an individual. The Company
loaned the principal sum of $206,000, with interest at a rate of 6.5%, and maturity date of August 19, 2022. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. This note is secured by certain real property situated in Collier
County, Florida. The outstanding principal and interest as of December 31, 2021, approximated $197,000 and is classified in current notes
receivable on the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&ldquo;DSS PureAir&rdquo;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&ldquo;Promissory Note 2&rdquo;) with a limited liability company registered in the state of Texas (&ldquo;Borrower&rdquo;). The
Promissory Note 2 has an aggregate principal balance up to $5,000,000, to be funded at request of the borrower. The Promissory Note 2,
which incurs interest at a rate of 6.5% due quarterly, has a maturity date of May 14, 2023. The Promissory Note 2 contains an options
conversion clause that allows the Company to convert all, or a portion of all, into new issued member units of the borrower with the
maximum principal amount equal to 18% of the total equity position at conversion. The outstanding principal and interest as of December
31, 2021, approximated $5,081,000, which is classified as Notes receivable on the consolidated balance sheet. Subsequent to the execution
of the Promissory Note 2, DSS PureAir entered into distribution agreement with Borrower, who is in the business of manufacturing and
supplying proactive air and surface purification systems, to sell its products within specified territories.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &ldquo;Subscription Agreement&rdquo;) with BioMed Technologies
Asia Pacific Holdings Limited (&ldquo;BioMed&rdquo;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase 525 ordinary shares or 4.99% of BioMed at a purchase price of approximately $632,000. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &ldquo;Distribution
Agreement&rdquo;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&rsquo;s PGut Premium Probiotics<SUP>&reg;</SUP>,
PGut Allergy Probiotics<SUP>&reg;</SUP>, PGut SupremeSlim Probiotics<SUP>&reg;</SUP>, PGut Kids Probiotics<SUP>&reg;</SUP>, and PGut
Baby Probiotics<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&ldquo;SPA&rdquo;) with Nano9, LLC. (&ldquo;Nano9&rdquo;),
a Utah limited partnership. For the consideration of $150,000 the Company obtained 1,000 membership units, or approximately 10% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of December 31, 2021, the fair value of the Company&rsquo;s investment
in Nano9 is not readily available, and therefore is recorded at cost of $150,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &ldquo;Vivacitas Agreement #1&rdquo;) with Vivacitas Oncology
Inc. (&ldquo;Vivacitas&rdquo;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&rsquo;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&rsquo;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&ldquo;Seller&rdquo;) to purchase from
the Seller&rsquo;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&ldquo;IOPL&rdquo;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Chan Heng Fai Ambrose, a related party, is the Chairman of the Company&rsquo;s board of directors and its
largest shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&ldquo;Vivacitas Agreement #2&rdquo;),
whereas Vivacitas wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services
of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at
the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022. As of December 31, 2021, the Company has received 90,000 shares of Vivacitas in accordance with the Vivacitas
Agreement #2.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&rsquo;s equity position in Vivacitas to approximately 4,070,000
shares or 19% as of December 31, 2021. As of December 31, 2021, the fair value of the Company&rsquo;s investment in Vivacitas
is not readily available, and therefore is recorded at cost in the amount of $4,035,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6. Goodwill</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the years ended December 31, 2021, and 2020 consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
    adjustment related to acquisition and subsequent push down accounting</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
    adjustment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded, at which time $25,093,000 was allocated to
goodwill. No additional quantitative testing was performed for the years ended December 31, 2020,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
as there were no changes in variables and inputs to the valuation model. During the fourth quarter of 2021, we used qualitative
factors to determine whether it was more likely than not (likelihood of more than 50%) that the fair value of a reporting unit exceeded
its carrying amount. No goodwill impairment was identified as a result of these tests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7. Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT>The definite-lived
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intangible assets<FONT>, to be amortized over 20 years,</FONT> balances and activity for the years ended
December 31, 2021, and 2020 consisted of the following:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">12/31/2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12/31/2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Gross Carrying</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Amount</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accumulated</B></FONT></P>
                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amortization</B></FONT></P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Net Carrying</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Amount</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Gross Carrying</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Amount</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Accumulated</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Amortization</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Net Carrying</P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Amount</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Definitive-lived:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">22,260,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">(1,112,940</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">21,147,060</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">22,260,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">22,260,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,260,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,112,940</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,147,060</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,260,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,260,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents future amortization
of developed technologies:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)"><TD STYLE="width: 80%; text-align: right">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,112,940</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,112,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,112,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,112,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,112,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2021, the fair value of the assets acquired
by DSS on August 21, 2020, was concluded. This impairment analysis was conducted for financial reporting purposes in connection with U.S.
GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the Company has a history of negative cash flows from operations,
its financing arrangement with DSS (see Note 8) provides the opportunity to fund ongoing operations. This, as well as there being no
other indicators present for impairment, has led management to conclude that no impairment is necessary for the years ended December
31, 2020, and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8. Debt</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on December 31, 2021, the Company executed a Revolving Promissory Note (&ldquo;Note&rdquo;) with
DSS, a related party, which accrues interest at a rate of 4.25% and is due in full at the maturity date of December 31, 2022. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. In the case of default, at DSS&rsquo;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge.
DSS has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from
the date these financial statements were available to be issued. As of December 31, 2021 and 2020, this Note had an outstanding balance
of $12,523,615 and $1,059,229, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9. Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2020, the Company issued 125,064,621 shares of common stock to Global BioMedical Pte. Ltd. in consideration of $2,779,214 of
funds previously provided by Global BioMedical Pte. Ltd. which have historically been accounted for as proceeds from stockholder
in additional paid in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2020, the Company&rsquo;s Board of Directors approved the total number of shares of stock this Corporation is authorized to
issue shall be 500,000,000 shares. This stock shall be divided into two classes to be designated as Common Stock and Preferred Stock.
The total number of authorized shares of Common Stock shall be 400,000,000 shares with par value of $.001 per share. Each share of Common
Stock when issued, shall have one (1) vote on all matters presented to the stockholders. The total number of authorized shares of Preferred
Stock shall be 100,000,000 shares with par value of $.001 per share. The board of directors shall have the sole authority to authorize
the issuance of the Preferred Stock from time to time in one or more classes or series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 23, 2021, the Company, the Company&rsquo;s
Board of Directors approved the total number of shares of Common Stock to be 3,000,000,000 shares with a par value of $0.001. Each share
of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
10. Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&rsquo;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of December 31, 2021, this funding approximates $43,000 per month, and incurred $509,176 in expenses. The Company
incurred expenses of $329,409 (predecessor &ndash; January 1, 2020 to August 21, 2020) and $184,284 (successor &ndash; August 22, 2020
to December 31, 2020). On December 31, 2021 and December 31, 2020, the Company owed this related party $0 and had prepaid monthly fees
approximating $43,000 and $35,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $17,000 per month. As of December 31, 2021, the Company incurred $155,361
in related expenses. The Company incurred expenses of $0 (predecessor &ndash; January 1, 2020 to August 21, 2020) and $26,359 (successor
&ndash; August 22, 2020 to December 31, 2020).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
11. Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Royalty
Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&ldquo;Chemia&rdquo;) pursuant to which Chemia transferred
to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period
of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on
the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual
property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it&rsquo;s
licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid
50% to the Company and 50% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&ldquo;Addendum&rdquo;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company 5% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses bore by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the years ended December 31, 2021 and 2020, there
were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&rsquo;s efforts will end up in
any future sales of the technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
12. Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the
financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance
for the amount of tax benefits which are not expected to be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax benefit for the years ended December 31, 2021, and 2020 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    Tax Expense (Benefit)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor
    Year Ended <BR> December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successor
                                            Period</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>August
                                            22, 2020 To<BR> December 31, 2020</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predecessor
                                            Period</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>January
                                            1, 2020, To<BR> August 21, 2020</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    tax payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current tax payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(456,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(78,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(96,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,068,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,524,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(109,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    increase in valuation allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    income tax benefit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,395,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(82,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
components of deferred tax assets and liabilities are approximately as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Tax Assets &amp; Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Tax assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Operating loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,258,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">923,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">815,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    deferred tax assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,258,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">923,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">815,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax liability:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,667,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,856,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    deferred tax liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,667,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,856,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    valuation allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(448,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(319,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(815,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,857,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,252,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Statutory United States federal rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">21.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">21.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income taxes net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effective rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (the &ldquo;Act&rdquo;). The legislation
significantly changed U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system
and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The Act permanently reduced the U.S. corporate
income tax rate from a maximum of 35% to a 21% rate, effective January 1, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&ldquo;CARES Act&rdquo;) was enacted in response to the economic
uncertainty resulting from the COVID-19 pandemic. The CARES Act includes many measures to assist companies, including temporary changes
to income and non-income-based laws, some of which were enacted as part of the Tax Cuts and Jobs Act of 2017 (&ldquo;TCJA&rdquo;).
Some of the key changes include eliminating the 80% of taxable income limitation by allowing corporate entities to fully utilize NOLs
to offset taxable income in 2018, 2019 and 2020, allowing NOLs originating in 2018, 2019 and 2020 to be carried back five years, enhanced
interest deductibility, and retroactively clarifying the immediate recovery of qualified improvement property costs rather than over
a 39-year recovery period. During the year ended December 31, 2020, the Company was not able to benefit from these provisions. The Company
will continue to monitor additional guidance issued and assess the impact that various provisions will have on its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and 2020, the Company has net operating loss carry forwards of approximately $5,253,000 and $3,423,000, respectively.
The Company does not have other temporary differences associated with the amortization of intangible assets. As of December 31, 2021,
and 2020, the total deferred tax assets carry-forward were $1,258,000 and $923,000, respectively. The deferred tax assets could be carried
forward indefinitely. The full utilization of the deferred tax assets in the future is dependent upon the Company&rsquo;s ability to
generate taxable income. Considering the development stage of the Company, management believed that it was probable that the Company
would not use tax assets in the near future. Accordingly, a valuation allowance of an equal amount has been established. During the years
ended December 31, 2021 and December 31, 2020, the valuation allowance increased by $129,000 and decreased by $363,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
13. Supplemental Cash Flow Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes supplemental cash flows for the years ended December 31, 2021, and 2020 associated with the acquisition of
Impact BioMedical:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    paid</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,010</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax provision</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,233,590</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,093,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of intangible assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,260,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in additional-paid-in-capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38,197,965</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in non-controlling interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,921,445</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
14. Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated all subsequent events and
transactions through June 24, 2022, the date that the consolidated financial statements were available to be issued and noted
no subsequent events requiring financial statement recognition or disclosure, except as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&ldquo;Global&rdquo;), and Impact BioLife Sciences, Inc. (&ldquo;BioLife
Sciences&rdquo;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&ldquo;GRDG Agreement&rdquo;), whereas GRDG would
transfer its 20% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, not contingent liability has been recognized under the GRDG Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="v_001"></A>Table
of Contents</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAGE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
    Financial Statements (unaudited)</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#af_002">Consolidated
    Balance Sheets <B>(unaudited)</B></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-18</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#af_003">Consolidated
    Statements of Operations <B>(unaudited)</B></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#af_004">Consolidated
    Statements of Stockholder&rsquo;s Equity <B>(unaudited)</B></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-20</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#af_005">Consolidated
    Statements of Cash Flows <B>(unaudited)</B></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-21</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#af_006">Notes
    to Consolidated Financial Statements <B>(unaudited)</B></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-22</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="af_002"></A>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">September
    30, 2022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current portion of notes
    receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">206,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">369,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">287,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other investments</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,882,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,817,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,081,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Goodwill</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,093,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,093,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other intangible assets,
    net</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,312,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,147,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,656,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,425,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&rsquo;
    EQUITY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">115,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued expenses and deferred
    revenue</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note
    payable, related party</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,280,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,524,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,336,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,645,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax liability, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">5,114,000</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,856,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,450,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,501,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments and contingencies
    (Note 9)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo; equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, $.001 par value; 3,000,000,000
    shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on December 31, 2021)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,092,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,574,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total stockholders&rsquo;
    equity of the company</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">33,091,000</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,609,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-controlling
    interest in subsidiary</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,115,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,315,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total stockholder&rsquo;s
    equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,206,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,924,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&rsquo; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,656,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,425,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="af_003"></A>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Nine Months Ended <BR> September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Costs and expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative (including stock based compensation)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">286,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">282,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research &amp; Development</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">704,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">645,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional Services</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">539,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">315,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">835,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">835,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    General Expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50<FONT STYLE="font-family: Times New Roman, Times, Serif">,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total costs and expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,414,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,111,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,414,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,111,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expense):</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest income</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(133,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(178,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations
    before income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,460,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,131,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income tax (expense)
    benefit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,258,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">228,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,718,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,903,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from continuing operations attributed to noncontrolling interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">282,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss attributable to common stockholders</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,518,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,621,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss per common share:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.03</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.02</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.03</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.02</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares used in computing
    loss per common share:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="af_004"></A>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Stockholder&rsquo;s Equity</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    Paid-in</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non- controlling
    <BR>Interest in</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsidiary</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, December 31, 2021</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,574,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,315,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,924,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,518,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(200,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,718,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, September
    30, 2022</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,092,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,115,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,206,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(271,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,860,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,772,000</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,621,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(282,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,903,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, September
    30, 2021</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,073,621</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,058,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,892,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,578,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,869,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="af_005"></A>Impact
BioMedical Inc and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Cash Flows</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            the Nine Months Ended</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">September
                                            30,</FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from operating
    activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,718,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,903,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used by operating activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation and amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">835,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">835,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">1,258,000</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">(228,000</P></TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease (increase) in
    assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">(44,000</P></TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses and other
    current assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase (decrease) in
    liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(71,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">91,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used by operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,708,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,237,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of investment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(65,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,166,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note
    receivable investment</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,353,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used by investing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(74,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,519,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Borrowings
    from parent</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,837,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,777,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,837,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,777,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">55,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at beginning of period</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">72,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at end of period</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the unaudited consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="af_006"></A>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Nature of Operations and Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nature
of Operations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &ldquo;Company&rdquo;, &ldquo;Impact BioMedical&rdquo;, &ldquo;We&rdquo;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&ldquo;Global BioLife&rdquo;), one of the Company&rsquo;s subsidiaries and the main operating company of the group, focuses
on research in in four main areas: (i) the &ldquo;Linebacker&rdquo; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &ldquo;Laetose,&rdquo;; (iii) a multi-use fragrance called &ldquo;3F&rdquo; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Linebacker</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Laetose</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &ldquo;Laetose,&rdquo;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&ldquo;Sweet Sense&rdquo;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet Sense Inc.
from Quality Ingredients, LLC for $91,000. Sweet Sense is now an 81.8% owned subsidiary of the Impact BioMedical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Functional
Fragrance Formulation (&ldquo;3F&rdquo;)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&ldquo;Chemia&rdquo;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equivir</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued 9,000 shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly&ndash;owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&ldquo;SGXST&rdquo;). On March 31, 2020 the Company issued 125,064,621 shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&rsquo;s common
stock issued and outstanding was split into nine shares of the Company&rsquo;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays our research, testing and marketing efforts or wider economic downturns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 12, 2020 Alset International Limited (&ldquo;Alset&rdquo;) a related party, Global BioMedical Pte Ltd., a related party, DSS, Inc
(&ldquo;DSS&rdquo;), a related party and DSS BioHealth Security Inc. (&ldquo;DSS BioHealth&rdquo;), a related party, signed Term Sheets
and subsequently on April 21, 2020, these four companies entered into Share Exchange Agreement (&ldquo;Share Exchange&rdquo;), based
on which Global BioMedical Pte Ltd. agreed to sell all of the issued and outstanding shares of the Company to DSS BioHealth in exchange
for the combination of common and preferred shares of DSS. Under the terms of the Share Exchange, DSS issued 483,334 shares of the DSS
Common Stock nominally valued at $6.48 per share, and 46,868 newly issued shares of the DSS Series A Convertible Preferred Stock (&ldquo;<U>Series
A Preferred Stock</U>&rdquo;), with a stated value of $46,868,000, or $1,000 per share, for a total consideration valued at $50 million.
Due to several factors, including a discount for illiquidity, the value of the Series A Preferred Stock was discounted from $46,868,000
to $35,187,000, thus reducing the final consideration given to approximately $38,319,000. The Company&rsquo;s Chairman, Heng Fai Ambrose
Chan, a related party, who is also the largest shareholder of Alset, at the time of the signing of the Share Exchange Agreement was the
beneficial owner of approximately 18.3% of the outstanding shares of DSS and is the Chairman of the Board of Directors of DSS. On August
21, 2020, the transaction was concluded, and the Company became a direct wholly owned subsidiary of DSS BioHealth. In connection with
the acquisition, and the related accounting determination, DSS BioHealth has elected to apply push-down accounting and reflect in its
financial statements of Impact BioMedical, the fair value of its assets and liabilities. The Company&rsquo;s Consolidated Financial Statements
for periods following the close of the acquisition are labeled &ldquo;Successor&rdquo; and reflect DSS BioHealth&rsquo; s basis in the
fair values of the assets and liabilities of Impact BioMedical. All periods prior to the closing of the acquisition reflect the historical
accounting basis in the Company&rsquo;s assets and liabilities and are labeled &ldquo;Predecessor&rdquo;. The fair value of the consideration
transferred was approximately $38,319,000. Utilizing an income approach, the Company has completed its valuations of certain developed
technology and pending patents assets acquired in the transaction as well the fair value of the non-controlling interests. More specifically,
a Multi-Period Excess Earnings Method (&ldquo;MPEEM&rdquo;) estimates the value of an intangible asset by quantifying the amount of residual
(or excess) estimated cash flows generated by the asset and discounting those cash flows to the present. These have been valued at approximately
$22,260,000 and $3,910,000, respectively, and are included on the Consolidated Balance Sheet at December 31, 2020. Estimated useful life
of these assets is twenty years, based on the remaining terms of the related patents, with annual amortization approximating $1,112,000.
The Company has also completed its valuation of goodwill and deferred tax liabilities of Impact BioMedical, and has recorded goodwill
of approximately $25,093,000, driven by other intangible assets that do not qualify for separate recognition, and a deferred tax liability
of approximately $5,234,000. The goodwill is not deductible for tax purposes and has been allocated to Impact BioMedical in totality
as a single reporting unit. The Company is committed to both funding research and developing intellectual property portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basis
of Presentation and Principles of Consolidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&ldquo;U.S. GAAP&rdquo;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&ndash;controlling
interest represents the minority equity investment in the Company&rsquo;s subsidiaries, plus the minority investors&rsquo; share of the
net operating results and other components of equity relating to the non&ndash;controlling interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of
    consolidated subsidiary</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">State or
    other jurisdiction of incorporation or organization</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date of
    incorporation or formation</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attributable</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">interest
                                            as of <BR> September 30, <BR> 2022</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attributable
    <BR> interest as of <BR> December 31, <BR> 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global BioMedical, Inc.</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 18, 2017</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90.9</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90.9</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global BioLife, Inc.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 14, 2017</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">BioLife Sugar, Inc</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 23, 2018</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Happy Sugar Inc</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">August 17, 2018</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sweet Sense Inc.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 30, 2018</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global Sugar Solutions Inc.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Nevada</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">November 7, 2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">80</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022 and December 31, 2021, the aggregate noncontrolling interest was equity of $3,115,000 and $3,315,000 respectively,
which are separately disclosed on the Consolidated Balance Sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Summary of Significant Accounting and Reporting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Use
of estimates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reclassifications</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
amounts on the accompanying consolidated statement of operations for the nine months ended September 30, 2021 have been reclassified
to conform to current year presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Earnings
(Loss) per Share</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed similar to basic income
(loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the nine months ended September 30, 2022 or 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&rsquo;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
and cash equivalents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were no cash equivalents as of September 30, 2022 and December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 5 for further
discussion on investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Goodwill</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No impairment was recognized during
the nine months ended September 30, 2022 or the year ended December 31, 2021 (see Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intangible
Assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired
intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually, as of December 31<SUP>st,
</SUP>or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their
estimated fair values. Impairment is tested under ASC 350. No impairment was recognized as of September 30, 2022 or December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Income
Taxes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a wholly owned subsidiary of DSS, Inc. and is included in its consolidated tax returns. For purposes of this financial statement
the portion of the consolidated tax provision of the parent and its subsidiaries allocated to the Company is calculated as if the Company
were a separate taxpayer that filed its own income tax returns. Any net benefit or cost recognized as a result of the filing of a consolidated
tax return with DSS is reflected in the income tax provision of DSS. As of December 31, 2021, DSS, Inc. has approximately $58.5 million
in net operating loss carry forwards (&ldquo;NOL&rdquo;) available to reduce future taxable income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our effective tax rate (ETR) from continuing
operations was -51% for the nine months ended September 30, 2022, and 43% for the year ended December 31, 2021. Management continuously
evaluates estimates as part of its accounting procedures. For the year ended December 31, 2021, the Company recorded a tax benefit associated
with net operating losses incurred that year. During the third quarter, and for the nine-months ended September 30, 2022, because of
delays in revenue generation associated with licensing agreements, the Company reevaluated the ultimate probability of the recognition
of its gross deferred tax assets and increased the valuation allowance against these deferred tax assets by $1,258,000, resulting in
the significant change to the ETR year-over-year.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $704,000 and $645,000 for the nine months ended
September 30, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Standards</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of September 30, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continuing
Operations and Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through September
30, 2023, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&rsquo;s management intends to take actions necessary to continue as a going concern. Management&rsquo;s
plans concerning these matters includes, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. Prepaid Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses as of September 30, 2022, and December 31, 2021 include mostly research and development fees paid to GRDG Sciences, LLC. (&ldquo;GRDG&rdquo;),
a related party, approximating $46,000 and $43,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. Notes Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&ldquo;Promissory Note 1&rdquo;) with an individual. The Company
loaned the principal sum of $206,000, with interest at a rate of 6.5%, and maturity date of August 19, 2022. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to August 19, 2023. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $206,000 and $197,000 as of September 30, 2022 and December 31, 2021, respectively. Promissory Note 1 is classified
in current notes receivable on the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&ldquo;DSS PureAir&rdquo;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&ldquo;Promissory Note 2&rdquo;) with a limited liability company registered in the state of Texas (&ldquo;Borrower&rdquo;). The
Promissory Note 2 has an aggregate principal balance up to $5,000,000, to be funded at the request of the borrower. Promissory Note 2,
which incurs interest at a rate of 6.5% due quarterly, has a maturity date of May 14, 2023. Promissory Note 2 contains an options conversion
clause that allows the Company to convert all, or a portion of all, into newly issued member units of the borrower with the maximum principal
amount equal to 18% of the total equity position at conversion. On June 1, 2022, 100% of the Company&rsquo;s interest in DSS PureAir
was assigned to DSS BioHealth Holdings, Inc., a related party, and wholly owned subsidiary of DSS BioHealth Security, Inc. Included in
this transaction was the outstanding principal and interest of Promissory Note 2 along with the related Note payable, related party.
The outstanding principal and interest at September 30, 2022, and December 31, 2021 is $0 and $5,081,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &ldquo;Subscription Agreement&rdquo;) with BioMed Technologies
Asia Pacific Holdings Limited (&ldquo;BioMed&rdquo;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase 525 ordinary shares or 4.99% of BioMed at a purchase price of approximately $632,000. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &ldquo;Distribution
Agreement&rdquo;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="margin-top: 0pt; border-bottom: Black 1.5pt solid; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&rsquo;s PGut Premium Probiotics<SUP>&reg;</SUP>,
PGut Allergy Probiotics<SUP>&reg;</SUP>, PGut SupremeSlim Probiotics<SUP>&reg;</SUP>, PGut Kids Probiotics<SUP>&reg;</SUP>, and PGut
Baby Probiotics<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&ldquo;SPA&rdquo;) with Nano9, LLC. (&ldquo;Nano9&rdquo;),
a Utah limited partnership. For the consideration of $150,000 the Company obtained 1,000 membership units, or approximately 10% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of Mach 31, 2022 and December 31, 2021, the fair value of the
Company&rsquo;s investment in Nano9 is not readily available, and therefore is recorded at cost of $150,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &ldquo;Vivacitas Agreement #1&rdquo;) with Vivacitas Oncology
Inc. (&ldquo;Vivacitas&rdquo;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&rsquo;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&rsquo;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&ldquo;Seller&rdquo;) to purchase from
the Seller&rsquo;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&ldquo;IOPL&rdquo;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Heng Fai Ambrose Chan, a related party, the Chairman of the Company&rsquo;s board of directors and its largest
shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&ldquo;Vivacitas Agreement #2&rdquo;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&rsquo;s equity position in Vivacitas to approximately 120,000
shares or 19% as of September 30, 2022. As of September 30, 2022, and December 31, 2021, the fair value of the Company&rsquo;s
investment in Vivacitas is not readily available, and therefore is recorded at cost in the amount of $4,100,000 and $4,035,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6. Goodwill</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the nine months ended September 30, 2022 and year ended December 31, 2021 consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,093,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Goodwill
    adjustment</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance at September 30, 2022</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,093,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021 and 2020, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests.
During the fourth quarter of 2021 and 2020, we used qualitative factors to determine whether it was more likely than not (likelihood
of more than 50%) that the fair value of a reporting unit exceeded its carrying amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7. Debt</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on September 30, 2022, the Company executed a Revolving Promissory Note (&ldquo;Note&rdquo;) with
DSS, a related party which accrues interest at a rate of 4.25% and is due in full at the maturity date of March 31, 2023. The revolving
nature of this Note permits principal amounts borrowed to be repaid and reborrowed. In the case of default, at DSS&rsquo;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate. DSS has not established a maximum borrowing amount and intends to continue to fund the operations
of the Company through a year from the date these financial statements were available to be issued. As of September 30, 2022 and December
31, 2021, this Note had an outstanding balance of $9,280,000 and $12,523,615, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="margin-top: 0pt; border-bottom: Black 1.5pt solid; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8. Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company should fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&rsquo;s subsidiaries and is
owned by Daryl Thompson, related party and a director of many subsidiaries of the Company, to do the development and research works on
the biomedical products for the Company. Monthly payments approximate to $43,000 and $42,000 for the nine months ended September 30,
2022 and 2021, respectively. The Company incurred expenses approximating $390,000 and $375,000 for the nine months ended September 30,
2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party, on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $17,000 per month. As of September 30, 2022 and 2021, the Company incurred
approximately $149,000 in related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on September 30, 2022, the Company executed a Revolving Promissory Note (&ldquo;Note&rdquo;) with
DSS, a related party which accrues interest at a rate of 4.25% and is due in full at the maturity date of September 30, 2023. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. In the case of default, at DSS&rsquo;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate. DSS has not established a maximum borrowing amount and intends to continue to fund the operations
of the Company through a year from the date these financial statements were available to be issued. As of September 30, 2022 and December
31, 2021, this Note had an outstanding balance of $9,280,000 and $12,523,615, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&ldquo;DSS PureAir&rdquo;), a wholly owned subsidiary of the Company, entered into a convertible
promissory note (&ldquo;Promissory Note 2&rdquo;) with a limited liability company registered in the state of Texas
(&ldquo;Borrower&rdquo;). The Promissory Note 2 has an aggregate principal balance up to $5,000,000, to be funded at request of the
borrower. The Promissory Note 2, which incurs interest at a rate of 6.5% due quarterly, has a maturity date of May 14, 2023. The
Promissory Note 2 contains an options conversion clause that allows the Company to convert all, or a portion of all, into new issued
member units of the borrower with the maximum principal amount equal to 18% of the total equity position at conversion. The
outstanding principal and interest as of March 31, 2022, approximated $5,164,000, which is classified as Notes receivable on the
consolidated balance sheet. Subsequent to the execution of the Promissory Note 2, DSS PureAir entered into distribution agreement
with Borrower, who is in the business of manufacturing and supplying proactive air and surface purification systems, to sell its
products within specified territories. In June of 2022, the Company transferred 100% of its interest in DSS Pure Air to DSS
Biohealth Holdings, Inc., a related party and wholly owned subsidiary of DSS BioHealth Security, Inc. Associated with this
transfer is Promissory Note 2 and the related Note payable, related party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
Biomedical, Inc. and Subsidiaries</B></FONT></P>

<DIV STYLE="margin-top: 0pt; border-bottom: Black 1.5pt solid; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9. Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&ldquo;Chemia&rdquo;) pursuant to which Chemia transferred
to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period
of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on
the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual
property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it&rsquo;s
licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid
50% to the Company and 50% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&ldquo;Addendum&rdquo;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company 5% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses bore by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the nine months ended September 30, 2022 and
2021, there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&rsquo;s efforts will
end up in any future sales of the technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&ldquo;Global&rdquo;), and Impact BioLife Sciences, Inc. (&ldquo;BioLife
Sciences&rdquo;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&ldquo;GRDG Agreement&rdquo;), whereas GRDG would
transfer its 20% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2022, Impact BioMedical entered into a License Agreement (&ldquo;Equivir License&rdquo;) with ProPhase Labs, Inc. (&ldquo;ProPhase&rdquo;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&rsquo;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of September
30, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
10. Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2020, the Company issued 125,064,621 shares of common stock to Global BioMedical Pte. Ltd. in consideration of $2,779,214 of
funds previously provided by Global BioMedial Pte. Ltd. which have historically been accounted for as proceeds from stockholder in additional
paid in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2020, the Company&rsquo;s Board of Directors approved the total number of shares of stock this Corporation is authorized to
issue shall be 500,000,000 shares. This stock shall be divided into two classes to be designated as Common Stock and Preferred Stock.
The total number of authorized shares of Common Stock shall be 400,000,000 shares with par value of $.001 per share. Each share of Common
Stock when issued, shall have one (1) vote on all matters presented to the stockholders. The total number of authorized shares of Preferred
Stock shall be 100,000,000 shares with par value of $.001 per share. The board of directors shall have the sole authority to authorize
the issuance of the Preferred Stock from time to time in one or more classes or series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Company, the Company&rsquo;s Board of Directors approved the total number of shares of Common Stock to be 3,000,000,000
shares with a par value of $0.001. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
11. Supplemental Cash Flow Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes supplemental cash flows for the nine-months ended September 30, 2022, and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 60%">Transfer of promissory note 2 to related party</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 16%">5,164,000</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 16%">&nbsp;&nbsp;&nbsp;&nbsp; -</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer of note payable, related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,164,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
12. Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all subsequent events and transactions through November 30, 2022, the date that the consolidated
financial statements were available to be issued, and noted no subsequent events requiring financial statement recognition or
disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: justify; width: 100%"><A HREF="#toc_001" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    11.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change in Auditors</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 2, 2021,
Freed Maxick CPAs, P.C. (the &ldquo;Freed Maxick&rdquo;) resigned as our independent registered public accounting firm, and on
June 2, 2022, we engaged Turner, Stone &amp; Company, L.L.P. (the &ldquo;Turner Stone&rdquo;) as our independent registered public
accounting firm, subject&nbsp;<FONT STYLE="background-color: white">to completion of Turner Stone&rsquo;s standard client acceptance
process and execution of an engagement letter</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Freed Maxick&rsquo;s
audit report on our financial statements for the year ended December 31, 2020 contained no adverse opinion or disclaimer of opinion,
nor was it qualified or modified as to uncertainty, audit scope or accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the year ended December
31, 2020, and through the interim period ended December 2, 2021, there were no &ldquo;disagreements&rdquo; (as such term is defined in
Item 304 of Regulation S-K) with Freed Maxick on any matter of accounting principles or practices, financial statement disclosure,
or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of the Freed Maxick, would have caused
them to make reference thereto in their reports on the financial statements for such periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">On
June 29, 2022, the Company&rsquo;s board of directors approved replacing Turner Stone as our independent registered public accounting
firm, with Grassi &amp; Co. CPAs, P.C. (the &ldquo;New Accountant&rdquo;) as our independent registered public accounting firm, effective
July 1, 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the year ended December
31, 2021, and through the interim period ended September 30, 2022, there were no &ldquo;disagreements&rdquo; (as such term is defined
in Item 304 of Regulation S-K) with Turner Stone on any matter of accounting principles or practices, financial statement disclosure,
or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of the Turner Stone, would have caused them
to make reference thereto in their reports on the financial statements for such periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Turner Stone&rsquo;s audit report on our financial statements for the
year ended December 31, 2021 contained no adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty,
audit scope or accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We authorized the former
accountants to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited
periods by the former accountants, including with respect to the subject matter of each reportable event.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Prior to retaining the
New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting principles to
a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company&rsquo;s
financial statements; or (ii) any matter that was the subject of a &ldquo;disagreement&rdquo; or a &ldquo;reportable event&rdquo; (as
those terms are defined in Item 304 of Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-size: 10pt"><B>Item 13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Other Expenses of Issuance and Distribution.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth an itemization of all estimated expenses in connection with the issuance and distribution of the securities
to be registered. All of the fees set forth below are estimates except for the SEC registration fee and transfer and distribution agent
fees and expenses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Item</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration
    Statement filing fee</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">10.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accountants
    fees and expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
    fees and expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printing</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfer
    and distribution agent fees and expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,010.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
    of Directors and Officers.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of the Amended and Restated Articles of Incorporation of the Company, as amended, as of the date of this Registration
Statement, the liability of directors and officers of the Company shall be eliminated or limited to the fullest extent permitted by the
Nevada Revised Statutes (&ldquo;NRS&rdquo;). If the NRS is amended to further eliminate or limit or authorize corporate action to further
eliminate or limit the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated
or limited to the fullest extent permitted by the NRS, as so amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
    Sales of Unregistered Securities.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    16.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits
    and Financial Statement Schedules.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the Exhibit Index immediately preceding the signature page hereto, which is incorporated by reference as if fully set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
financial statement schedules are provided because the information called for is not required or is shown either in our consolidated
financial statements or notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    17.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Undertakings.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    The undersigned registrant hereby undertakes to file, during any period in which offers or sales are being made, a post-effective
    amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
    recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
    set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
    (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
    end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
    424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering
    price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and (iii) To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act of 1933, each
    such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
    the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to remove from registration by means of a post-effective amendment any of the securities
    being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Options: NewSection; Value: 48 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
    to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
    will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424 (&sect; 230.424 of this chapter);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933
    and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
    of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
    being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
    submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
    in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
    to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
    time it was declared effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
    prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 48 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    <BR>
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Articles of Incorporation of Impact BioMedical, Inc. dated July 29, 2020</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315221003571/ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex3-3.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of Sichenzia Ross Ference LLP</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex10-1.htm" STYLE="-sec-extract: exhibit">Share Exchange Agreement dated as of April 27, 2020, among Document Security Systems, Inc., DSS BioHealth Security, Inc., Singapore eDevelopment Limited and Global BioMedical Pte Ltd.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-2.htm" STYLE="-sec-extract: exhibit">Subscription Agreement dated December 19, 2020, between the Company and BioMed Technologies Asia Pacific Holdings Limited</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note with Dustin Michael Crum dated February 21, 2021</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-4.htm" STYLE="-sec-extract: exhibit">Stock Purchase Agreement dated March 15, 2021 between the Company and Vivacitas Oncology Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-5.htm" STYLE="-sec-extract: exhibit">Convertible Promissory Note dated May 14, 2021</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-6.htm" STYLE="-sec-extract: exhibit">Revolving Promissory Note dated December 31, 2020</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-7.htm" STYLE="-sec-extract: exhibit">Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated August 15, 2018</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-8.htm" STYLE="-sec-extract: exhibit">Addendum to Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated November 27, 2018</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-9.htm" STYLE="-sec-extract: exhibit">Distribution Agreement by and between BioMed Technologies Asia Pacific Holdings Limited and Impact BioMedical, Inc., dated December 9, 2020</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-10.htm" STYLE="-sec-extract: exhibit">Global BioLife, Inc. Stockholders&rsquo; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated April 26, 2017</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-11.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Global BioLife, Inc. Stockholders&rsquo; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated May 22, 2018</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-12.htm" STYLE="-sec-extract: exhibit">Amendment No. 2 to Global BioLife, Inc. Stockholders&rsquo; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated August 2020</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-13.htm" STYLE="-sec-extract: exhibit">Impact BioLife Science, Inc. Stockholders Agreement among Impact BioLife Science, Inc., Impact BioMedical, Inc. and GRDG Sciences, LLC, dated December 11, 2020</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.14**</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex10-14.htm" STYLE="-sec-extract: exhibit">Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated May 16, 2022</A></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-16.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Revolving Promissory Note dated December 31, 2021.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-17.htm" STYLE="-sec-extract: exhibit">Amendment No. 2 to Revolving Promissory Note dated March 31, 2022.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-18.htm" STYLE="-sec-extract: exhibit">License Agreement with ProPhase Labs, Inc. dated March 17, 2022.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-19.htm" STYLE="-sec-extract: exhibit">License Agreement with ProPhase Labs, Inc. dated July 18, 2022.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-20.htm" STYLE="-sec-extract: exhibit">Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated February 15, 2022.</A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">16.1**</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex16-1.htm" STYLE="-sec-extract: exhibit">Letter from Freed Maxick CPAs, P.C.</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex21-1.htm" STYLE="-sec-extract: exhibit">List of subsidiaries of Impact BioMedical, Inc.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Turner, Stone &amp; Company L.L.P.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-2.htm">Consent of Freed Maxick CPAs, P.C.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Sichenzia Ross Ference LLP (included as part of Exhibit 5.1).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex107.htm" STYLE="-sec-extract: exhibit">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">To
                                            be filed by amendment</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 48 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">Pursuant to the requirements of
the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the city of West Henrietta, on the 31st day of January, 2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPACT
    BIOMEDICAL, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Frank D. Heuszel</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    January 31, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons
in the capacities indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Frank D. Heuszel</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">January 31, 2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    *</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer) and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">January 31, 2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    *</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasurer
    and Secretary (Principal Financial Officer and Principal Accounting Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">January 31, 2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    *</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    &ldquo;JT&rdquo; Thatch </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">January 31, 2023</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    *</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">January 31, 2023</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    By: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Frank D. Heuszel</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attorney-in-fact</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 11.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 11.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 11.05pt; text-align: center">Your
Vision Our Focus

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 11.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="height: 81pt; width: 81pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated June 24, 2022, in Amendment No. 8 to the Registration Statement (No. 333-253037) on Form
S-1 of Impact BioMedical, Inc., for the registration of its common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus included in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Turner, Stone &amp; Company, L.L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner,
    Stone &amp; Company, L.L.P.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Accountants
    and Consultants</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>12700
    Park Central Drive, Suite 1400
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">Dallas,
    Texas 75251</P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: 972-239-1660 &frasl; Facsimile: 972-239-1665</FONT></P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toll
    Free: 877-853-4195</FONT></FONT></P>
                                                                             <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Web
    site: turnerstone.com</FONT>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_002.jpg" ALT="" STYLE="height: 61px; width: 180px"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use in this Amendment No. 8 to the Registration Statement (No. 333-253037) on Form S-1 of Impact BioMedical, Inc., of
our report dated September 29, 2021, relating to the consolidated financial statements of Impact BioMedical, Inc. as of and for the period
ended December 31, 2020, appearing in the Prospectus, which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus included in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Freed Maxick CPAs, P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rochester,
New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>forms-1a_001.jpg
<TEXT>
begin 644 forms-1a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4H _P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH9+JWB_P!9/$G^
M\X%-2\M93A+B%SZ*X- %BBBB@ HHHH **** "BC(II91U8#ZF@+CJ*:&!Z$'
MZ&G9H"X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?!SQIKP61=+-C V#YMZWE<?[OWOTKT?2/V;[5 'UO799#U,=G$$'_?39_D*
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MS&UMF!;'^TYX'X9^M>F:-!X&\'R1VVCV<$<K$(UPB[V],M(W./H:Y?4-9O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KPO]I7_D$^'_\ KO-_Z"M>Z5X7^TK_ ,@GP_\
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M/NCZ4M(/NCZ4M>&>J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[BWBF0_PR(&'ZUR.L?##PYJJ,8K<V,QZ/;<#\5Z?EBM_1?$.F^(+-;C3[I)
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MX#M/%6F7-[=W<\(CF\I$B [*"22<_P!X?E6E.?LZ*=0B<.>JU X.BK6I6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK*PVDG-]$>,ZI=C4-7O;U00+B=Y0&ZC<Q//YU4HHKKBK*QSMW"BBBF 4444
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M%>K?\*4UC_GK:?\ ?9_PH_X4IK'_ #UM/^^S_A1^[_G7WA[_ /*SRFBO5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *:?O4ZFG[U 'RO?_ /(1NO\ KL_\S5>K%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@;+8_ ?I7-Z3KVJ:%([Z;>/;F08< !E;ZJ00?RI=7\0:KKTD;ZE>O<>6,(N
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M1_$D>K0_AHT%Z4^F+TI]<QN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MZBY>7R_4]6#)_P +CN%) F>PVP$G^/RQT]\9KR==/O99;E1;2E[96:?Y3^[
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M_D:6ZFDM_AAHDT+LDL>H2.CJ<%2,D$55L;VWOOA_?Z3//%%<6=PMU;"60*9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BDVBG44 -VBC:*=10 W:
M*-HIU% #=HHVBG44 -VBD(&*=7.^)_%EIX5B@EO;6[EBF8J'MT5@I'.#EAU_
MH:J$7.7+%79,I**O+8C\##_BEU_Z^;C_ -'/72;17F7@;QUI[K;:''9WKW4T
M\K JJ; &=GR3NS@ \\=CUKT^ML5"4*LE)6NS.A.,H+EZ";11M%.HKG-ANT4;
M13J* &[11M%.HH ;M%&T4ZB@!NVEQ2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#<9#?C657"SIQYF:4\1&H[([$&EJO')NJ<5S'0+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ)J$)EEM1.51"C,&.]LD)A=W.3UQVJQ)H.FZC8Z=-:O91R3:FME(UDT_E[6
M()\[G<.>G'-'MD@]FSC**[71;K3(?&]I:0:)!&8KY8HI3/*7 #8RP+8+=#P
M.O!KE]6GCGU.=XK:&W4.1LB+D$Y//S,3G\<4XU>:5K"<+)Z[%*BBBM2 KUCX
M0'&E:Q_UVC_]!->3UZO\(?\ D$ZQ_P!=H_\ T$URXS^$S?#?Q$>E6S9J^O2L
MVUK17I7D,]1#Z***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH C<'J*H3PPR2B22UAD=<X9D!-:1%1M&#33L)HRRD/_/G;_P#?
ML4FV'_GSM_\ OV*T3 /2CR!Z57,+E,[;#_SY6_\ W['^%&V'_GRM_P#OV/\
M"M'R!Z4>0/2CF#E,[;#_ ,^5O_W['^%&V'_GRM_^_8_PK1\@>E!@&.E-2$XZ
M'!_#N4W/A1)+B-+B0SR9>4;F//J:ZO;#_P ^5O\ ]^Q_A7.?"V(/X+C/_3>3
M^==IY(]*VQ+M6DO,SH*]./H9VV'_ )\K?_OV/\*-L/\ SY6__?L?X5H^0/2C
MR!Z5AS&O*9VV'_GRM_\ OV/\*-L/_/E;_P#?L?X5H^0/2CR!Z4<P<IG@1J<K
M:0 ]B$%.;S)FRWY5>\@>E.$(':E<+$,$>*N"FJN*?2904444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 2B@UR=OX@US4;J_73M+LGAM+N2UWS7;(
MS%,9. A]:<8.5VNA,I*.YUE%<[]M\6?] ?2__ Y__C='VWQ9_P! ?2__  .?
M_P"-U?LGW7WD^T79_<=%17._;?%G_0'TO_P.?_XW1]M\6?\ 0'TO_P #G_\
MC='LGW7WH/:+L_N.BHKG?MOBS_H#Z7_X'/\ _&Z/MOBS_H#Z7_X'/_\ &Z/9
M/NOO0>T79_<=%17._;?%G_0'TO\ \#G_ /C='VWQ9_T!]+_\#G_^-T>R?=?>
M@]HNS^XZ*BN=^V^+/^@/I?\ X'/_ /&Z/MOBS_H#Z7_X'/\ _&Z/9/NOO0>T
M79_<=%17._;?%G_0'TO_ ,#G_P#C='VWQ9_T!]+_ / Y_P#XW1[)]U]Z#VB[
M/[CHJ*YW[;XL_P"@/I?_ ('/_P#&Z/MOBS_H#Z7_ .!S_P#QNCV3[K[T'M%V
M?W'145SOVWQ9_P! ?2__  .?_P"-T?;?%G_0'TO_ ,#G_P#C='LGW7WA[1=G
M]QT5%<?JVO\ B;1]+N-0N='T_P F!=S;+UB>N.FP>M2C4/&I_P"8)IG_ (%G
M_"G[&5KW7WH7MHWM9_<SJZ*Y3^T/&O\ T!=,_P# L_X4?VAXU_Z NF?^!9_P
MH]B^Z^]![5=G]S.KHKE/[0\:_P#0%TS_ ,"S_A1_:'C7_H"Z9_X%G_"CV+[K
M[T'M5V?W,ZNBN4_M#QK_ - 73/\ P+/^%']H>-?^@+IG_@6?\*/8ONOO0>U7
M9_<SJZ*Y3^T/&O\ T!=,_P# L_X4?VAXU_Z NF?^!9_PH]B^Z^]![5=G]S.K
MQ1BN4_M#QK_T!=,_\"S_ (4?VAXU_P"@+IG_ (%G_"CV+[K[T'M5V?W,ZO%&
M*Y3^T/&O_0%TS_P+/^%']H>-?^@+IG_@6?\ "CV+[K[T'M5V?W,ZO%(1P:Y7
M^T/&O_0%TS_P+/\ A1_:'C7_ * NF?\ @6?\*/8ONOO0>T79_<RE\*O^1+3_
M *^)/YUVWX\UY]X<T3QMX?T=+&V&AF,.S_OGE+@D_P"R,5=OKWQUIVFW-[,G
MAYHK:)Y7"&<L0H).,]^*UKP4ZLG&2U?<SIRY()-/1':XI<5QUG>>-[RR@NHX
M= "31K(H9Y@0&&1GCWJQO\=_\\?#W_?R;_XFL72L[77WFBJI]']QU&*,5R^_
MQW_SQ\/?]_)O_B:-_CO_ )X^'O\ OY-_\31[/S7WC]IY/[CJ,4M<MO\ '?\
MSQ\/?]_)O_B:-_CO_GCX>_[^3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\
M?R;_ .)HW^._^>/A[_OY-_\ $T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_P")
MHW^._P#GCX>_[^3?_$T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_XFC?X[_P">
M/A[_ +^3?_$T>S\U]X>T\G]QU-%<MO\ '?\ SQ\/?]_)O_B:-_CO_GCX>_[^
M3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\ ?R;_ .)HW^._^>/A[_OY-_\
M$T>S\U]X>T\G]QU-%<7J6I>--+TRXOIX-!,5O&9'"23%B ,\9 YJY;W?C"YM
MXITM-$"R(' -Q+G!&?[E#I.U[JWJ+VJO:S^XZBBN<\SQE_SZZ'_X$2__ !%'
MF>,O^?70_P#P(E_^(I>S\U]X^==G]QT=%<YYGC+_ )]=#_\  B7_ .(H\SQE
M_P ^NA_^!$O_ ,11[/S7WASKL_N.CHKG/,\9?\^NA_\ @1+_ /$4>9XR_P"?
M70__  (E_P#B*/9^:^\.==G]QT=%<YYGC+_GUT/_ ,")?_B*/,\9?\^NA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC=VT\_+[[')74I3BX2_KN>AP>;]GC$Y4R[1O*#"EL<X![9J:JWVRW_Y^(?\
MOX*/MEO_ ,_$/_?P5P<LNQU\R[EFBJWVRW_Y^(?^_@H^V6__ #\0_P#?P4<K
M[!S1[EFBJWVRW_Y^(?\ OX*/MEO_ ,_$/_?P4<K[!S1[EJBHP^5W @@]"#2A
M@:DH?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44T
MJ0Q-([!40%F)[ =:D[5D^)21X8U4@X(LY<'_ (":<5=V$W97/+M6^+VHM>.-
M+M+>.W4X5I@69QZ]1BJ'_"V_$O\ <L/^_)_^*KA!THKVEAZ25N4\IUZCZG=_
M\+;\2_W+#_OR?_BJ/^%M^)?[EA_WY/\ \57"457U>E_*3[:IW.[_ .%M^)?[
MEA_WY/\ \51_PMOQ+_<L/^_)_P#BJX2BCZO2_E#VU3N=W_PMOQ+_ '+#_OR?
M_BJA@^*.NVQE,%OIT?FR&63; 1N8]2?FZ\"N*HH^KT_Y0]M4[G=_\+;\2_W+
M#_OR?_BJ/^%M^)?[EA_WY/\ \57"44?5Z7\H>VJ=SN_^%M^)?[EA_P!^3_\
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M16],]ZL6[<5E^,?^1<;_ *ZI7GT(J56*?<[:[:I2:['G;LTC%G8LQZECDTW
M]*6BOJ[(^=NQ,#THP/2ME_)N-.'V58-L4*F:(QA9%((W.'Q\P/UXSTXISZ(N
M9TB=GD\P"'T:,[>3[_.O3WKF6(A]I6-?92M=&)@>E&!Z5MKI=F4EF5F>$7#0
MQ@W,<1(7JV6&#U' %2-HEI%Y>^Z219'8"47$:*J@[0VUN6Z$\$?6D\7270?L
M9F!@>E&!Z5JZNEK'':+!$R,802V\$-\S#LHR>.OI3[;R[C3T@MA;_:55_,26
M,%I.I!5\<$#MD=.^:KVRY%+E%[-\W+<Q\#THP/2MHZ3;) @EF59&@\S>;A
M2-P78?F/&!G/4]*2[TZSB-Y%"9_,ME5RTC*58$@$8 [;ASGMTI+$TV[)![&2
M5S&P/2C ]*V_[)MY;N&.$O\ 9G+$W'G(RL%7<>,#8<=F/%5+^UMX(8Y(7VL6
M*M%]H24C&,'*=CGH1VIQQ$)245U!TII7,_ ]*4?*<@D'U%%%=%D979Z%X2U"
M:[T=UG8NT,FT,QY(QD5T*29&?2N2\%?\@J\_Z[#_ -!%=-"?E/TKY?%12KR2
M/?PTFZ,6SR_4[^;4;V6661F!8[5SP!V %4L#TIS??/UI*^EA",8I(\&<FY78
MF!Z48'I2T5=D*[$P/2C ]*6BBR"[$P/2C ]*6BBR"[$P/2C ]*6BBR"[$P/2
MC ]*6BBR"[$P/2C ]*6BBR"[.D\&W\R:NMF79H95;Y2<@$#.1^5=VDOSD5YW
MX2_Y&6V_W7_]!-=U&W[TU\_F44JVG8]G -NEKW-13D4^HHNE2UYIWA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 '>LCQ+_R*VK_ /7G+_Z
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MU::?-;6]JL1N4GA$#([ #/E[CM#-D@#.,^E8-;PDI*YE*+B['H'PB_Y&6_\
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M<L23[U.L>:E6+VKY>3E4?-)W/J81A2CRP5C#N[]K#5[6&<1K9SPR'S#G*R(
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M3CKQC%+VR4K6&J;<;G*S0RV\SPSQO%*APR.I#*?0@]*96WXE :ZL9R/WD]A
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MQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E%
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ML9;:#]UA@CC/'XBKIP=2:@MV1.:A%R?0M^"/^0%-_P!?MQ_Z-:NEQ7C'P_\
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M9*_F_ /[2E_*>O\ ]I67_/[;_P#?U:/[2LO^?VW_ ._JUY!@>E&!1_9"_F_
M/[2?\I[,LBLH92"#T(.0:>&!KSSP9?3)JALR[-#*K-M)X4CG(KN(Y?F(KS,1
MAW0J<C=SOH5E6AS%ZBF*<BGUSFX4444 -)Q5>2]MHFV27$2-Z/( :H>([R2P
MT2>6-BLAPJL.Q/&:\M8EV+,2S'J2<UWX3 ^WBY-V1Q8G%^QERI7/7O[3LO\
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M-JXZGDY/3GUM6'B.UM+?2A+I\TMQICM)!(ET$1B6W#<NPDC/HPS0U4Y;+?\
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MKTK.M>U:*]*^<9[J'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NJ_RKAS#_ '=_+\SKP/\ &1TMKVK17I6=:]JT5Z5\XSW4/HHHJ1A1110
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M/U1G/>/K^ATM%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_\ D8H?^N;_ ,J[B)OWIKY[,8)5].Q[. DW2U[FHIR*?44?2I:\X[PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&?\ U$O^X?Y5-4,_
M^HE_W#_*G'<F6QXSWHH[T5]BMCYE[A1113$%%%% !1110 4444 %%%% !111
M0!N^#_\ D8HO^N3_ ,J[>+_6FN(\'_\ (Q1?]<G_ )5V\7^M-?/YE_&^7^9[
M.7_POF:<72I:BBZ5+7F'H!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN?*4R'((WGD@8[#C\<U!79&7,KG.U9V-WP?_ ,C%%_UR?^5=O%_K37$>#_\
MD8HO^N3_ ,J[>+_6FO!S+^-\O\SV,O\ X7S-.+I4M11=*EKS#T HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M68[UTBN@P+RW "M*S9(&<GZDX%5J**(P4=A-M[A1115B-WP?_P C%%_UR?\
ME7;Q?ZTUQ'@__D8HO^N3_P J[>+_ %IKP,R_C?+_ #/9R_\ A?,TXNE2U%%T
MJ6O+/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9_\
M42_[A_E4U0S_ .HE_P!P_P J<=R9;'C/>BCO17V*V/F7N%%%%,04444 %%%%
M !1110 4444 %%%% &[X/_Y&*+_KD_\ *NWB_P!::XCP?_R,47_7)_Y5V\7^
MM-?/YE_&^7^9[.7_ ,+YFG%TJ6HHNE2UYAZ 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?S_ .M1_P (9JO]ZU_[^?\ UJ[;R&]31Y#>IH_M*OW0?4*7F<3_ ,(9JO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-1a_002.jpg
<TEXT>
begin 644 forms-1a_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4H _P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH9+JWB_P!9/$G^
M\X%-2\M93A+B%SZ*X- %BBBB@ HHHH **** "BC(II91U8#ZF@+CJ*:&!Z$'
MZ&G9H"X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?!SQIKP61=+-C V#YMZWE<?[OWOTKT?2/V;[5 'UO799#U,=G$$'_?39_D*
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MS&UMF!;'^TYX'X9^M>F:-!X&\'R1VVCV<$<K$(UPB[V],M(W./H:Y?4-9O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KPO]I7_D$^'_\ KO-_Z"M>Z5X7^TK_ ,@GP_\
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M/NCZ4M(/NCZ4M>&>J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[BWBF0_PR(&'ZUR.L?##PYJJ,8K<V,QZ/;<#\5Z?EBM_1?$.F^(+-;C3[I)
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MX#M/%6F7-[=W<\(CF\I$B [*"22<_P!X?E6E.?LZ*=0B<.>JU X.BK6I6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >!?%#_D;I/]P?S-<57:_%#_ )&Z3_<'\S7%5]''
MX(>B/$G\<O4****!!1110 4444 %%%% !1110 4444 >[:$6UWX1"!$ E-E)
M;JI.?F3*K^> ?QKPFO6?@[K"LE[HLK'<#]IB!YXX5A_Z#^9KSWQ3IAT?Q/J-
MCA56*8E O0(WS+_XZ17%A_<JSA\SIK>]3C/Y'H/P5/\ R'/I;_\ M2O._$G_
M "-.K_\ 7[-_Z&:ET#Q1JGAI[AM-E1!. )%>,,#C.#SZ9/YUEW-Q+=W4US.^
M^:9S)(V ,L3DGCWK6G3:JRGT9G*HG3C'L:WA+7G\.>(K:_!/DY\N=1_%&>OY
M<'Z@5]%VHM9V_M"W*.;B)!YJG(=!DKS_ ,#/YU\LUT&G>./$FDV4=G9:F\=O
M&,(C1(^T>@+*3BLL3AG4=X[FE"NJ>DMBGXD_Y&G5_P#K]F_]#-9=23S27-Q)
M/,Y>61B[L>I).2:CKL@K*QS-W=SWGP+_ ,DK@_ZXW'_HR2O!JZ&P\;:[IFAG
M2+6Y1+;#!<Q*64,22 <=R3^=<]7/0I2A*3?5FU6HIQBET05[9\(+9H/"UW=2
M#:LUR=I/=54#/YY_*O$Z]QU%AX,^$RVN=ET\'D@!\'S9,EB#[98_A48O6*@N
MK*PVDG-]$>,ZI=C4-7O;U00+B=Y0&ZC<Q//YU4HHKKBK*QSMW"BBBF 4444
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M%>K?\*4UC_GK:?\ ?9_PH_X4IK'_ #UM/^^S_A1^[_G7WA[_ /*SRFBO5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *:?O4ZFG[U 'RO?_ /(1NO\ KL_\S5>K%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@;+8_ ?I7-Z3KVJ:%([Z;>/;F08< !E;ZJ00?RI=7\0:KKTD;ZE>O<>6,(N
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M1_$D>K0_AHT%Z4^F+TI]<QN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MZBY>7R_4]6#)_P +CN%) F>PVP$G^/RQT]\9KR==/O99;E1;2E[96:?Y3^[
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M_D:6ZFDM_AAHDT+LDL>H2.CJ<%2,D$55L;VWOOA_?Z3//%%<6=PMU;"60*9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BDVBG44 -VBC:*=10 W:
M*-HIU% #=HHVBG44 -VBD(&*=7.^)_%EIX5B@EO;6[EBF8J'MT5@I'.#EAU_
MH:J$7.7+%79,I**O+8C\##_BEU_Z^;C_ -'/72;17F7@;QUI[K;:''9WKW4T
M\K JJ; &=GR3NS@ \\=CUKT^ML5"4*LE)6NS.A.,H+EZ";11M%.HKG-ANT4;
M13J* &[11M%.HH ;M%&T4ZB@!NVEQ2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#<9#?C657"SIQYF:4\1&H[([$&EJO')NJ<5S'0+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ)J$)EEM1.51"C,&.]LD)A=W.3UQVJQ)H.FZC8Z=-:O91R3:FME(UDT_E[6
M()\[G<.>G'-'MD@]FSC**[71;K3(?&]I:0:)!&8KY8HI3/*7 #8RP+8+=#P
M.O!KE]6GCGU.=XK:&W4.1LB+D$Y//S,3G\<4XU>:5K"<+)Z[%*BBBM2 KUCX
M0'&E:Q_UVC_]!->3UZO\(?\ D$ZQ_P!=H_\ T$URXS^$S?#?Q$>E6S9J^O2L
MVUK17I7D,]1#Z***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@#B_B
ME_R(EW_UUB_]"%>!5[[\4O\ D1+O_KK%_P"A"O J]; _POF>;B_XGR"BBBNT
MY23R)A;BX,3^27*"3:=I8#)&>F<$<5'75:G&+8>%K%1^Z^SI<'/1FDD))_(*
M/PKI=3C36O&4>H0HHO=-U9+>Z51]^'S<1R?A]T_\!K"5:S6G?\'8T5.Z?R_'
M4\PHKM[KPW9_:6O;YBXO;J8@+J$%MY2+(5SB7)<\$X& ,=>>,NZ\.VYM"-.N
M3=W$>H?8W=&!CD#?ZIUQTSAAU-.->,@E2<;G.45THT.QDUK5(+>.[NK.R.W>
M;B*!2<[2S2N-J@G.!@DU9G\*V5OJ<ADFF^PQ::-09$E21SG V"11M/S?Q $8
M[4>VB+V4MCE6MYD@CG>&18921'(5(5R.N#WQ38XWED6.-&>1R%55&2Q/0 5V
M5U:6NI:'X8MK*&],,T]R/*&UY0<KD _*#_O$# ZCBJ&L:%;V6AP:K:[HF^U&
M!X_ML5SSMW!@\0 '0\'GI0JRZ@Z;Z'..CQR-'(K(ZDAE88(([&FUT'C%%_M[
M[4HP;VWANF'^TZ M^N3^-<_6D)<T;DR5G8*]7^$/_()UC_KM'_Z":\HKU?X0
M_P#()UC_ *[1_P#H)KGQ?\)FV&_B(]'M>M:*]*SK7K6BO2O(9ZB'T445(PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH C<'J*H3PPR2B22UAD=<X9D!-:1%1M&#33L)HRRD/_/G;_P#?
ML4FV'_GSM_\ OV*T3 /2CR!Z57,+E,[;#_SY6_\ W['^%&V'_GRM_P#OV/\
M"M'R!Z4>0/2CF#E,[;#_ ,^5O_W['^%&V'_GRM_^_8_PK1\@>E!@&.E-2$XZ
M'!_#N4W/A1)+B-+B0SR9>4;F//J:ZO;#_P ^5O\ ]^Q_A7.?"V(/X+C/_3>3
M^==IY(]*VQ+M6DO,SH*]./H9VV'_ )\K?_OV/\*-L/\ SY6__?L?X5H^0/2C
MR!Z5AS&O*9VV'_GRM_\ OV/\*-L/_/E;_P#?L?X5H^0/2CR!Z4<P<IG@1J<K
M:0 ]B$%.;S)FRWY5>\@>E.$(':E<+$,$>*N"FJN*?2904444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 2B@UR=OX@US4;J_73M+LGAM+N2UWS7;(
MS%,9. A]:<8.5VNA,I*.YUE%<[]M\6?] ?2__ Y__C='VWQ9_P! ?2__  .?
M_P"-U?LGW7WD^T79_<=%17._;?%G_0'TO_P.?_XW1]M\6?\ 0'TO_P #G_\
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MQW_SQ\/?]_)O_B:-_CO_ )X^'O\ OY-_\31[/S7WC]IY/[CJ,4M<MO\ '?\
MSQ\/?]_)O_B:-_CO_GCX>_[^3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\
M?R;_ .)HW^._^>/A[_OY-_\ $T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_P")
MHW^._P#GCX>_[^3?_$T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_XFC?X[_P">
M/A[_ +^3?_$T>S\U]X>T\G]QU-%<MO\ '?\ SQ\/?]_)O_B:-_CO_GCX>_[^
M3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\ ?R;_ .)HW^._^>/A[_OY-_\
M$T>S\U]X>T\G]QU-%<7J6I>--+TRXOIX-!,5O&9'"23%B ,\9 YJY;W?C"YM
MXITM-$"R(' -Q+G!&?[E#I.U[JWJ+VJO:S^XZBBN<\SQE_SZZ'_X$2__ !%'
MF>,O^?70_P#P(E_^(I>S\U]X^==G]QT=%<YYGC+_ )]=#_\  B7_ .(H\SQE
M_P ^NA_^!$O_ ,11[/S7WASKL_N.CHKG/,\9?\^NA_\ @1+_ /$4>9XR_P"?
M70__  (E_P#B*/9^:^\.==G]QT=%<YYGC+_GUT/_ ,")?_B*/,\9?\^NA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC=VT\_+[[')74I3BX2_KN>AP>;]GC$Y4R[1O*#"EL<X![9J:JWVRW_Y^(?\
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M#_OR?_BJ/^%M^)?[EA_WY/\ \57"44?5Z7\H>VJ=SN_^%M^)?[EA_P!^3_\
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M16],]ZL6[<5E^,?^1<;_ *ZI7GT(J56*?<[:[:I2:['G;LTC%G8LQZECDTW
M]*6BOJ[(^=NQ,#THP/2ME_)N-.'V58-L4*F:(QA9%((W.'Q\P/UXSTXISZ(N
M9TB=GD\P"'T:,[>3[_.O3WKF6(A]I6-?92M=&)@>E&!Z5MKI=F4EF5F>$7#0
MQ@W,<1(7JV6&#U' %2-HEI%Y>^Z219'8"47$:*J@[0VUN6Z$\$?6D\7270?L
M9F!@>E&!Z5JZNEK'':+!$R,802V\$-\S#LHR>.OI3[;R[C3T@MA;_:55_,26
M,%I.I!5\<$#MD=.^:KVRY%+E%[-\W+<Q\#THP/2MHZ3;) @EF59&@\S>;A
M2-P78?F/&!G/4]*2[TZSB-Y%"9_,ME5RTC*58$@$8 [;ASGMTI+$TV[)![&2
M5S&P/2C ]*V_[)MY;N&.$O\ 9G+$W'G(RL%7<>,#8<=F/%5+^UMX(8Y(7VL6
M*M%]H24C&,'*=CGH1VIQQ$)245U!TII7,_ ]*4?*<@D'U%%%=%D979Z%X2U"
M:[T=UG8NT,FT,QY(QD5T*29&?2N2\%?\@J\_Z[#_ -!%=-"?E/TKY?%12KR2
M/?PTFZ,6SR_4[^;4;V6661F!8[5SP!V %4L#TIS??/UI*^EA",8I(\&<FY78
MF!Z48'I2T5=D*[$P/2C ]*6BBR"[$P/2C ]*6BBR"[$P/2C ]*6BBR"[$P/2
MC ]*6BBR"[$P/2C ]*6BBR"[.D\&W\R:NMF79H95;Y2<@$#.1^5=VDOSD5YW
MX2_Y&6V_W7_]!-=U&W[TU\_F44JVG8]G -NEKW-13D4^HHNE2UYIWA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 '>LCQ+_R*VK_ /7G+_Z
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MU::?-;6]JL1N4GA$#([ #/E[CM#-D@#.,^E8-;PDI*YE*+B['H'PB_Y&6_\
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M<L23[U.L>:E6+VKY>3E4?-)W/J81A2CRP5C#N[]K#5[6&<1K9SPR'S#G*R(
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M3CKQC%+VR4K6&J;<;G*S0RV\SPSQO%*APR.I#*?0@]*96WXE :ZL9R/WD]A
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MQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E%
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ML9;:#]UA@CC/'XBKIP=2:@MV1.:A%R?0M^"/^0%-_P!?MQ_Z-:NEQ7C'P_\
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M9*_F_ /[2E_*>O\ ]I67_/[;_P#?U:/[2LO^?VW_ ._JUY!@>E&!1_9"_F_
M/[2?\I[,LBLH92"#T(.0:>&!KSSP9?3)JALR[-#*K-M)X4CG(KN(Y?F(KS,1
MAW0J<C=SOH5E6AS%ZBF*<BGUSFX4444 -)Q5>2]MHFV27$2-Z/( :H>([R2P
MT2>6-BLAPJL.Q/&:\M8EV+,2S'J2<UWX3 ^WBY-V1Q8G%^QERI7/7O[3LO\
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M-JXZGDY/3GUM6'B.UM+?2A+I\TMQICM)!(ET$1B6W#<NPDC/HPS0U4Y;+?\
MKS!.'-<KZ=H$NIZ8)X N\W7D^8\VU44(78L-O0 $YW=NAJYH_AV&36M,$TUM
M?Z==2/&9+=G4;E7)4[@K \J>F.>O6H=-\4/86S0M:+*LMTT\PWE0Z-&R,@P.
M,AC@YX]*6T\2P:;<V'V+3Y$MK65YS'+<!WD=EVY+!    ,#;Z^M.7M&W8:]F
MK7+6E:!9'4;7[<T*Q/IK7NR:61ED.UR,[$!4#;DC.<#@G.*HS^')F=C'<6*S
MO$US'9QF7>8N3E=RXQM&X!FW8[9H_P"$B_?6\GV7_4Z:UACS.N58;^G^UT]N
MM6)/%LT^FI;22:I'(EN+<"VU QP$!=H)BV'MC(!&?;-)JK>Z_K447"UG_6AS
M5%%%=)D%>Q?"G_D4+[_K]/\ Z M>.U[%\*?^10OO^OT_^@+7+C?X1T87^(=[
M:UH+TK/M:T%Z5Y#/30^BBBI&%%%% !1110 4444 %%%% !1110 4444 %0S_
M .HE_P!P_P JFJ&?_42_[A_E3CN3+8\9[T4=Z*^Q6Q\R]S2BL8Q;P,\-S<3W
M"EDBMR!M0$C)^5LG(/&.*<VGJUE)Y4,OG_;!"@D&U\$'@CH#G%0QWT+6T,-U
M;M)Y'^K>.38P!).#D$$9/M4SZU(7DD2)5D:[%T#G(!&>,?C7$U7OI_6O^1NG
M3MK_ %I_F-BTL"XB_?0W$0N$BF$;-\N3T.0,YP>1GI3;O3#&\KPS0.BS>6RJ
MY^0G. 20!V/()''6G_VG#"W^BVK1JTRS2!Y=^=IR%!P,#D]<GI2G5HD<M#9A
M?,F6657DW*Q4DA0,# R3US1_M%[_ .0_W5FA]EI2-?68>6&XMYW9"8BPY R0
M<@'N*KZ59I>W$R.DK^7$TBQQ'#,1CCH?Y5;;7SY]K)Y<\GV=VDS-.79MP QG
M' &/2L^PO%M))B\32I+$T3!7VD XY!P?Y4TJS@[[_P#!_P A/V2DK;7+L^E1
MQW)1%D&+4SM'(^'0@="=O/KC Z]JKS:5+$DQ\Z%Y8 &EA5CNC''7C!P2 <$U
M*-85 J10%8TMWA4,^YAN))).!GD],"F3ZHDGVF5+<QW%RNV5S)N7G!;:N.,D
M=R>]3'ZPFK_U_2&_9/\ K^NI9N-+A^V7:IB*.%8CDN<+N"Y.,$GD^W]*;J&F
MQ&_N5@:WAMK?Y6?+D Y( .026X[#'%12ZOYCW;>3C[0L2_?^[LQ[<YQ3H]:=
M+B]<+*BW3[R(9BCJ<DC#8/')[4*%=*_]=!\U)MHH7-L]K,8G*MP&5E.0RD9!
M'L14-7[RX@N(-^9I+EWY:64NRH!@ G !R?;C%4*ZZ4I./O;G/-)/0W?!_P#R
M,47_ %R?^5=O%_K37$>#_P#D8HO^N3_RKMXO]::\/,OXWR_S/7R_^%\S3BZ5
M+4472I:\P] *0TM(: .=\9_\B[+_ +Z?SKS:O2?&?_(NR_[Z?SKS:OH,K_@_
M,\3,/XWR"BBM3^R(O)!%R_G&V^T[#$ F/3=NZ_A7?.K"'Q''&#EL9=%7/[.G
M9H%B1F:2+SCOVJ%7GG.< <=3BE?3)HK6::4A=@0KM(97#$C(8'';MFE[:GW'
MR2[%*BM#3-+^WF+YF1&G6-CE0,$9."3UQT&/\*:^FRRSR"WC41HP0%[A",D=
M W"D^PI>WI\SBWL'LY6YK%&BK=G827.HK9L3$^2&!7)& 21CN>.E->U#,PMF
M:4)&7?<@1DP<'(R?;H3UI^UAS6%R2M<K45;BTR\F562-0KJ&#/(J@@D@<DCG
M(/'7BG+I5XTSQ"-/,5MA7S4Y;N%YY(]!FG[:FNJ&H2?0I459CL+B6U>Y5%$*
M,5+O(JC(&<<GD^W>JU4IQEL2TUN%=GX,_P"0;??]=5_E7&5V?@S_ )!M]_UU
M7^5<>8?[N_E^9U8'^,CI;7M6BO2LZU[5HKTKYQGNH?1114C"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $/2O(_C1_K-&_W9?_ &6O7#TKR/XT?ZS1O]V7
M_P!EKHPG\9&&)_A,\JHHJQ9V=SJ%TEK:1&29^BY Z<DDG@ #DD\"O:/*-NQU
MRV%O8>=<W]C=V*F))K-0_F1%BVTC>A4@L>03D'IQ5F3Q;!]HENH[:0RG6?[0
M1&QMV8/RD^O/I7.7MA<6$BQW CRZ[T:*59%89(R&4D'D$=>U.L-.FU$W(A9%
M^SV[W#[R1E5&2!@=:R=.#]Y_UU+4I+W?ZVL;4&L:5IK[;$WL\4M]#<RF>)$*
M)&Q(50&.XG<>?EZ=.:?_ &UHMN\JQ6]U<V]W>QW-S%<*J[40L=BD$[B=QY^7
MITYKEZMRZ;=074EM,L<<L<8D97E1?E*AA@DX)P1P.?:ATH]6'/)G4KXJTR"[
MTED29TLKB:61DLX8-P=5  2,XR,=2?\  <SI<UM!<-+-<WEK(@S#/: ,Z-]"
MR]L\AACWJC13C2C%:!*HY;G4W6OZ;?R:C#<+=1PW20_Z0D:-*[Q]7=-RC+9)
M/S<''6NHM;J'4[:SN;"SG.)]L$OV8W+6K"**/<Y61%3[N06#9QG Z5Y=5BUL
MKB],PMX]_DQ--)\P&$7J>:B5"+6CL5&J[G2V6MZ5I5K);;"9UM[BVD:&VBD$
MSL'42"9CO P0-H '&>Y!Q=0U&&ZT?2;2-7$EG'(DA8#!+2%ACGT-9E%7&DD[
MDN;:MT"BBBM2#WKP1_R3_2/]Q_\ T8U=1;]*Y?P1_P D_P!(_P!Q_P#T8U=1
M;]*\*K\<O5GKT_@7H<;\6_\ D2X_^OR/^35X?7N'Q;_Y$N/_ *_(_P"35X?7
MHX'^$SAQ?\0EMH&NKJ&W0@/*ZHI;H"3CFKIT'4VN[BVM[*XNF@E>)VMH6<;E
M.#C ^GYBJ^FS);ZK9S2MMCCG1V.,X 8$UOW^MV[V]Q';7;CS-:DN\*&&8^-K
M?S]Q71-RNDC"*5FW_6AE)X?U-]%DU5;28VL<GEL1&W'!RW3&T8P3G@U =(U-
M8()SIUX(;AE6&0P-MD+= IQ@D]L5N:CJ&G7UMK2QWD:%]4-Y KQOB9,.,#"G
M!Y'WL5L?\)+IJZX=2@ETR."YFA:92ET9UC61&P0<Q97;V[#CTK)U:G8ODAW_
M *N<<-"U<RK$-)OC(RAE06[Y(.<$#'0X/Y&HHM*U&>[DM(;"ZDN8L^9$D+,Z
M8X.5 R*U6U>,V/B%?M4GG7UQ&R?>S*H=B<G\1UK4_M/1KF^N+B:YC:0K:%?M
M'G^6Q2+#G$6&,@;H6..3SS5<]3JA.$;V3.?7P]JC:-)J@LYOLL4OEN?*;(P#
MENF-H(P3G@U$^C7IU![&WMYKJ>-0Y6&"0M@@'[I4-W':MK5]1T[4;;6UAO4C
M:34S=P!XW_?)AQ@84X/(^]CZU8U+5M.U.36;=+];=;IK:2.=XY-C^6FUD8*I
M8<G(^4C*_0TE4GU7]:#<(=&<U%I6HSSR00Z?=231ML>)(6+*W/! &0>#Q[&D
MBTK49[N2TAL+J2YBSYD*0LSIC@Y4#(K?U#7+233]4MX+J1GDAM+=9,,#<"($
M,Q]NF ><8[U9_M/1KF^N+B:YC:0K:%?M'G^6Q2+#G$6&,@;H6..3SS3=2?5"
M<(]&<ZVE,NA/J3R%62[%J82F"#M+9SGVQC%9U=K//IVO_P!IV<5[Y4<VJ2WW
MFF)B%@$;DO@X]AC.>:XJKIR<KW_K04XI;>?Y_P"05[%\*?\ D4+[_K]/_H"U
MX[7L7PI_Y%"^_P"OT_\ H"UAC/X1KA?XAWMK6@O2L^UK07I7DL]-#Z***D84
M444 %%%% !1110 4444 %%%% !1110 5#/\ ZB7_ '#_ "J:H9_]1+_N'^5.
M.Y,MCQGO11WHK[%;'S+W"BBBF(****0%E]/N%,*HAE::(2JL8+$ G'/'K3#:
M70N! ;:83GD1^6=WKTZUJ?VA JJ4E*L-.\G(!!W[NGY?A217MNUND+7'EL]D
M83(5)"-O+8.!G!''&>M<?MJJZ'1R0?4R9(I(9&CE1HY%.&5A@C\*95FXC@$9
M=;PS2JP0+L8 J%Z@GL#P!U^E5JZH2YD8R5F%%%%62%%%% &[X/\ ^1BB_P"N
M3_RKMXO]::XCP?\ \C%%_P!<G_E7;Q?ZTUX&9?QOE_F>SE_\+YFG%TJ6HHNE
M2UY9Z 4AI:0T <[XS_Y%V7_?3^=>;5Z3XS_Y%V7_ 'T_G7FU?097_!^9XF8?
MQOD%;JZS L$*-+<LD=OY36I4>6[8(R3N]2#]WM6%17;5HQJ;G)"HX.Z-;^TK
M=U2)UD$9LQ;NRJ"RL&W @9Y&<=QWIW]H61T]M/S<"$*H641J6)W%CE=PP.<=
M3TK'HJ/JT/Z[EJK(U;/4;:SCCC'FN$NTFW; "5 (Z9Z_C^-):ZC$EF;>0[<2
MF16\A)LY !&'QCIU!K+J6XMY;68Q3+MD !(R#U&1T]C1*A3;UW8*I)+3H2M<
M)/J#SW$LIWL6\Q$57SV.W./P!_&K[:I;O(%D,\H:W:&2X=1O;)R"1GG' Y;I
MWK&HJI4(2MY"522O;J=3:36]QIOEV]O+<)#L788B[$@NV[8KK@?-W/MSUJM'
M>VVG:A(;@F6=+DR-*D$;EQP<98_(0<]/Z5S]%8_4U=W>C+^L.RLM476NHY-.
M^R@,)&N&ER<!<%0.OX5#>1PQ7;QV[EXE. Y.<^I^F<X]J@HKHC3Y7H92FY;A
M79^#/^0;??\ 75?Y5QE=GX,_Y!M]_P!=5_E7-F'^[OY?F=&!_C(Z6U[5HKTK
M.M>U:*]*^<9[J'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TKR
M/XT?ZS1O]V7_ -EKUP]*\C^-'^LT;_=E_P#9:Z,)_&1AB?X3/*JT="FN8-6C
MEM9[:&=0VW[2P$;C!!1BWRX(R.<#GJ*SJ*]IJZL>4MSMHC86EY(;&6RLM6FL
M&V^5=!H8)MX^Y*20I:,'G<<$XR.R_P!H1;I!>WT$U^-&N(KB<3*_F.2=B[P<
M.VW R">P[5Q%/BBDGE6*&-Y)&^ZJ*23^%8^Q[O\ K_(U55]$=KJ,T4;^(-2A
MU&U'VR&%K017*F4GS(V^Z#E2,=#@^F<$B2]U,SZQ?W-QJL4]O-H[K;EKM7PQ
MB0%<9RK%L\$ DUP=%'L5_7W"]H_U.Z2_18H7&H6XT#^SO+>R\]<F7RR"##G<
M7\WYM^/0YXINL:T;^;Q#;27T4UH$B:SB,B^7O$B9*#IG!;)'7G-</11[!7O_
M %_PX>U?+8[/68)M?ELXS?I'=2/(3:'4%N+>!%0,74ID1+P1M.< =<5C^&YX
M8'U3SI4CWZ;.B;V W,1P!GJ3Z5E6PN2T@M1,6,;;Q%G.S&6SCMCK4-.-.T7$
M3G=J78[;^VMWE6#:@GV Z(4>'S $,HB.,CNX8+C// %0:G)<7MG:P6FKV<6D
M26\$2VSW"@))\H?,?)5M^YB^.F>><'DYH9;>9X9XWBE0X9'4AE/H0>E,I>Q5
M[H?M':Q)<0_9[F6'S(Y/+<IOC;*M@XR#W!J.BBMD9L]Z\$?\D_TC_<?_ -&-
M746_2N7\$?\ )/\ 2/\ <?\ ]&-746_2O#J_'+U9Z]/X%Z'&_%O_ )$N/_K\
MC_DU>'U[A\6_^1+C_P"OR/\ DU>'UZ.!_A'#B_X@4445V',%%%% $D$$US,L
M,$3RRM]U(U+,?H!4=;_@K_D<-._WV_\ 036MHXMQ#X9LVL+&1+]Y$N7DMU=W
M7S"H^8C*X!X(P>G/%93J<K+C"ZN<5175R6L\?ART?3M-MKBU>&4WEP\"N4D#
M,,&0C,9"A"H!&2>^<5SM]8W.FWDEI=Q^7/'C<FX'&0".1QT(IPJ*3L*4'%7*
MU%%%:$A1110 5[%\*?\ D4+[_K]/_H"UX[7L7PI_Y%"^_P"OT_\ H"URXW^$
M=&%_B'>VM:"]*S[6M!>E>0STT/HHHJ1A1110 4444 %%%% !1110 4444 %%
M%% !4,_^HE_W#_*IJAG_ -1+_N'^5..Y,MCQGO11WHK[%;'S+W"BBBF(E6TG
M<0E(7;S<^6%&2V.#@#FF^3+^\_=O^[^_\I^7G'/IS6]%\NKZ0%X46J%<>X8G
M]<U-:FVO[.XO)6"^9Y4=V,XY\Q?G^C#)^H-<3Q36K6G_  ?Z^9TJBFM_ZM<Y
MBBNCNS!:LLLUA*56X!4O9)&FSG<N03OR.A/IG-.&GQV[_98D1Y KS[A")7*%
M@J!5/!XYP>QSU%'UQ6O8/J[O:YS5220R1I&[KA9%WH<]1DC^8-;TMK&NKW2P
MP(\XMEDBB,:X+D+NPG(S@L<<_I5EK6:2.V=X(Q+'"BO$ELLA7+/GY"0JCCD]
MCQQS2>,2L[ L.W=',+#(\4DJKE(\;SD<9Z<5'6TT20ZGK$**%B6*0!1T ##;
M^N*Q:Z*57G,IPY0HHHK8S-WP?_R,47_7)_Y5V\7^M-<1X/\ ^1BB_P"N3_RK
MMXO]::\#,OXWR_S/9R_^%\S3BZ5+4472I:\L] *0TM(: .=\9_\ (NR_[Z?S
MKS:O2?&?_(NR_P"^G\Z\VKZ#*_X/S/$S#^-\@HHHKTSA"BBG.CQMM=65AV88
M-(!M=%=:@(GU)[:Y59'2$(Z.,G"X.T^WM7.T5G4I*HU?^M47";BM#HI+H.;M
M[6YCCNY%A8R>:$+#;\P#$@ [L$C/.*Q;J)@1,T\,K2.^?*/((/4C P#VJO1U
M.!44Z'LY77]:%SJ<RU"BG.CQNR.K*ZG#*PP0:&C=55F1@KC*DCANW%;\QE8;
M1113$%=GX,_Y!M]_UU7^5<979^#/^0;??]=5_E7#F'^[OY?F=>!_C(Z6U[5H
MKTK.M>U:*]*^<9[J'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NJ_RKAS#_ '=_+\SKP/\ &1TMKVK17I6=:]JT5Z5\XSW4/HHHJ1A1110
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M/U1G/>/K^ATM%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY&V(S'L":
MDJ&?_42_[A_E36Y+V/(]0O9=0NY)YI&?+$@$\ =A53 ]*7O17U\(QC&R/FI2
M;=V)@>E&!Z4M%59"N)@>E&!Z4M%%D%Q,#THP/2EHHL@N)@>E&!Z4M%%D%Q,#
MTHP/2EHHL@N)@>E&!Z4M%%D%V=/X-OYEU0V3.S0RJS!2?ND<Y%=Q'+\Q%>>^
M#_\ D8H?^N;_ ,J[B)OWIKY[,8)5].Q[. DW2U[FHIR*?44?2I:\X[PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&?\ U$O^X?Y5-4,_
M^HE_W#_*G'<F6QXSWHH[T5]BMCYE[A1113$%%%% !1110 4444 %%%% !111
M0!N^#_\ D8HO^N3_ ,J[>+_6FN(\'_\ (Q1?]<G_ )5V\7^M-?/YE_&^7^9[
M.7_POF:<72I:BBZ5+7F'H!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN?*4R'((WGD@8[#C\<U!79&7,KG.U9V-WP?_ ,C%%_UR?^5=O%_K37$>#_\
MD8HO^N3_ ,J[>+_6FO!S+^-\O\SV,O\ X7S-.+I4M11=*EKS#T HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M68[UTBN@P+RW "M*S9(&<GZDX%5J**(P4=A-M[A1115B-WP?_P C%%_UR?\
ME7;Q?ZTUQ'@__D8HO^N3_P J[>+_ %IKP,R_C?+_ #/9R_\ A?,TXNE2U%%T
MJ6O+/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9_\
M42_[A_E4U0S_ .HE_P!P_P J<=R9;'C/>BCO17V*V/F7N%%%%,04444 %%%%
M !1110 4444 %%%% &[X/_Y&*+_KD_\ *NWB_P!::XCP?_R,47_7)_Y5V\7^
MM-?/YE_&^7^9[.7_ ,+YFG%TJ6HHNE2UYAZ 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?S_ .M1_P (9JO]ZU_[^?\ UJ[;R&]31Y#>IH_M*OW0?4*7F<3_ ,(9JO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-1a_003.jpg
<TEXT>
begin 644 forms-1a_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4H _P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH9+JWB_P!9/$G^
M\X%-2\M93A+B%SZ*X- %BBBB@ HHHH **** "BC(II91U8#ZF@+CJ*:&!Z$'
MZ&G9H"X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?!SQIKP61=+-C V#YMZWE<?[OWOTKT?2/V;[5 'UO799#U,=G$$'_?39_D*
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MS&UMF!;'^TYX'X9^M>F:-!X&\'R1VVCV<$<K$(UPB[V],M(W./H:Y?4-9O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KPO]I7_D$^'_\ KO-_Z"M>Z5X7^TK_ ,@GP_\
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M/NCZ4M(/NCZ4M>&>J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[BWBF0_PR(&'ZUR.L?##PYJJ,8K<V,QZ/;<#\5Z?EBM_1?$.F^(+-;C3[I)
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MX#M/%6F7-[=W<\(CF\I$B [*"22<_P!X?E6E.?LZ*=0B<.>JU X.BK6I6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK*PVDG-]$>,ZI=C4-7O;U00+B=Y0&ZC<Q//YU4HHKKBK*QSMW"BBBF 4444
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M%>K?\*4UC_GK:?\ ?9_PH_X4IK'_ #UM/^^S_A1^[_G7WA[_ /*SRFBO5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *:?O4ZFG[U 'RO?_ /(1NO\ KL_\S5>K%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@;+8_ ?I7-Z3KVJ:%([Z;>/;F08< !E;ZJ00?RI=7\0:KKTD;ZE>O<>6,(N
MJK]%4 9]\53I3NUT;N2JD=&]TO\ /_,[;6/%&LZ!X6\,1Z7>?9UFLBSCRD?)
M!&/O U%/K^I^(/ACJTVIW7VB2*[B1#Y:I@<'^$"N(O-5O=0MK2WNIO,BLX_+
M@78HV+Z<#G\:(]5O8=+GTN.;%G/())(]B_,PZ'.,_K3^KJVRO>_XW_(2K-/?
M2UOPM^9Z!XSO=&@;2IKK0);V"2QC%O<I>M$FT _* %(R/ZUGA(O'GB/3[>2R
MFTRTM;#H)/,DDB3.-I8#.<XS@]#UKGM+\8:]HMM]FL-2DCA!RL;HLBK] P./
MPJO)XBUB76$U9]0G-\GW9MW*CT Z8Y/'3DTE0DMO.SN_R&ZJ?X7VZ>9VWA:?
M1[BS\0+IFC7-LL>F3*]U-<&3<,<!EVA03C/7L:QH/^2277_867_T6*H3^.?$
MEPDB2ZF3'+&\3HL,:JRM][("XS[]?>LI=4O5TE]+$V+%YO/:+8.7QC.<9Z=L
MTE1G=M^76^PW5C9)>?3NK'2^*P3X,\(N.5\B9<^^X4NLNP^&'AI Q"F:X)7/
M!(<X_F:Q;/Q3K=AI3Z9:W[I9L&!B**V W7!()&<GH1UJG/JM[<Z9:Z;+-NM+
M4LT,>P#:6.3SC)Y]35JG+;SO^?\ F3SQW\K?A8Z36R3\-/#&3G][<_\ H=<?
M5R?5;VYTRUTV6;=:6I9H8]@&TL<GG&3SZFJ=:4XN-[]6V9RDG;R04445H2>R
M_"O_ )$ZZ_Z^V_\ 05KNK7I7"_"O_D3KK_K[;_T%:[JUZ5XN(_B2/5H?PT:"
M]*?3%Z4^N8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FG[U.II^]0!\KW__
M "$;K_KL_P#,U7JQ?_\ (1NO^NS_ ,S6WX&TJSUGQ3;VE\-T6UG\O./-*C(7
M/^>E?0.2C#F?0\6UY61SE%=5JWB"-UO-.O?"NF6D@!2,P0&&6)NQ)_B^AZU1
MTSPM>:CI[:A)<6EC8[MB7%Y+Y:R-Z+@$G\O7TJ54TO+0;AK9:F'16IJGA^_T
MJ]AMI%2;[0 UO+;OYB3@G *$=>?QK6E\!ZA"&CEU'2%O$3>UB;L><.,XQC&<
M>]-U8)7N)4Y-VL<K16BFBW+^'I-;#Q?98[@6Y0D[]Q&<XQC'XT)HMR_AZ36P
M\7V6.X%N4)._<1G.,8Q^-/GB+E9G45U<7@#4WL[:\FO=.MK2XA2:.>XN#&A+
M]$Y'WL=AQ[T7%G?7/A;08)WTJ"SFGE6"=MRN"&PQE;&-N?3VJ/;1V17LY;LY
M2BNZ\7^#K+33!-9ZAIEN@M8F>![IVDD<G!=00<J>OX'BN7UK1+O0=3:PNC&\
MH565XB2KAAD$$@']*<*T9[!*G*.YFT5IZ[H=UX?OELKQX6G,2R,(F)V;NQR!
MS696B::NB&FG9A1757MG;+\-M+N5MX5N)+V1'F" .P ; +=2*FE^'6J6UUY%
MY?Z7:;B!"]Q<;!.2 <(",G&0#P.:R]M'J7[.70X^BM-]!U./7?[%-JQO_,\L
M1 CD]>O3&.<^E:-]X,NK*VN)/[4TFXEME+36T%V&E0#KE2!T[X-6ZD5;7<2I
MR;M8YNBBBK)/9?A7_P B==?]?;?^@K7=6O2N%^%?_(G77_7VW_H*UW5KTKQ<
M1_$D>K0_AHT%Z4^F+TI]<QN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MZBY>7R_4]6#)_P +CN%) F>PVP$G^/RQT]\9KR==/O99;E1;2E[96:?Y3^[
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M_D:6ZFDM_AAHDT+LDL>H2.CJ<%2,D$55L;VWOOA_?Z3//%%<6=PMU;"60*9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BDVBG44 -VBC:*=10 W:
M*-HIU% #=HHVBG44 -VBD(&*=7.^)_%EIX5B@EO;6[EBF8J'MT5@I'.#EAU_
MH:J$7.7+%79,I**O+8C\##_BEU_Z^;C_ -'/72;17F7@;QUI[K;:''9WKW4T
M\K JJ; &=GR3NS@ \\=CUKT^ML5"4*LE)6NS.A.,H+EZ";11M%.HKG-ANT4;
M13J* &[11M%.HH ;M%&T4ZB@!NVEQ2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#<9#?C657"SIQYF:4\1&H[([$&EJO')NJ<5S'0+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ)J$)EEM1.51"C,&.]LD)A=W.3UQVJQ)H.FZC8Z=-:O91R3:FME(UDT_E[6
M()\[G<.>G'-'MD@]FSC**[71;K3(?&]I:0:)!&8KY8HI3/*7 #8RP+8+=#P
M.O!KE]6GCGU.=XK:&W4.1LB+D$Y//S,3G\<4XU>:5K"<+)Z[%*BBBM2 KUCX
M0'&E:Q_UVC_]!->3UZO\(?\ D$ZQ_P!=H_\ T$URXS^$S?#?Q$>E6S9J^O2L
MVUK17I7D,]1#Z***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:0T <7\4O^1$N_P#K
MK%_Z$*\"KWWXI?\ (B7?_76+_P!"%>!5ZV!_A?,\W%_Q/D;7A&>&V\6Z9/<2
MQQ1),"TDC!54>I)X%;-W=D^&]4M]6FTWYI$>RCL6@W&7)!9A <8VYY?U&.:X
MRBNB=+FE<PC/E5COM2O+.]N_$%I:WULEQ=P6HAE,JK'(J(-\?F$X4\#J0#MQ
M3-*O;:QO/"ME=WUJ\UI<222RB562"-B-J;P=IZ$\$@9KA**GV"M:_P#5K#=2
MYW%IJ]B- &IR3Q_VOIL<EI;(6&Z0.?D<#T0,_P"2U-#J=@NI6Z-+:2-+H$=J
MC2R$1K+@91V5@5R 5/(QGGC-<#10Z"=Q^V=[G72:HMK=:'!>PZ9%9V=WYQAL
MIFN"BEE+9;>XP<9V@YX.1R,V;EUMM*\5>=JUI,;R1'@CCNED,O[T'?@$X.#T
M.&Z\5Q%%#H[?UUN)5+'?:I>6E_<Z]:6E];+/=0VGE2M,J1R*B#>F\G:#G'!/
M\.*S--MHDAU&"[O+2\O$BA6&VFU#9;N,\@N'4,4&, -CKC.*Y2BFJ-E9,'4N
M[M'H5U?6":NQ6ZL<#P\]N3!-NC\P*1L#,22>@&23TKBK[2Y]/M[&:9HR+R'S
MXU4DE5R0-W'&<52J>[O+B^E66YDWLJ+&O  55&  !P  *(TW%Z,4IJ2LR"O5
M_A#_ ,@G6/\ KM'_ .@FO**]7^$/_()UC_KM'_Z":SQ?\)FF&_B(]'M>M:*]
M*SK7K6BO2O(9ZB'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "D-+2&@#B_BE_R(EW_P!=8O\ T(5X%7OOQ2_Y$2[_ .NL7_H0KP*O6P/\
M+YGFXO\ B?(****[3E"BBB@#9\,V-OJ.JR07,?F1BVGD W$?,L;,IX]P*=9^
M&IKJSLKI[^QMTO9&B@6=WW,X(&,*IP.>O3U(J'P]J<.DZE)<SK(R-;31 1@$
MY="HZD<9-3+K%NMEH,)27=I\[R2G PP9U8;>>N >N*QGS<^FVGZEKEY-=[O]
M"*+0+CR[J6\N+:QBMIOL[O<ECF3NH"*Q)&/3'O6=<0FWN9(3)')L8KOB;<K>
MX/<5T5[KNFZK#?VUV+J&&34)+VWEBB61AOX*LI91T Y#?G6/-_9/V2X\D7HN
M?/\ W&\H4\K_ &L<[NG3BB$I?:'.,?LE"BBBMC,**** "O5_A#_R"=8_Z[1_
M^@FO**]7^$/_ ""=8_Z[1_\ H)KEQG\)F^&_B(]'M>M:*]*SK7K6BO2O(9ZB
M'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH C<'J*H3PPR2B22UAD=<X9D!-:1%1M&#33L)HRRD/_/G;_P#?
ML4FV'_GSM_\ OV*T3 /2CR!Z57,+E,[;#_SY6_\ W['^%&V'_GRM_P#OV/\
M"M'R!Z4>0/2CF#E,[;#_ ,^5O_W['^%&V'_GRM_^_8_PK1\@>E!@&.E-2$XZ
M'!_#N4W/A1)+B-+B0SR9>4;F//J:ZO;#_P ^5O\ ]^Q_A7.?"V(/X+C/_3>3
M^==IY(]*VQ+M6DO,SH*]./H9VV'_ )\K?_OV/\*-L/\ SY6__?L?X5H^0/2C
MR!Z5AS&O*9VV'_GRM_\ OV/\*-L/_/E;_P#?L?X5H^0/2CR!Z4<P<IG@1J<K
M:0 ]B$%.;S)FRWY5>\@>E.$(':E<+$,$>*N"FJN*?2904444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 2B@UR=OX@US4;J_73M+LGAM+N2UWS7;(
MS%,9. A]:<8.5VNA,I*.YUE%<[]M\6?] ?2__ Y__C='VWQ9_P! ?2__  .?
M_P"-U?LGW7WD^T79_<=%17._;?%G_0'TO_P.?_XW1]M\6?\ 0'TO_P #G_\
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MQW_SQ\/?]_)O_B:-_CO_ )X^'O\ OY-_\31[/S7WC]IY/[CJ,4M<MO\ '?\
MSQ\/?]_)O_B:-_CO_GCX>_[^3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\
M?R;_ .)HW^._^>/A[_OY-_\ $T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_P")
MHW^._P#GCX>_[^3?_$T>S\U]X>T\G]QU-%<MO\=_\\?#W_?R;_XFC?X[_P">
M/A[_ +^3?_$T>S\U]X>T\G]QU-%<MO\ '?\ SQ\/?]_)O_B:-_CO_GCX>_[^
M3?\ Q-'L_-?>'M/)_<=317+;_'?_ #Q\/?\ ?R;_ .)HW^._^>/A[_OY-_\
M$T>S\U]X>T\G]QU-%<7J6I>--+TRXOIX-!,5O&9'"23%B ,\9 YJY;W?C"YM
MXITM-$"R(' -Q+G!&?[E#I.U[JWJ+VJO:S^XZBBN<\SQE_SZZ'_X$2__ !%'
MF>,O^?70_P#P(E_^(I>S\U]X^==G]QT=%<YYGC+_ )]=#_\  B7_ .(H\SQE
M_P ^NA_^!$O_ ,11[/S7WASKL_N.CHKG/,\9?\^NA_\ @1+_ /$4>9XR_P"?
M70__  (E_P#B*/9^:^\.==G]QT=%<YYGC+_GUT/_ ,")?_B*/,\9?\^NA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC=VT\_+[[')74I3BX2_KN>AP>;]GC$Y4R[1O*#"EL<X![9J:JWVRW_Y^(?\
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M#_OR?_BJ/^%M^)?[EA_WY/\ \57"44?5Z7\H>VJ=SN_^%M^)?[EA_P!^3_\
M%4?\+;\2_P!RP_[\G_XJN$HH^KTOY0]M4[G=_P#"V_$O]RP_[\G_ .*I1\6_
M$88$QV)&>1Y1Y_6N#HH^KTOY0]M4[GOO@CQK'XJMIXY8!;WMN 716RK*?XA_
M6NMCDS7BOPA_Y&:^_P"O!O\ T-:]?A?YS]:\K$4U"HU$]&A-R@FS2SQ7G/Q6
MU^[TG3K2SLIFADNF8NZ'#;%QP#VY->AJ>*\D^,__ !\:/_N2_P UI8:*=5)A
MB&U3;1Y<TDCL6:1V8G))8Y-)N;^\WYTE%>W9'EW8NYO[S?G1N;^\WYTE%%D%
MV+N;^\WYT;F_O-^=)119!=B[F_O-^=&YO[S?G2446"[%W-_>;\Z-S?WF_.DH
MHL@NQ=S?WF_.C<W]YOSI**+(+L7<W]YOSJQ9ZC>Z=<+/9W4L$JG(9'(Y]_6J
MU%)Q3#F9](>'=6?5_#6GZC( ))H@7_W@2"?Q(K;C?(KD/!)QX T;_KDW_H9K
MJ+<\5X51)2:7<]>FVXIG/?$36+C1?"4\]JYCFE=84<=5SG)_(5\^R,TKEY69
MW/5F.2:]O^+G_(FQ_P#7W'_Z"U>'UZ6!25.YP8MOGL)M'H*-H]!2T5V6.>[$
MVCT%&T>@I:*+!=B;1Z"C:/04M%%@U$VCT%&T>@I:*+!J)M'H*-H]!2T46#43
M:/04;1Z"EHHL&HJ%HVW1LR,.A4X->[?#G6KK5_"6Z[D,DUM,8/,8\L  1G\#
MBO"*]C^%!QX0O/\ K^;_ - 6N3&).G<Z,*W[2QZ+%)D5G>)+Z6PT.::%MLA(
M16],]ZL6[<5E^,?^1<;_ *ZI7GT(J56*?<[:[:I2:['G;LTC%G8LQZECDTW
M]*6BOJ[(^=NQ,#THP/2ME_)N-.'V58-L4*F:(QA9%((W.'Q\P/UXSTXISZ(N
M9TB=GD\P"'T:,[>3[_.O3WKF6(A]I6-?92M=&)@>E&!Z5MKI=F4EF5F>$7#0
MQ@W,<1(7JV6&#U' %2-HEI%Y>^Z219'8"47$:*J@[0VUN6Z$\$?6D\7270?L
M9F!@>E&!Z5JZNEK'':+!$R,802V\$-\S#LHR>.OI3[;R[C3T@MA;_:55_,26
M,%I.I!5\<$#MD=.^:KVRY%+E%[-\W+<Q\#THP/2MHZ3;) @EF59&@\S>;A
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 '>LCQ+_R*VK_ /7G+_Z
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MU::?-;6]JL1N4GA$#([ #/E[CM#-D@#.,^E8-;PDI*YE*+B['H'PB_Y&6_\
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M<L23[U.L>:E6+VKY>3E4?-)W/J81A2CRP5C#N[]K#5[6&<1K9SPR'S#G*R(
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M3CKQC%+VR4K6&J;<;G*S0RV\SPSQO%*APR.I#*?0@]*96WXE :ZL9R/WD]A
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MQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E% $?EBCRQ4E%
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ML9;:#]UA@CC/'XBKIP=2:@MV1.:A%R?0M^"/^0%-_P!?MQ_Z-:NEQ7C'P_\
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M9*_F_ /[2E_*>O\ ]I67_/[;_P#?U:/[2LO^?VW_ ._JUY!@>E&!1_9"_F_
M/[2?\I[,LBLH92"#T(.0:>&!KSSP9?3)JALR[-#*K-M)X4CG(KN(Y?F(KS,1
MAW0J<C=SOH5E6AS%ZBF*<BGUSFX4444 -)Q5>2]MHFV27$2-Z/( :H>([R2P
MT2>6-BLAPJL.Q/&:\M8EV+,2S'J2<UWX3 ^WBY-V1Q8G%^QERI7/7O[3LO\
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M-JXZGDY/3GUM6'B.UM+?2A+I\TMQICM)!(ET$1B6W#<NPDC/HPS0U4Y;+?\
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MKTK.M>U:*]*^<9[J'T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NJ_RKAS#_ '=_+\SKP/\ &1TMKVK17I6=:]JT5Z5\XSW4/HHHJ1A1110
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M/U1G/>/K^ATM%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_\ D8H?^N;_ ,J[B)OWIKY[,8)5].Q[. DW2U[FHIR*?44?2I:\X[PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&?\ U$O^X?Y5-4,_
M^HE_W#_*G'<F6QXSWHH[T5]BMCYE[A1113$%%%% !1110 4444 %%%% !111
M0!N^#_\ D8HO^N3_ ,J[>+_6FN(\'_\ (Q1?]<G_ )5V\7^M-?/YE_&^7^9[
M.7_POF:<72I:BBZ5+7F'H!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN?*4R'((WGD@8[#C\<U!79&7,KG.U9V-WP?_ ,C%%_UR?^5=O%_K37$>#_\
MD8HO^N3_ ,J[>+_6FO!S+^-\O\SV,O\ X7S-.+I4M11=*EKS#T HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M68[UTBN@P+RW "M*S9(&<GZDX%5J**(P4=A-M[A1115B-WP?_P C%%_UR?\
ME7;Q?ZTUQ'@__D8HO^N3_P J[>+_ %IKP,R_C?+_ #/9R_\ A?,TXNE2U%%T
MJ6O+/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9_\
M42_[A_E4U0S_ .HE_P!P_P J<=R9;'C/>BCO17V*V/F7N%%%%,04444 %%%%
M !1110 4444 %%%% &[X/_Y&*+_KD_\ *NWB_P!::XCP?_R,47_7)_Y5V\7^
MM-?/YE_&^7^9[.7_ ,+YFG%TJ6HHNE2UYAZ 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?S_ .M1_P (9JO]ZU_[^?\ UJ[;R&]31Y#>IH_M*OW0?4*7F<3_ ,(9JO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 -@# 2(  A$! Q$!_\0
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M4#[JGZ5R&I>,O$FKG_3M;O91_=\TJOY# K3D?4CF['MESIFI3N&U#4+8,/\
MGYOD)'_CQJG]@M/-\K^W]%\W^Y]M7/\ A7A5M:7-]-Y=O#)-(><*,_B:UT\'
M:VZ%C:JOH&E7)_6CECU"[/:;?2;^*3S+&^M&DZ V]ZF3^HJ/5+;6682:C;3E
ME&/-:+K]6 Y_$UX5>Z3J&F8:ZM9(AG ;J,_4<5>TWQEXDT@_Z#K=[$/[OFEE
M_(Y%'(N@<S/;?#>NG1+J5G!:&5"&4?WA]T_GQ^-8K,78LQR2<DUS>G_%=;G$
M?B31X;OUNK3]S-]2/NL?K776":;XAMS<>'+\7>T9>TD&RX3_ (#_ !?45+BQ
MIHJ44K*R.4=2K X((P171Z%X6EO;HS7H$=C$-[2!AB0=>#Z>I[5*5RF[$WA7
M1=Z2ZI?L(M/1&!#=)1WS[?UZ5D7UA R27FF.\MF&PRL/GB]-P]#V/X=:W]3U
M:V\0/_8UF6MXT(%L1]R4CLP[#T/Y^V!!<_V+=W*Q2)/(83%N3E 3C/7[P'/M
MFJ=A*YT/A;Q3]W3-38/$PV1ROSC_ &6]1[_Y'3QEM&G2!B6TZ0[8F//D,>B$
M_P!T]CVZ>E>25WWA/74U.V;1]1Q(^PK&7_Y:+CE3[C^7TIQET)E'J=G16;82
MR6UPVFW+L[(N^"5NLD?H3W9>A]>#WK2K4S"BBB@ JO?7:V5H\[*6(X5!U=CP
M%'N20*L5F8^WZT<\P6...S3,/_95/_CWM28%*^O/^$;T*2YE99+^<Y)_ORD?
M^@J.GL!7F,LKS2O+*Q>1R69CU)-;/BK5SJNL/L;-O 3'%CH?5OQ/Z8K#K&3N
MS:*L%3V=Y/87<=S;.4E0Y!_H?:H**DH[.YUKPYKD"S:I!-!=J,$Q#EOH>X^M
M8\C?VMBQTV!;73X,R.TK\#L7D;^GY5G6%B]_<^4K*B*I>25_NQH.K&N%\<>.
M(]0B.A:$6CTB-OWDO1[MA_$W^SZ"M$G(AZ&OXB^(MMHR/IWA-_,N/NS:JR\G
MVB!Z#WKR^XN9[N=Y[F:2:9SEI)&+,Q]R:N:9H=_JSXM83LS@RMP@_'_"NJA\
M&Z9IT/GZK>[E'49\M?IZFKNEH39LX2M30M&DUK4! K%(E&Z1\=![>YJ_KE[X
M?-F;72K/]YN!\_!&!^/)I-%\10:/HMS!% _VV5B5DP-O3 S].:+NV@6U.DN]
M>TGPR@L+.W\R1.&1#C!_VF[FH+/Q]:RRJEU:/ I."ZOO ^O K@68LQ9B2Q.2
M3WI*7(A\S/:2(+RVY"302KGD JP->8>)]&_L?4RL8_T>;+Q>WJ/P_P *Z[P/
M=//H;1.V3!*57V4@$?J35/X@(IM+)S]\2,!]"!G^0J8Z2L4]5<X.I;>YGM)T
MGMII(9D.5DC8JRGV(KJ="\&&\@CN]0D:.)QN6)>&(]2>U6Y9O!MA,81;B9@<
M,RAG _$G^57S=B+&YX=^(MMK*)IWBQQ'<?=AU55Y'H)0.H]Z[:.XNM$233[M
MC+IUVF<Q/E64_P <9Z?A^=>;KX=\/:Y9F73CY9SC?&Q^4^A4_P#UJM^'_$,G
MA:<>&O$C--HTIW6]R!S;D_Q+[>JU.CVW'L=RVC7EK"U_:W,+6>UMMR) N01@
MK@\ANV*QJMW]E+83^2[AXV DBD4Y613T8?6JE9LM!3XI7AE26)BDB$,K#J"*
M94]I:R7MRMO#@R/G:#W(!./QQ2&>E6-Y_P )'H45S$RQW\!R#_<E _\ 06'7
MV)K8L;M;VT2=5*DY#(>J,."I]P017F7A;5CI.LH)&VV\Y$<H/0>A_ _IFO0L
M?8-:&.(+[/'99E'_ +,H_P#'?>MHNYE)6-.BBBK((+VZ6RLI[EAD1(6P.^.@
M_&L'5[A]!\*,-_\ IDY*LX[R/DL?YX_"M/4O](N[&R_A>3SI/]V/!_\ 0BGZ
MUQGCR_\ /U6*S4_+;IEA_M-S_+'YU$G9%11DZ+(MDMUJ,D:R+"GEI&XRKN_
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MO+.YT^[DM;R"2">,[7CD7!!^E08R<"F!]5_#+Q?)XP\*K<70 O;9_(G(_B(
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MSSV:9A_[*I_\>]JN"ZDR?0N65JME906RG(B0+D]\=_QHJ>BM3(*KWUHM[:/
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DMDA6VMXX@>NQ<$_4]ZGHHIB"BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex23-1_002.jpg
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !E ?,# 2(  A$! Q$!_\0
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MI^;:2Z;(WS0GS(Q_LD\_D?YUV-:)W1#5F%%%%,04444 %%%% !1110 4444
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M/Z58G\4Z-;2>7+>;7VAL>4YX(R.WH:6;Q1HT"Q-+>;1*F]/W3G*Y(ST]C0[
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M7K>33=3 F.GY%P8!B3#$'Y3]W)KM**E1&Y?U]QY_)'!<Z1;PR[S<R:FHO%?
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M2=CS^5G;P_\ V5=PF*2VOHU,18,0C$D#(Z]36AIJ7-KXLM["XRPMH)%BE/\
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MA;ZA:7OA.VTBW+2ZB2 J+&?D._.[.,#BN^HHM_7SN*YS>F C4O$()R=RY/\
MP U3CMY[KX=PQVZ,[;0Q1>K*'R17844<NG]=[A<Y*ZU&SUJ33K;3(W:>&=';
M]T5\A1U!./PP*RUAU$:3J$T5TWV#[7(MQ;I&N[;GE@Q!_*O0:*.7^ON&G8X;
M59K"VN8Y[2]FLV-JJ([P>;#<)CA>_/KD5T^@2RS:);/-;);N5_U:)M &>"!V
MSUK2HII6N)L****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
